-- Table structure for table `knowledge_base_articles`
--

CREATE TABLE `knowledge_base_articles` (
  `id` int(11) NOT NULL,
  `name` varchar(255) NOT NULL,
  `desc` text NOT NULL,
  `category_id` int(11) NOT NULL,
  `created_at` timestamp NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NULL DEFAULT NULL ON UPDATE current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

--
-- Dumping data for table `knowledge_base_articles`
--

INSERT INTO `knowledge_base_articles` (`id`, `name`, `desc`, `category_id`, `created_at`, `updated_at`) VALUES
(6, 'Article in intro', 'Article in introduction category testtest', 4, '2020-02-03 15:24:27', '2020-02-11 15:50:20'),
(7, 'Article in Databases', 'Article in Databases luremipsum', 5, '2020-02-03 17:26:33', '2020-02-11 15:50:13'),
(8, 'Article in Other', 'Article in Other luremipsum', 10, '2020-02-03 17:26:45', '2020-02-11 15:50:07');

-- --------------------------------------------------------

--
-- Table structure for table `knowledge_base_categories`
--

CREATE TABLE `knowledge_base_categories` (
  `id` int(11) NOT NULL,
  `name` varchar(255) NOT NULL,
  `icon` varchar(255) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NULL DEFAULT NULL ON UPDATE current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

--
-- Dumping data for table `knowledge_base_categories`
--

INSERT INTO `knowledge_base_categories` (`id`, `name`, `icon`, `created_at`, `updated_at`) VALUES
(4, 'Introduction', 'fas fa-home', '2020-02-03 13:31:54', '2021-01-05 13:31:19'),
(5, 'Databases', 'fas fa-database', '2020-02-03 15:21:17', '2020-02-03 15:21:17'),
(6, 'Basic Search', 'fas fa-search', '2020-02-03 15:21:35', '2020-02-03 15:21:35'),
(7, 'Advanced Search', 'fas fa-cogs', '2020-02-03 15:21:58', '2020-02-03 15:21:58'),
(8, 'Sharing &amp; Printing', 'fas fa-share-alt', '2020-02-03 15:22:11', '2020-02-03 15:22:11'),
(9, 'FAQs', 'fas fa-book', '2020-02-03 15:22:29', '2020-02-03 15:22:29'),
(10, 'Other', 'fas fa-cube', '2020-02-03 15:22:40', '2020-02-03 15:22:40');

-- --------------------------------------------------------

--
-- Table structure for table `migrations`
--

CREATE TABLE `migrations` (
  `id` int(10) UNSIGNED NOT NULL,
  `migration` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `batch` int(11) NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `migrations`
--

INSERT INTO `migrations` (`id`, `migration`, `batch`) VALUES
(1, '2016_03_01_193027_create_sent_emails_table', 1),
(2, '2016_09_07_193027_create_sent_emails_Url_Clicked_table', 1),
(3, '2016_11_10_213551_add-message-id-to-sent-emails-table', 1);

-- --------------------------------------------------------

--
-- Table structure for table `notifications`
--

CREATE TABLE `notifications` (
  `id` int(11) NOT NULL,
  `user_id` int(11) NOT NULL,
  `type` enum('user','juniorreviewer','seniorreviewer','all') COLLATE utf8_unicode_ci NOT NULL DEFAULT 'all',
  `link` text COLLATE utf8_unicode_ci DEFAULT NULL,
  `title` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `message` text COLLATE utf8_unicode_ci NOT NULL,
  `email_subscribed` tinyint(1) DEFAULT NULL,
  `created_at` timestamp NOT NULL DEFAULT current_timestamp(),
  `updated_at` datetime NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Dumping data for table `notifications`
--

INSERT INTO `notifications` (`id`, `user_id`, `type`, `link`, `title`, `message`, `email_subscribed`, `created_at`, `updated_at`) VALUES
(39, 8, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(40, 9, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(41, 10, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(42, 14, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(43, 31, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(44, 36, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(45, 39, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(46, 40, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(47, 42, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(48, 43, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(49, 46, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(50, 48, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(51, 63, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(52, 73, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(53, 74, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(54, 75, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(55, 76, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(56, 77, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(57, 79, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(58, 84, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(59, 86, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(60, 87, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(61, 88, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(62, 89, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(63, 90, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(64, 91, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(65, 92, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(66, 93, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(67, 94, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(68, 95, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(69, 96, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(70, 97, 'all', NULL, 'admin', 'test', NULL, '2020-03-23 16:28:19', '2020-03-23 16:28:19'),
(71, 10, 'user', NULL, 'admin', 'hello world', NULL, '2020-03-23 16:36:55', '2020-03-23 16:36:55'),
(72, 31, 'user', NULL, 'admin', 'hello world', NULL, '2020-03-23 16:36:55', '2020-03-23 16:36:55'),
(73, 36, 'user', NULL, 'admin', 'hello world', NULL, '2020-03-23 16:36:55', '2020-03-23 16:36:55'),
(74, 40, 'user', NULL, 'admin', 'hello world', NULL, '2020-03-23 16:36:55', '2020-03-23 16:36:55'),
(75, 42, 'user', NULL, 'admin', 'hello world', NULL, '2020-03-23 16:36:55', '2020-03-23 16:36:55'),
(76, 43, 'user', NULL, 'admin', 'hello world', NULL, '2020-03-23 16:36:55', '2020-03-23 16:36:55'),
(77, 46, 'user', NULL, 'admin', 'hello world', NULL, '2020-03-23 16:36:55', '2020-03-23 16:36:55'),
(78, 48, 'user', NULL, 'admin', 'hello world', NULL, '2020-03-23 16:36:55', '2020-03-23 16:36:55'),
(79, 63, 'user', NULL, 'admin', 'hello world', NULL, '2020-03-23 16:36:55', '2020-03-23 16:36:55'),
(80, 73, 'user', NULL, 'admin', 'hello world', NULL, '2020-03-23 16:36:55', '2020-03-23 16:36:55'),
(81, 74, 'user', NULL, 'admin', 'hello world', NULL, '2020-03-23 16:36:55', '2020-03-23 16:36:55'),
(82, 75, 'user', NULL, 'admin', 'hello world', NULL, '2020-03-23 16:36:55', '2020-03-23 16:36:55'),
(83, 76, 'user', NULL, 'admin', 'hello world', NULL, '2020-03-23 16:36:55', '2020-03-23 16:36:55'),
(84, 77, 'user', NULL, 'admin', 'hello world', NULL, '2020-03-23 16:36:55', '2020-03-23 16:36:55'),
(85, 79, 'user', NULL, 'admin', 'hello world', NULL, '2020-03-23 16:36:55', '2020-03-23 16:36:55'),
(86, 84, 'user', NULL, 'admin', 'hello world', NULL, '2020-03-23 16:36:55', '2020-03-23 16:36:55'),
(87, 10, 'all', NULL, 'news 1', 'message', NULL, '2020-03-23 16:37:35', '2020-03-23 16:37:35'),
(88, 10, 'all', NULL, 'news 2', 'message', NULL, '2020-03-23 16:37:41', '2020-03-23 16:37:41'),
(89, 8, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(90, 9, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(91, 10, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(92, 14, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(93, 31, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(94, 36, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(95, 39, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(96, 40, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(97, 42, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(98, 43, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(99, 46, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(100, 48, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(101, 63, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(102, 73, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(103, 74, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(104, 75, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(105, 76, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(106, 77, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(107, 79, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(108, 84, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(109, 86, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(110, 87, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(111, 88, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(112, 89, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(113, 90, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(114, 91, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(115, 92, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(116, 93, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(117, 94, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(118, 95, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(119, 96, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26'),
(120, 97, 'all', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1-CFTYUQzm99D47HkjVb5qyFs-H7LQLF81-QkMrmostleNWg_e', 'news 3', 'link message', NULL, '2020-03-23 16:42:26', '2020-03-23 16:42:26');

-- --------------------------------------------------------

--
-- Table structure for table `pages`
--

CREATE TABLE `pages` (
  `id` int(11) NOT NULL,
  `parent` enum('Dashboard','Accounts','Content','Setup','NO') CHARACTER SET utf8 COLLATE utf8_unicode_ci DEFAULT NULL,
  `route` varchar(255) CHARACTER SET utf8 COLLATE utf8_unicode_ci NOT NULL,
  `name` varchar(255) CHARACTER SET utf8 COLLATE utf8_unicode_ci NOT NULL,
  `sort` int(11) NOT NULL DEFAULT 1,
  `menu` enum('show','hide') DEFAULT 'show',
  `role_editable` tinyint(1) NOT NULL DEFAULT 1,
  `add` tinyint(1) NOT NULL DEFAULT 1,
  `edit` tinyint(1) NOT NULL DEFAULT 1,
  `del` tinyint(1) NOT NULL DEFAULT 1,
  `suspend` tinyint(1) NOT NULL DEFAULT 1,
  `activity_log` tinyint(1) NOT NULL DEFAULT 1,
  `preview` tinyint(1) NOT NULL DEFAULT 1,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

--
-- Dumping data for table `pages`
--

INSERT INTO `pages` (`id`, `parent`, `route`, `name`, `sort`, `menu`, `role_editable`, `add`, `edit`, `del`, `suspend`, `activity_log`, `preview`, `created_at`, `updated_at`) VALUES
(1, 'Accounts', 'Moderator', 'Moderators', 1, 'show', 1, 1, 1, 1, 1, 1, 1, NULL, NULL),
(2, 'Content', 'Connector', 'Connectors', 5, 'show', 1, 0, 1, 0, 1, 1, 1, NULL, '2021-01-04 11:35:30'),
(3, 'Accounts', 'HKMPUser', 'HKMP Users', 3, 'show', 1, 1, 1, 1, 1, 1, 1, NULL, NULL),
(4, 'Accounts', 'Reviewer', 'Reviewers', 2, 'show', 1, 1, 1, 1, 1, 1, 1, NULL, NULL),
(5, 'Content', 'Speciality', 'Specialities', 8, 'show', 1, 1, 1, 1, 1, 1, 1, NULL, NULL),
(6, 'Content', 'Keyword', 'Keywords', 9, 'show', 1, 1, 1, 1, 1, 1, 1, NULL, NULL),
(7, 'Accounts', 'Role', 'Roles', 4, 'show', 0, 1, 1, 1, 1, 1, 1, NULL, NULL),
(8, 'Content', 'Rss', 'Rss', 6, 'show', 1, 1, 1, 1, 1, 1, 1, NULL, NULL),
(9, 'Content', 'Category', 'Categories', 7, 'show', 1, 1, 1, 1, 1, 1, 1, NULL, NULL),
(10, 'Content', 'Article', 'Publications', 10, 'show', 1, 0, 1, 0, 1, 1, 1, NULL, '2021-01-05 14:18:57'),
(11, 'Setup', 'Feedback', 'Feedback', 14, 'show', 1, 0, 0, 0, 0, 0, 1, NULL, '2021-01-05 16:10:45'),
(12, 'Setup', 'Setting', 'About us', 13, 'show', 1, 0, 1, 0, 0, 0, 1, NULL, '2021-01-05 15:53:52'),
(13, 'Setup', 'Notification', 'Notifications', 11, 'show', 1, 1, 0, 0, 0, 0, 1, NULL, '2021-01-05 14:15:30'),
(14, NULL, 'Expert', 'Experts', 15, 'show', 1, 1, 1, 1, 0, 1, 1, NULL, '2021-01-05 16:29:09'),
(15, NULL, 'Institution', 'Institutions', 16, 'show', 1, 1, 1, 0, 1, 1, 1, NULL, '2021-01-05 17:40:31'),
(16, 'Setup', 'PromotedMessage', 'Promoted Messages', 12, 'show', 1, 1, 1, 1, 0, 1, 1, NULL, '2021-01-05 15:54:04'),
(17, NULL, 'Dashboard', 'Dashboard', 1, 'show', 0, 0, 0, 0, 0, 0, 1, NULL, '2021-01-05 17:42:37'),
(18, NULL, 'Reports', 'Reports', 17, 'show', 1, 0, 0, 0, 0, 0, 1, NULL, '2021-01-05 17:47:32'),
(19, 'Content', 'PublicationType', 'publication types', 20, 'show', 1, 1, 1, 1, 0, 1, 1, NULL, '2021-01-05 14:16:41'),
(20, 'Content', 'KnowledgeBaseCategory', 'Knowledge Base Categories', 21, 'show', 1, 1, 1, 1, 0, 1, 1, NULL, '2021-01-05 14:16:32'),
(21, 'Content', 'KnowledgeBaseArticle', 'Knowledge Base articles', 22, 'show', 1, 1, 1, 1, 0, 1, 1, NULL, '2021-01-05 14:16:53'),
(22, 'Content', 'RssArticles', 'Rss Articles', 6, 'show', 1, 0, 0, 1, 1, 1, 1, NULL, '2021-01-04 12:13:58'),
(23, 'Setup', 'EmailTemplates', 'Email Templates', 11, 'show', 1, 1, 1, 1, 0, 1, 1, NULL, '2021-01-05 14:32:31'),
(24, 'Setup', 'Email', 'Emails', 11, 'show', 1, 1, 0, 0, 0, 0, 1, NULL, '2021-01-05 14:51:45'),
(25, 'Setup', 'EmailShortlist', 'Email Shortlists', 11, 'hide', 1, 1, 1, 1, 1, 1, 1, NULL, NULL),
(26, 'Accounts', 'UserGroup', 'Users Groups', 6, 'show', 1, 1, 1, 1, 0, 1, 1, NULL, '2021-01-04 11:07:59'),
(27, 'Setup', 'EmailReport', 'Email Report', 6, 'hide', 1, 0, 0, 0, 0, 0, 1, NULL, '2021-01-05 14:52:53'),
(28, 'Content', 'ResourceType', 'Resource Type', 6, 'show', 1, 1, 1, 1, 0, 1, 1, NULL, '2021-01-04 12:58:33'),
(29, 'Content', 'ArticleLog', 'Article Log', 6, 'hide', 1, 0, 0, 0, 0, 0, 1, NULL, '2021-01-04 20:32:54'),
(30, 'NO', 'Page', 'Page', 11, 'hide', 0, 1, 1, 1, 1, 1, 1, NULL, NULL),
(38, NULL, 'Permission', 'Permission', 0, 'hide', 0, 0, 0, 0, 0, 0, 0, '2020-12-31 13:28:51', '2020-12-31 13:28:51'),
(43, 'Accounts', 'ActivityLog', 'Activity Log', 1, 'hide', 0, 0, 0, 0, 0, 0, 0, NULL, '2021-01-04 10:46:02'),
(44, NULL, 'EmailShortlistRss', 'Email Shortlist Rss', 0, 'hide', 1, 0, 0, 0, 1, 0, 1, '2021-01-04 12:33:17', '2021-01-04 12:33:17'),
(45, NULL, 'EmailShortlistPublication', 'Email Shortlist Publication', 0, 'hide', 1, 0, 0, 0, 1, 0, 1, '2021-01-04 12:34:05', '2021-01-04 12:34:05'),
(46, NULL, 'ArticleReject', 'Article Reject', 0, 'hide', 1, 0, 0, 0, 1, 0, 0, '2021-01-04 19:08:16', '2021-01-04 19:08:16'),
(47, NULL, 'ArticlePublish', 'Article Publish', 0, 'hide', 1, 0, 0, 0, 1, 0, 0, '2021-01-04 19:09:16', '2021-01-04 19:09:16');

-- --------------------------------------------------------

--
-- Table structure for table `page_tests`
--

CREATE TABLE `page_tests` (
  `id` int(11) NOT NULL,
  `url` text DEFAULT NULL,
  `isCrawled` tinyint(1) DEFAULT NULL,
  `title` text DEFAULT NULL,
  `status` int(11) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NULL DEFAULT NULL ON UPDATE current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `password_resets`
--

CREATE TABLE `password_resets` (
  `email` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `token` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `password_resets`
--

INSERT INTO `password_resets` (`email`, `token`, `created_at`) VALUES
('owner@intrazero.com', '$2y$10$3YH08FV./FuVRFSC9LNbJetxQLuLGPKp45CYxky0pwsmLEDqsjhXK', '2019-10-07 14:41:28');

-- --------------------------------------------------------

--
-- Table structure for table `permissions`
--

CREATE TABLE `permissions` (
  `id` int(11) NOT NULL,
  `role_id` int(10) UNSIGNED NOT NULL,
  `page_id` int(11) NOT NULL,
  `preview` tinyint(1) NOT NULL DEFAULT 1,
  `add` tinyint(1) NOT NULL DEFAULT 1,
  `edit` tinyint(1) NOT NULL DEFAULT 1,
  `suspend` tinyint(1) NOT NULL DEFAULT 1,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  `activity_log` tinyint(4) NOT NULL DEFAULT 1,
  `del` tinyint(4) NOT NULL DEFAULT 1
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

--
-- Dumping data for table `permissions`
--

INSERT INTO `permissions` (`id`, `role_id`, `page_id`, `preview`, `add`, `edit`, `suspend`, `created_at`, `updated_at`, `activity_log`, `del`) VALUES
(641, 1, 7, 1, 1, 1, 1, '2019-09-04 01:04:40', '2019-09-04 01:04:40', 1, 1),
(829, 2, 1, 0, 0, 0, 0, '2019-10-23 21:59:18', '2019-10-23 21:59:18', 1, 1),
(830, 2, 2, 1, 0, 1, 1, '2019-10-23 21:59:18', '2019-10-23 21:59:18', 1, 1),
(831, 2, 3, 0, 0, 0, 0, '2019-10-23 21:59:18', '2019-10-23 21:59:18', 1, 1),
(832, 2, 4, 0, 0, 0, 0, '2019-10-23 21:59:18', '2019-10-23 21:59:18', 1, 1),
(833, 2, 5, 0, 0, 0, 0, '2019-10-23 21:59:18', '2019-10-23 21:59:18', 1, 1),
(834, 2, 6, 1, 1, 1, 1, '2019-10-23 21:59:18', '2019-10-23 21:59:18', 1, 1),
(835, 2, 7, 0, 0, 0, 0, '2019-10-23 21:59:18', '2019-10-23 21:59:18', 1, 1),
(836, 2, 8, 1, 1, 1, 1, '2019-10-23 21:59:18', '2019-10-23 21:59:18', 1, 1),
(837, 2, 9, 1, 1, 1, 1, '2019-10-23 21:59:18', '2019-10-23 21:59:18', 1, 1),
(838, 2, 10, 1, 0, 0, 1, '2019-10-23 21:59:18', '2019-10-23 21:59:18', 1, 1),
(839, 2, 11, 0, 0, 0, 0, '2019-10-23 21:59:18', '2019-10-23 21:59:18', 1, 1),
(840, 2, 12, 0, 0, 0, 0, '2019-10-23 21:59:18', '2019-10-23 21:59:18', 1, 1),
(841, 2, 13, 0, 0, 0, 0, '2019-10-23 21:59:18', '2019-10-23 21:59:18', 1, 1),
(911, 2, 14, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1019, 12, 1, 1, 1, 1, 1, '2020-03-23 11:23:41', '2020-03-23 11:23:41', 1, 1),
(1020, 12, 2, 1, 0, 1, 1, '2020-03-23 11:23:41', '2020-03-23 11:23:41', 1, 1),
(1021, 12, 3, 1, 1, 1, 1, '2020-03-23 11:23:41', '2020-03-23 11:23:41', 1, 1),
(1022, 12, 4, 1, 1, 1, 1, '2020-03-23 11:23:41', '2020-03-23 11:23:41', 1, 1),
(1023, 12, 5, 1, 1, 1, 1, '2020-03-23 11:23:41', '2020-03-23 11:23:41', 1, 1),
(1024, 12, 6, 1, 1, 1, 1, '2020-03-23 11:23:41', '2020-03-23 11:23:41', 1, 1),
(1025, 12, 7, 0, 0, 0, 0, '2020-03-23 11:23:41', '2020-03-23 11:23:41', 1, 1),
(1026, 12, 8, 1, 1, 1, 1, '2020-03-23 11:23:41', '2020-03-23 11:23:41', 1, 1),
(1027, 12, 9, 1, 1, 1, 1, '2020-03-23 11:23:41', '2020-03-23 11:23:41', 1, 1),
(1028, 12, 10, 1, 0, 0, 1, '2020-03-23 11:23:41', '2020-03-23 11:23:41', 1, 1),
(1029, 12, 11, 1, 0, 0, 0, '2020-03-23 11:23:41', '2020-03-23 11:23:41', 1, 1),
(1030, 12, 12, 0, 0, 1, 0, '2020-03-23 11:23:41', '2020-03-23 11:23:41', 1, 1),
(1031, 12, 13, 1, 1, 0, 0, '2020-03-23 11:23:41', '2020-03-23 11:23:41', 1, 1),
(1032, 12, 14, 1, 1, 1, 1, '2020-03-23 11:23:41', '2020-03-23 11:23:41', 1, 1),
(1033, 12, 15, 1, 1, 1, 1, '2020-03-23 11:23:41', '2020-03-23 11:23:41', 1, 1),
(1034, 12, 16, 0, 0, 0, 0, '2020-03-23 11:23:41', '2020-03-23 11:23:41', 1, 1),
(1035, 12, 17, 0, 0, 0, 0, '2020-03-23 11:23:41', '2020-03-23 11:23:41', 1, 1),
(1036, 12, 18, 0, 0, 0, 0, '2020-03-23 11:23:41', '2020-03-23 11:23:41', 1, 1),
(1037, 12, 19, 0, 0, 0, 0, '2020-03-23 11:23:41', '2020-03-23 11:23:41', 1, 1),
(1038, 12, 20, 0, 0, 0, 0, '2020-03-23 11:23:41', '2020-03-23 11:23:41', 1, 1),
(1039, 12, 21, 0, 0, 0, 1, '2020-03-23 11:23:41', '2020-03-23 11:23:41', 1, 1),
(1040, 12, 22, 1, 0, 1, 1, '2020-03-23 11:23:41', '2020-03-23 11:23:41', 1, 1),
(1049, 1, 30, 1, 1, 1, 1, '2019-09-04 01:04:40', '2019-09-04 01:04:40', 1, 1),
(1050, 2, 15, 1, 1, 1, 1, '2020-12-31 12:49:25', '2020-12-31 12:49:25', 1, 1),
(1051, 2, 16, 1, 1, 1, 1, '2020-12-31 12:49:25', '2020-12-31 12:49:25', 1, 1),
(1052, 2, 17, 1, 1, 1, 1, '2020-12-31 12:49:25', '2020-12-31 12:49:25', 1, 1),
(1053, 2, 18, 1, 1, 1, 1, '2020-12-31 12:49:25', '2020-12-31 12:49:25', 1, 1),
(1054, 2, 19, 1, 1, 1, 1, '2020-12-31 12:49:25', '2020-12-31 12:49:25', 1, 1),
(1055, 2, 20, 1, 1, 1, 1, '2020-12-31 12:49:25', '2020-12-31 12:49:25', 1, 1),
(1056, 2, 21, 1, 1, 1, 1, '2020-12-31 12:49:25', '2020-12-31 12:49:25', 1, 1),
(1057, 2, 22, 1, 1, 1, 1, '2020-12-31 12:49:25', '2020-12-31 12:49:25', 1, 1),
(1059, 2, 23, 1, 1, 1, 1, '2020-12-31 12:49:25', '2020-12-31 12:49:25', 1, 1),
(1060, 12, 23, 1, 1, 1, 1, '2020-12-31 12:49:25', '2020-12-31 12:49:25', 1, 1),
(1062, 2, 24, 1, 1, 1, 1, '2020-12-31 12:49:25', '2020-12-31 12:49:25', 1, 1),
(1063, 12, 24, 1, 1, 1, 1, '2020-12-31 12:49:25', '2020-12-31 12:49:25', 1, 1),
(1065, 2, 25, 1, 1, 1, 1, '2020-12-31 12:49:25', '2020-12-31 12:49:25', 1, 1),
(1066, 12, 25, 1, 1, 1, 1, '2020-12-31 12:49:25', '2020-12-31 12:49:25', 1, 1),
(1068, 2, 26, 1, 1, 1, 1, '2020-12-31 12:49:25', '2020-12-31 12:49:25', 1, 1),
(1069, 12, 26, 1, 1, 1, 1, '2020-12-31 12:49:25', '2020-12-31 12:49:25', 1, 1),
(1071, 2, 27, 1, 1, 1, 1, '2020-12-31 12:49:25', '2020-12-31 12:49:25', 1, 1),
(1072, 12, 27, 1, 1, 1, 1, '2020-12-31 12:49:25', '2020-12-31 12:49:25', 1, 1),
(1074, 2, 28, 1, 1, 1, 1, '2020-12-31 12:49:25', '2020-12-31 12:49:25', 1, 1),
(1075, 12, 28, 1, 1, 1, 1, '2020-12-31 12:49:25', '2020-12-31 12:49:25', 1, 1),
(1077, 2, 29, 1, 1, 1, 1, '2020-12-31 12:49:26', '2020-12-31 12:49:26', 1, 1),
(1078, 12, 29, 1, 1, 1, 1, '2020-12-31 12:49:26', '2020-12-31 12:49:26', 1, 1),
(1080, 2, 30, 1, 1, 1, 1, '2020-12-31 12:49:26', '2020-12-31 12:49:26', 1, 1),
(1081, 12, 30, 1, 1, 1, 1, '2020-12-31 12:49:26', '2020-12-31 12:49:26', 1, 1),
(1100, 2, 35, 1, 1, 1, 1, '2020-12-31 12:59:25', '2020-12-31 12:59:25', 1, 1),
(1101, 12, 35, 1, 1, 1, 1, '2020-12-31 12:59:25', '2020-12-31 12:59:25', 1, 1),
(1104, 2, 36, 1, 1, 1, 1, '2020-12-31 13:00:16', '2020-12-31 13:00:16', 1, 1),
(1105, 12, 36, 1, 1, 1, 1, '2020-12-31 13:00:16', '2020-12-31 13:00:16', 1, 1),
(1111, 1, 38, 1, 1, 1, 1, '2020-12-31 13:28:51', '2020-12-31 13:28:51', 1, 1),
(1112, 2, 38, 1, 1, 1, 1, '2020-12-31 13:28:51', '2020-12-31 13:28:51', 1, 1),
(1113, 12, 38, 1, 1, 1, 1, '2020-12-31 13:28:51', '2020-12-31 13:28:51', 1, 1),
(1115, 14, 17, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1116, 14, 1, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1117, 14, 7, 0, 0, 0, 0, NULL, NULL, 1, 1),
(1118, 14, 8, 0, 0, 0, 0, NULL, NULL, 1, 1),
(1119, 14, 22, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1120, 14, 26, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1121, 14, 27, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1122, 14, 28, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1123, 14, 29, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1124, 14, 9, 0, 0, 0, 0, NULL, NULL, 1, 1),
(1125, 14, 5, 0, 0, 0, 0, NULL, NULL, 1, 1),
(1126, 14, 10, 1, 0, 0, 1, NULL, NULL, 1, 1),
(1127, 14, 13, 1, 1, 0, 0, NULL, NULL, 1, 1),
(1128, 14, 23, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1129, 14, 24, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1130, 14, 25, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1131, 14, 30, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1132, 14, 16, 0, 0, 0, 0, NULL, NULL, 1, 1),
(1133, 14, 12, 0, 0, 0, 0, NULL, NULL, 1, 1),
(1134, 14, 11, 1, 0, 0, 0, NULL, NULL, 1, 1),
(1135, 14, 14, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1136, 14, 15, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1137, 14, 18, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1138, 14, 19, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1139, 14, 20, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1140, 14, 21, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1141, 15, 1, 1, 1, 1, 1, '2020-12-31 13:48:31', '2020-12-31 13:48:31', 1, 1),
(1144, 14, 2, 1, 1, 1, 1, '2020-12-31 13:48:31', '2020-12-31 13:48:31', 1, 1),
(1145, 15, 2, 1, 1, 1, 1, '2020-12-31 13:48:31', '2020-12-31 13:48:31', 1, 1),
(1148, 14, 3, 1, 1, 1, 1, '2020-12-31 13:48:31', '2020-12-31 13:48:31', 1, 1),
(1149, 15, 3, 1, 1, 1, 1, '2020-12-31 13:48:31', '2020-12-31 13:48:31', 1, 1),
(1152, 14, 4, 1, 1, 1, 1, '2020-12-31 13:48:31', '2020-12-31 13:48:31', 1, 1),
(1153, 15, 4, 1, 1, 1, 1, '2020-12-31 13:48:31', '2020-12-31 13:48:31', 1, 1),
(1156, 15, 5, 1, 1, 1, 1, '2020-12-31 13:48:31', '2020-12-31 13:48:31', 1, 1),
(1159, 14, 6, 1, 1, 1, 1, '2020-12-31 13:48:31', '2020-12-31 13:48:31', 1, 1),
(1160, 15, 6, 1, 1, 1, 1, '2020-12-31 13:48:31', '2020-12-31 13:48:31', 1, 1),
(1163, 15, 7, 1, 1, 1, 1, '2020-12-31 13:48:31', '2020-12-31 13:48:31', 1, 1),
(1166, 15, 8, 1, 1, 1, 1, '2020-12-31 13:48:31', '2020-12-31 13:48:31', 1, 1),
(1169, 15, 9, 1, 1, 1, 1, '2020-12-31 13:48:31', '2020-12-31 13:48:31', 1, 1),
(1172, 15, 10, 1, 1, 1, 1, '2020-12-31 13:48:31', '2020-12-31 13:48:31', 1, 1),
(1175, 15, 11, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1178, 15, 12, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1181, 15, 13, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1184, 15, 14, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1187, 15, 15, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1190, 15, 16, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1193, 15, 17, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1196, 15, 18, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1199, 15, 19, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1202, 15, 20, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1205, 15, 21, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1208, 15, 22, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1211, 15, 23, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1214, 15, 24, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1217, 15, 25, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1220, 15, 26, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1223, 15, 27, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1226, 15, 28, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1229, 15, 29, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1232, 15, 30, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1236, 2, 39, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1237, 12, 39, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1238, 14, 39, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1239, 15, 39, 1, 1, 1, 1, '2020-12-31 13:48:32', '2020-12-31 13:48:32', 1, 1),
(1268, 17, 17, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1269, 17, 1, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1270, 17, 7, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1271, 17, 8, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1272, 17, 22, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1273, 17, 26, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1274, 17, 27, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1275, 17, 28, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1276, 17, 29, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1277, 17, 9, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1278, 17, 5, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1279, 17, 10, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1280, 17, 13, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1281, 17, 23, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1282, 17, 24, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1283, 17, 25, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1284, 17, 30, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1285, 17, 16, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1286, 17, 12, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1287, 17, 11, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1288, 17, 14, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1289, 17, 15, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1290, 17, 18, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1291, 17, 19, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1292, 17, 20, 1, 0, 0, 0, NULL, NULL, 0, 1),
(1293, 17, 21, 1, 0, 0, 0, NULL, NULL, 0, 1),
(1294, 16, 17, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1295, 16, 1, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1296, 16, 7, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1297, 16, 8, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1298, 16, 22, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1299, 16, 26, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1300, 16, 27, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1301, 16, 28, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1302, 16, 29, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1303, 16, 9, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1304, 16, 5, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1305, 16, 10, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1306, 16, 13, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1307, 16, 23, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1308, 16, 24, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1309, 16, 25, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1310, 16, 30, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1311, 16, 16, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1312, 16, 12, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1313, 16, 11, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1314, 16, 14, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1315, 16, 15, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1316, 16, 18, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1317, 16, 19, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1318, 16, 20, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1319, 16, 21, 1, 0, 0, 1, NULL, NULL, 1, 1),
(1352, 2, 40, 1, 1, 1, 1, '2020-12-31 14:25:02', '2020-12-31 14:25:02', 1, 1),
(1353, 12, 40, 1, 1, 1, 1, '2020-12-31 14:25:02', '2020-12-31 14:25:02', 1, 1),
(1354, 14, 40, 1, 1, 1, 1, '2020-12-31 14:25:02', '2020-12-31 14:25:02', 1, 1),
(1538, 1, 43, 1, 1, 1, 1, '2020-12-31 14:25:02', '2020-12-31 14:25:02', 1, 1),
(1539, 14, 38, 1, 1, 1, 1, '2021-01-04 12:33:18', '2021-01-04 12:33:18', 1, 1),
(1540, 2, 43, 1, 1, 1, 1, '2021-01-04 12:33:18', '2021-01-04 12:33:18', 1, 1),
(1541, 12, 43, 1, 1, 1, 1, '2021-01-04 12:33:18', '2021-01-04 12:33:18', 1, 1),
(1542, 14, 43, 1, 1, 1, 1, '2021-01-04 12:33:18', '2021-01-04 12:33:18', 1, 1),
(1544, 2, 44, 1, 1, 1, 1, '2021-01-04 12:33:18', '2021-01-04 12:33:18', 1, 1),
(1545, 12, 44, 1, 1, 1, 1, '2021-01-04 12:33:18', '2021-01-04 12:33:18', 1, 1),
(1546, 14, 44, 1, 1, 1, 1, '2021-01-04 12:33:18', '2021-01-04 12:33:18', 1, 1),
(1548, 2, 45, 1, 1, 1, 1, '2021-01-04 12:34:05', '2021-01-04 12:34:05', 1, 1),
(1549, 12, 45, 1, 1, 1, 1, '2021-01-04 12:34:05', '2021-01-04 12:34:05', 1, 1),
(1550, 14, 45, 1, 1, 1, 1, '2021-01-04 12:34:05', '2021-01-04 12:34:05', 1, 1),
(1669, 2, 46, 1, 1, 1, 1, '2021-01-04 19:08:16', '2021-01-04 19:08:16', 1, 1),
(1670, 12, 46, 1, 1, 1, 1, '2021-01-04 19:08:16', '2021-01-04 19:08:16', 1, 1),
(1671, 14, 46, 1, 1, 1, 1, '2021-01-04 19:08:16', '2021-01-04 19:08:16', 1, 1),
(1673, 2, 47, 1, 1, 1, 1, '2021-01-04 19:09:16', '2021-01-04 19:09:16', 1, 1),
(1674, 12, 47, 1, 1, 1, 1, '2021-01-04 19:09:16', '2021-01-04 19:09:16', 1, 1),
(1675, 14, 47, 1, 1, 1, 1, '2021-01-04 19:09:16', '2021-01-04 19:09:16', 1, 1),
(1707, 1, 44, 1, 0, 0, 1, NULL, NULL, 0, 0),
(1708, 1, 45, 1, 0, 0, 1, NULL, NULL, 0, 0),
(1709, 1, 46, 0, 0, 0, 1, NULL, NULL, 0, 0),
(1710, 1, 47, 0, 0, 0, 1, NULL, NULL, 0, 0),
(1711, 1, 1, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1712, 1, 4, 1, 1, 0, 1, NULL, NULL, 1, 1),
(1713, 1, 3, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1714, 1, 2, 1, 0, 1, 1, NULL, NULL, 1, 0),
(1715, 1, 8, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1716, 1, 22, 1, 0, 0, 1, NULL, NULL, 1, 1),
(1717, 1, 26, 1, 1, 1, 0, NULL, NULL, 1, 1),
(1718, 1, 27, 1, 0, 0, 0, NULL, NULL, 0, 0),
(1719, 1, 28, 1, 1, 1, 0, NULL, NULL, 1, 1),
(1720, 1, 29, 1, 0, 0, 0, NULL, NULL, 0, 0),
(1721, 1, 9, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1722, 1, 5, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1723, 1, 6, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1724, 1, 10, 1, 0, 1, 1, NULL, NULL, 1, 0),
(1725, 1, 13, 1, 1, 0, 0, NULL, NULL, 0, 0),
(1726, 1, 23, 1, 1, 1, 0, NULL, NULL, 1, 1),
(1727, 1, 24, 1, 1, 0, 0, NULL, NULL, 0, 0),
(1728, 1, 25, 1, 1, 1, 1, NULL, NULL, 1, 0),
(1729, 1, 16, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1730, 1, 12, 0, 0, 1, 0, NULL, NULL, 1, 1),
(1731, 1, 11, 1, 0, 0, 0, NULL, NULL, 1, 1),
(1732, 1, 14, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1733, 1, 15, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1734, 1, 18, 1, 1, 1, 1, NULL, NULL, 1, 1),
(1735, 1, 19, 1, 1, 1, 0, NULL, NULL, 1, 1),
(1736, 1, 20, 1, 1, 1, 0, NULL, NULL, 1, 1),
(1737, 1, 21, 1, 1, 1, 0, NULL, NULL, 1, 1);

-- --------------------------------------------------------

--
-- Table structure for table `promoted_messages`
--

CREATE TABLE `promoted_messages` (
  `id` int(11) NOT NULL,
  `start_date` date NOT NULL,
  `end_date` date NOT NULL,
  `details` text CHARACTER SET utf8 COLLATE utf8_unicode_ci NOT NULL,
  `group_type` enum('All','Researcher','Senior Reviewer','Junior Reviewer','Guest') CHARACTER SET utf8 COLLATE utf8_unicode_ci NOT NULL DEFAULT 'All',
  `created_at` timestamp NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NULL DEFAULT NULL ON UPDATE current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

--
-- Dumping data for table `promoted_messages`
--

INSERT INTO `promoted_messages` (`id`, `start_date`, `end_date`, `details`, `group_type`, `created_at`, `updated_at`) VALUES
(5, '2020-02-01', '2020-02-08', 'detaillssssssssssss', 'Guest', '2020-01-18 17:41:42', '2020-01-18 17:47:37');

-- --------------------------------------------------------

--
-- Table structure for table `publication_types`
--

CREATE TABLE `publication_types` (
  `id` int(11) NOT NULL,
  `name` varchar(255) NOT NULL,
  `created_at` timestamp NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NULL DEFAULT NULL ON UPDATE current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

--
-- Dumping data for table `publication_types`
--

INSERT INTO `publication_types` (`id`, `name`, `created_at`, `updated_at`) VALUES
(1, 'Abbreviations', '2020-02-07 17:25:33', '2021-01-05 13:10:44'),
(2, 'Abstracts', '2020-02-07 17:25:33', '2021-01-05 13:12:03'),
(3, 'Academic Dissertations', '2020-02-07 17:25:33', NULL),
(4, 'Account Books', '2020-02-07 17:25:33', NULL),
(5, 'Addresses', '2020-02-07 17:25:33', NULL),
(6, 'Advertisements', '2020-02-07 17:25:33', NULL),
(7, 'Almanacs', '2020-02-07 17:25:33', NULL),
(8, 'Anecdotes', '2020-02-07 17:25:33', NULL),
(9, 'Animation', '2020-02-07 17:25:33', NULL),
(10, 'Annual Reports', '2020-02-07 17:25:33', NULL),
(11, 'Aphorisms and Proverbs', '2020-02-07 17:25:33', NULL),
(12, 'Architectural Drawings', '2020-02-07 17:25:33', NULL),
(13, 'Atlases', '2020-02-07 17:25:33', NULL),
(14, 'Autobiography', '2020-02-07 17:25:33', NULL),
(15, 'Bibliography', '2020-02-07 17:25:33', NULL),
(16, 'Biobibliography', '2020-02-07 17:25:33', NULL),
(17, 'Biography', '2020-02-07 17:25:33', NULL),
(18, 'Book Illustrations', '2020-02-07 17:25:33', NULL),
(19, 'Book Reviews', '2020-02-07 17:25:33', NULL),
(20, 'Bookplates', '2020-02-07 17:25:33', NULL),
(21, 'Broadsides', '2020-02-07 17:25:33', NULL),
(22, 'Caricatures', '2020-02-07 17:25:33', NULL),
(23, 'Cartoons', '2020-02-07 17:25:33', NULL),
(24, 'Case Reports', '2020-02-07 17:25:33', NULL),
(25, 'Catalogs', '2020-02-07 17:25:33', NULL),
(26, 'CD-DVD', '2020-02-07 17:25:33', NULL),
(27, 'Charts', '2020-02-07 17:25:33', NULL),
(28, 'Chronology', '2020-02-07 17:25:33', NULL),
(29, 'Classical Article', '2020-02-07 17:25:33', NULL),
(30, 'Clinical Conference', '2020-02-07 17:25:33', NULL),
(31, 'Clinical Trial', '2020-02-07 17:25:33', NULL),
(32, 'Clinical Trial, Phase I', '2020-02-07 17:25:33', NULL),
(33, 'Clinical Trial, Phase II', '2020-02-07 17:25:33', NULL),
(34, 'Clinical Trial, Phase III', '2020-02-07 17:25:33', NULL),
(35, 'Clinical Trial, Phase IV', '2020-02-07 17:25:33', NULL),
(36, 'Collected Correspondence', '2020-02-07 17:25:33', NULL),
(37, 'Collected Works', '2020-02-07 17:25:33', NULL),
(38, 'Collections', '2020-02-07 17:25:33', NULL),
(39, 'Comment', '2020-02-07 17:25:33', NULL),
(40, 'Comparative study', '2020-02-07 17:25:33', NULL),
(41, 'Congresses', '2020-02-07 17:25:33', NULL),
(42, 'Consensus Development Conference', '2020-02-07 17:25:33', NULL),
(43, 'Consensus Development Conference, NIH', '2020-02-07 17:25:33', NULL),
(44, 'Consultant reports', '2020-02-07 17:25:33', NULL),
(45, 'Controlled Clinical Trial', '2020-02-07 17:25:33', NULL),
(46, 'Cookbooks', '2020-02-07 17:25:33', NULL),
(47, 'Corrected and Republished Article', '2020-02-07 17:25:33', NULL),
(48, 'Country Cooperation Strategy', '2020-02-07 17:25:33', NULL),
(49, 'Country Office publications', '2020-02-07 17:25:33', NULL),
(50, 'Country profile', '2020-02-07 17:25:33', NULL),
(51, 'Database', '2020-02-07 17:25:33', NULL),
(52, 'Dataset', '2020-02-07 17:25:33', NULL),
(53, 'Diaries', '2020-02-07 17:25:33', NULL),
(54, 'Dictionary', '2020-02-07 17:25:33', NULL),
(55, 'Directories', '2020-02-07 17:25:33', NULL),
(56, 'Directory', '2020-02-07 17:25:33', NULL),
(57, 'Document', '2020-02-07 17:25:33', NULL),
(58, 'Documentaries and Factual Films', '2020-02-07 17:25:33', NULL),
(59, 'Drawings', '2020-02-07 17:25:33', NULL),
(60, 'Duplicate Publication', '2020-02-07 17:25:33', NULL),
(61, 'Editorial', '2020-02-07 17:25:33', NULL),
(62, 'Electronic Supplementary Materials', '2020-02-07 17:25:33', NULL),
(63, 'Encyclopedias', '2020-02-07 17:25:33', NULL),
(64, 'English Abstract', '2020-02-07 17:25:33', NULL),
(65, 'Ephemera', '2020-02-07 17:25:33', NULL),
(66, 'Essays', '2020-02-07 17:25:33', NULL),
(67, 'Eulogies', '2020-02-07 17:25:33', NULL),
(68, 'Evaluation Studies', '2020-02-07 17:25:33', NULL),
(69, 'Examination Questions', '2020-02-07 17:25:33', NULL),
(70, 'Executive action documents', '2020-02-07 17:25:33', NULL),
(71, 'Exhibitions', '2020-02-07 17:25:33', NULL),
(72, 'Festschrift', '2020-02-07 17:25:33', NULL),
(73, 'Fictional Works', '2020-02-07 17:25:33', NULL),
(74, 'Forms', '2020-02-07 17:25:33', NULL),
(75, 'Formularies', '2020-02-07 17:25:33', NULL),
(76, 'Funeral Sermons', '2020-02-07 17:25:33', NULL),
(77, 'General speeches and messages', '2020-02-07 17:25:33', NULL),
(78, 'General speeches and messages [Webcast]', '2020-02-07 17:25:33', NULL),
(79, 'Government Publications', '2020-02-07 17:25:33', NULL),
(80, 'Guidebooks', '2020-02-07 17:25:33', NULL),
(81, 'Guideline', '2020-02-07 17:25:33', NULL),
(82, 'Handbooks', '2020-02-07 17:25:33', NULL),
(83, 'Herbals', '2020-02-07 17:25:33', NULL),
(84, 'Historical Article', '2020-02-07 17:25:33', NULL),
(85, 'Humor', '2020-02-07 17:25:33', NULL),
(86, 'In vitro', '2020-02-07 17:25:33', NULL),
(87, 'Incunabula', '2020-02-07 17:25:33', NULL),
(88, 'Indexes', '2020-02-07 17:25:33', NULL),
(89, 'Information circulars', '2020-02-07 17:25:33', NULL),
(90, 'Instructional Films and Videos', '2020-02-07 17:25:33', NULL),
(91, 'Interactive Tutorial', '2020-02-07 17:25:33', NULL),
(92, 'Intercountry meeting reports', '2020-02-07 17:25:33', NULL),
(93, 'Interview', '2020-02-07 17:25:33', NULL),
(94, 'Introductory Journal Article', '2020-02-07 17:25:33', NULL),
(95, 'Journal Article', '2020-02-07 17:25:33', NULL),
(96, 'Juvenile Literature', '2020-02-07 17:25:33', NULL),
(97, 'Laboratory Manuals', '2020-02-07 17:25:33', NULL),
(98, 'Lecture Notes', '2020-02-07 17:25:33', NULL),
(99, 'Lectures', '2020-02-07 17:25:33', NULL),
(100, 'Legal Cases', '2020-02-07 17:25:33', NULL),
(101, 'Legislation', '2020-02-07 17:25:33', NULL),
(102, 'Letter', '2020-02-07 17:25:33', NULL),
(103, 'Manuscripts', '2020-02-07 17:25:33', NULL),
(104, 'Maps', '2020-02-07 17:25:33', NULL),
(105, 'Meeting Abstracts', '2020-02-07 17:25:33', NULL),
(106, 'Meta-Analysis', '2020-02-07 17:25:33', NULL),
(107, 'Multicenter Study', '2020-02-07 17:25:33', NULL),
(108, 'News', '2020-02-07 17:25:33', NULL),
(109, 'Newspaper Article', '2020-02-07 17:25:33', NULL),
(110, 'Nurses\' Instruction', '2020-02-07 17:25:33', NULL),
(111, 'Observational Study', '2020-02-07 17:25:33', NULL),
(112, 'Outlines', '2020-02-07 17:25:33', NULL),
(113, 'Overall', '2020-02-07 17:25:33', NULL),
(114, 'Patents', '2020-02-07 17:25:33', NULL),
(115, 'Patient Education Handout', '2020-02-07 17:25:33', NULL),
(116, 'Periodical Index', '2020-02-07 17:25:33', NULL),
(117, 'Periodicals and Newsletters', '2020-02-07 17:25:33', NULL),
(118, 'Personal Narratives', '2020-02-07 17:25:33', NULL),
(119, 'Pharmacopoeias', '2020-02-07 17:25:33', NULL),
(120, 'Photographs', '2020-02-07 17:25:33', NULL),
(121, 'Phrases', '2020-02-07 17:25:33', NULL),
(122, 'Pictorial Works', '2020-02-07 17:25:33', NULL),
(123, 'Poetry', '2020-02-07 17:25:33', NULL),
(124, 'Popular Works', '2020-02-07 17:25:33', NULL),
(125, 'Portraits', '2020-02-07 17:25:33', NULL),
(126, 'Postcards', '2020-02-07 17:25:33', NULL),
(127, 'Posters', '2020-02-07 17:25:33', NULL),
(128, 'Practice Guideline', '2020-02-07 17:25:33', NULL),
(129, 'Pragmatic Clinical Trial', '2020-02-07 17:25:33', NULL),
(130, 'Price Lists', '2020-02-07 17:25:33', NULL),
(131, 'Problems and Exercises', '2020-02-07 17:25:33', NULL),
(132, 'Programmed Instruction', '2020-02-07 17:25:33', NULL),
(133, 'Programs', '2020-02-07 17:25:33', NULL),
(134, 'Prospectuses', '2020-02-07 17:25:33', NULL),
(135, 'Publication Components', '2020-02-07 17:25:33', NULL),
(136, 'Publication Formats', '2020-02-07 17:25:33', NULL),
(137, 'Publications', '2020-02-07 17:25:33', NULL),
(138, 'Published Erratum', '2020-02-07 17:25:33', NULL),
(139, 'Randomized Controlled Trial', '2020-02-07 17:25:33', NULL),
(140, 'Research Support, American Recovery and Reinvestment Act', '2020-02-07 17:25:33', NULL),
(141, 'Research Support, N.I.H.,Extramural', '2020-02-07 17:25:33', NULL),
(142, 'Research Support, N.I.H.,Intramural', '2020-02-07 17:25:33', NULL),
(143, 'Research Support, Non-U.S. Gov\'t', '2020-02-07 17:25:33', NULL),
(144, 'Research Support, U.S. Government', '2020-02-07 17:25:33', NULL),
(145, 'Research Support, U.S. Gov\'t, Non-P.H.S.', '2020-02-07 17:25:33', NULL),
(146, 'Research Support, U.S. Gov\'t, P.H.S.', '2020-02-07 17:25:33', NULL),
(147, 'Resource Guides', '2020-02-07 17:25:33', NULL),
(148, 'Retracted Publication', '2020-02-07 17:25:33', NULL),
(149, 'Retraction of Publication', '2020-02-07 17:25:33', NULL),
(150, 'Review', '2020-02-07 17:25:33', NULL),
(151, 'Scientific Integrity Review', '2020-02-07 17:25:33', NULL),
(152, 'Sermons', '2020-02-07 17:25:33', NULL),
(153, 'Staff mission reports', '2020-02-07 17:25:33', NULL),
(154, 'Statistics', '2020-02-07 17:25:33', NULL),
(155, 'Study Characteristics', '2020-02-07 17:25:33', NULL),
(156, 'Support of Research', '2020-02-07 17:25:33', NULL),
(157, 'Tables', '2020-02-07 17:25:33', NULL),
(158, 'Technical Committee reports', '2020-02-07 17:25:33', NULL),
(159, 'Technical Report', '2020-02-07 17:25:33', NULL),
(160, 'Technical working papers', '2020-02-07 17:25:33', NULL),
(161, 'Terminology', '2020-02-07 17:25:33', NULL),
(162, 'Textbooks', '2020-02-07 17:25:33', NULL),
(163, 'Twin Study', '2020-02-07 17:25:33', NULL),
(164, 'Unedited Footage', '2020-02-07 17:25:33', NULL),
(165, 'Union Lists', '2020-02-07 17:25:33', NULL),
(166, 'Unpublished Works', '2020-02-07 17:25:33', NULL),
(167, 'Validation Studies', '2020-02-07 17:25:33', NULL),
(168, 'Video-Audio Media', '2020-02-07 17:25:33', NULL),
(169, 'Webcasts', '2020-02-07 17:25:33', NULL);

-- --------------------------------------------------------

--
-- Table structure for table `qualifiers`
--

CREATE TABLE `qualifiers` (
  `id` int(11) UNSIGNED NOT NULL,
  `name` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `created_at` timestamp NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NULL DEFAULT NULL ON UPDATE current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Dumping data for table `qualifiers`
--

INSERT INTO `qualifiers` (`id`, `name`, `created_at`, `updated_at`) VALUES
(146, 'abnormalities', '2019-09-30 15:34:06', '2019-09-30 15:34:06'),
(147, 'administration &amp; dosage', '2019-09-30 15:34:13', '2019-09-30 15:34:13'),
(148, 'adverse effects', '2019-09-30 15:34:18', '2019-09-30 15:34:18'),
(149, 'agonists', '2019-09-30 15:34:24', '2019-09-30 15:34:24'),
(150, 'analogs &amp; derivatives', '2019-09-30 15:34:32', '2019-09-30 15:34:32'),
(151, 'analysis', '2019-09-30 15:34:38', '2019-09-30 15:34:38'),
(152, 'anatomy &amp; histology', '2019-09-30 15:34:49', '2019-09-30 15:34:49'),
(153, 'antagonists &amp; inhibitors', '2019-09-30 15:34:55', '2019-09-30 15:34:55'),
(154, 'biosynthesis', '2019-09-30 15:35:00', '2019-09-30 15:35:00'),
(155, 'blood', '2019-09-30 15:35:08', '2019-09-30 15:35:08'),
(156, 'blood supply', '2019-09-30 15:35:12', '2019-09-30 15:35:12'),
(157, 'cerebrospinal fluid', '2019-09-30 15:35:20', '2019-09-30 15:35:20'),
(158, 'chemical synthesis', '2019-09-30 15:35:29', '2019-09-30 15:35:29'),
(159, 'chemically induced', '2019-09-30 15:35:36', '2019-09-30 15:35:36'),
(160, 'chemistry', '2019-09-30 15:35:42', '2019-09-30 15:35:42'),
(161, 'classification', '2019-09-30 15:35:50', '2019-09-30 15:35:50'),
(162, 'complications', '2019-09-30 15:35:59', '2019-09-30 15:35:59'),
(163, 'congenital', '2019-09-30 15:36:04', '2019-09-30 15:36:04'),
(164, 'cytology', '2019-09-30 15:36:09', '2019-09-30 15:36:09'),
(166, 'deficiency', '2019-09-30 15:36:40', '2019-09-30 15:36:40'),
(167, 'diagnosis', '2019-09-30 15:36:46', '2019-09-30 15:36:46'),
(168, 'diagnostic imaging', '2019-09-30 15:36:56', '2019-09-30 15:36:56'),
(169, 'diet therapy', '2019-09-30 15:37:01', '2019-09-30 15:37:01'),
(170, 'drug effects', '2019-09-30 15:37:07', '2019-09-30 15:37:07'),
(171, 'drug therapy', '2019-09-30 15:37:12', '2019-09-30 15:37:12'),
(172, 'economics', '2019-09-30 15:37:18', '2019-09-30 15:37:18'),
(173, 'education', '2019-09-30 15:37:25', '2019-09-30 15:37:25'),
(174, 'embryology', '2019-09-30 15:37:33', '2019-09-30 15:37:33'),
(175, 'enzymology', '2019-09-30 15:37:40', '2019-09-30 15:37:40'),
(176, 'epidemiology', '2019-09-30 15:37:48', '2019-09-30 15:37:48'),
(177, 'ethics', '2019-09-30 15:37:53', '2019-09-30 15:37:53'),
(178, 'ethnology', '2019-09-30 15:38:00', '2019-09-30 15:38:00'),
(179, 'etiology', '2019-09-30 15:38:04', '2019-09-30 15:38:04'),
(180, 'genetics', '2019-09-30 15:38:11', '2019-09-30 15:38:11'),
(181, 'growth &amp; development', '2019-09-30 15:38:20', '2019-09-30 15:38:20'),
(182, 'history', '2019-09-30 15:38:27', '2019-09-30 15:38:27'),
(183, 'immunology', '2019-09-30 15:38:33', '2019-09-30 15:38:33'),
(184, 'injuries', '2019-09-30 15:38:38', '2019-09-30 15:38:38'),
(185, 'innervation', '2019-09-30 15:38:45', '2019-09-30 15:38:45'),
(186, 'instrumentation', '2019-09-30 15:38:51', '2019-09-30 15:38:51'),
(187, 'isolation &amp; purification', '2019-09-30 15:39:40', '2019-09-30 15:39:40'),
(188, 'legislation &amp; jurisprudence', '2019-09-30 15:39:50', '2019-09-30 15:39:50'),
(189, 'manpower', '2019-09-30 15:40:19', '2019-09-30 15:40:19'),
(190, 'metabolism', '2019-09-30 15:40:23', '2019-09-30 15:40:23'),
(191, 'methods', '2019-09-30 15:40:33', '2019-09-30 15:40:33'),
(192, 'microbiology', '2019-09-30 15:40:40', '2019-09-30 15:40:40'),
(193, 'mortality', '2019-09-30 15:40:46', '2019-09-30 15:40:46'),
(194, 'nursing', '2019-09-30 15:40:51', '2019-09-30 15:40:51'),
(195, 'organization &amp; administration', '2019-09-30 15:40:57', '2019-09-30 15:40:57'),
(196, 'parasitology', '2019-09-30 15:41:03', '2019-09-30 15:41:03'),
(197, 'pathogenicity', '2019-09-30 15:41:09', '2019-09-30 15:41:09'),
(198, 'pathology', '2019-09-30 15:41:14', '2019-09-30 15:41:14'),
(199, 'pharmacokinetics', '2019-09-30 15:41:19', '2019-09-30 15:41:19'),
(200, 'pharmacology', '2019-09-30 15:41:26', '2019-09-30 15:41:26'),
(201, 'physiology', '2019-09-30 15:41:34', '2019-09-30 15:41:34'),
(202, 'physiopathology', '2019-09-30 15:41:40', '2019-09-30 15:41:40'),
(203, 'poisoning', '2019-09-30 15:41:49', '2019-09-30 15:41:49'),
(204, 'prevention &amp; control', '2019-09-30 15:41:55', '2019-09-30 15:41:55'),
(205, 'psychology', '2019-09-30 15:42:02', '2019-09-30 15:42:02'),
(206, 'radiation effects', '2019-09-30 15:42:08', '2019-09-30 15:42:08'),
(207, 'radiotherapy', '2019-09-30 15:42:13', '2019-09-30 15:42:13'),
(208, 'rehabilitation', '2019-09-30 15:42:18', '2019-09-30 15:42:18'),
(209, 'secondary', '2019-09-30 15:42:23', '2019-09-30 15:42:23'),
(210, 'secretion', '2019-09-30 15:42:29', '2019-09-30 15:42:29'),
(211, 'standards', '2019-09-30 15:42:34', '2019-09-30 15:42:34'),
(212, 'statistics &amp; numerical data', '2019-09-30 15:43:01', '2019-09-30 15:43:01'),
(213, 'supply &amp; distribution', '2019-09-30 15:43:41', '2019-09-30 15:43:41'),
(214, 'surgery', '2019-09-30 15:43:50', '2019-09-30 15:43:50'),
(215, 'therapeutic use', '2019-09-30 15:43:59', '2019-09-30 15:43:59'),
(216, 'therapy', '2019-09-30 15:44:07', '2019-09-30 15:44:07'),
(217, 'toxicity', '2019-09-30 15:44:13', '2019-09-30 15:44:13'),
(218, 'transmission', '2019-09-30 15:44:20', '2019-09-30 15:44:20'),
(219, 'transplantation', '2019-09-30 15:44:26', '2019-09-30 15:44:26'),
(220, 'trends', '2019-09-30 15:44:34', '2019-09-30 15:44:34'),
(221, 'ultrastructure', '2019-09-30 15:44:38', '2019-09-30 15:44:38'),
(222, 'urine', '2019-09-30 15:44:46', '2019-09-30 15:44:46'),
(223, 'utilization', '2019-09-30 15:44:53', '2019-09-30 15:44:53'),
(224, 'veterinary', '2019-09-30 15:45:00', '2019-09-30 15:45:00'),
(225, 'virology', '2019-09-30 15:45:25', '2019-09-30 15:45:25'),
(228, 'Human Rights', '2019-09-30 15:59:24', '2019-09-30 15:59:24'),
(230, 'Health Research', '2019-09-30 15:59:42', '2019-09-30 15:59:42'),
(231, 'Statistics and Health Surveys', '2019-09-30 15:59:48', '2019-09-30 15:59:48'),
(233, 'Knowledge Management', '2019-09-30 15:59:59', '2019-09-30 15:59:59'),
(235, 'Food Safety', '2019-09-30 16:00:09', '2019-09-30 16:00:09');

-- --------------------------------------------------------

--
-- Table structure for table `resource_types`
--

CREATE TABLE `resource_types` (
  `id` int(10) UNSIGNED NOT NULL,
  `name_en` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `status` enum('approved','suspended') COLLATE utf8_unicode_ci NOT NULL DEFAULT 'suspended',
  `created_at` timestamp NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NULL DEFAULT NULL ON UPDATE current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Dumping data for table `resource_types`
--

INSERT INTO `resource_types` (`id`, `name_en`, `status`, `created_at`, `updated_at`) VALUES
(16, 'resource type', 'approved', '2020-12-29 10:16:59', '2021-01-04 17:50:14'),
(18, 'resource type 2', 'approved', '2020-12-30 10:27:40', '2020-12-30 17:53:37');

-- --------------------------------------------------------

--
-- Table structure for table `roles`
--

CREATE TABLE `roles` (
  `id` int(10) UNSIGNED NOT NULL,
  `title` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `permissions` text COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `roles`
--

INSERT INTO `roles` (`id`, `title`, `permissions`, `created_at`, `updated_at`) VALUES
(1, 'main super admin', NULL, '2019-09-03 20:46:01', '2019-09-04 01:04:40'),
(2, 'root', NULL, '2019-10-23 06:00:00', '2019-10-23 06:00:00'),
(12, 'super admin', NULL, '2019-09-03 20:46:01', '2019-09-04 01:04:40'),
(14, 'Moderator', NULL, '2019-09-04 01:06:27', '2020-02-13 18:28:58');

-- --------------------------------------------------------

--
-- Table structure for table `rss`
--

CREATE TABLE `rss` (
  `id` int(10) UNSIGNED NOT NULL,
  `name` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `source` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `link` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `category_id` int(10) UNSIGNED NOT NULL,
  `status` enum('allowed','suspended') COLLATE utf8_unicode_ci NOT NULL,
  `created_at` timestamp NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NULL DEFAULT NULL ON UPDATE current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

--
-- Dumping data for table `rss`
--

INSERT INTO `rss` (`id`, `name`, `source`, `link`, `category_id`, `status`, `created_at`, `updated_at`) VALUES
(21, 'COVID-19', 'PubMed', 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1Z3442Lm0S47VKyHFncGUzrHUM8d_3JLouqJ0RPEqlstqhkMks', 13, 'allowed', '2020-03-24 07:00:03', '2021-01-06 15:41:59'),
(22, 'Latest News', 'WHO', 'https://www.who.int/rss-feeds/news-english.xml', 13, 'allowed', '2020-03-24 11:01:52', '2020-03-25 08:06:41'),
(23, 'Public Health Emergencies', 'WHO', 'https://www.who.int/feeds/entity/hac/en/rss.xml', 13, 'suspended', '2020-03-25 06:25:05', '2020-06-03 22:05:15'),
(24, 'Disease Outbreak', 'WHO', 'https://www.who.int/feeds/entity/csr/don/en/rss.xml', 13, 'allowed', '2020-03-25 06:33:39', '2020-03-25 08:07:46'),
(25, 'Medical Products', 'WHO', 'https://www.who.int/feeds/entity/medicines/publications/drugalerts/en/rss.xml', 13, 'allowed', '2020-03-25 06:38:30', '2021-01-06 15:42:19'),
(26, 'Latest Headlines', 'BMJ', 'http://feeds.bmj.com/bmj/recent', 13, 'allowed', '2020-03-25 08:00:47', '2021-01-06 15:42:28');

-- --------------------------------------------------------

--
-- Table structure for table `rss_articles`
--

CREATE TABLE `rss_articles` (
  `id` int(11) NOT NULL,
  `title` text CHARACTER SET utf8 COLLATE utf8_unicode_ci NOT NULL,
  `body` longtext CHARACTER SET utf8 COLLATE utf8_unicode_ci NOT NULL,
  `href` text CHARACTER SET utf8 COLLATE utf8_unicode_ci NOT NULL,
  `rss_id` int(10) UNSIGNED NOT NULL,
  `status` enum('pending','published','rejected') CHARACTER SET utf8 COLLATE utf8_unicode_ci NOT NULL,
  `created_at` timestamp NULL DEFAULT current_timestamp(),
  `updated_at` timestamp NULL DEFAULT NULL ON UPDATE current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

--
-- Dumping data for table `rss_articles`
--

INSERT INTO `rss_articles` (`id`, `title`, `body`, `href`, `rss_id`, `status`, `created_at`, `updated_at`) VALUES
(43, 'Prisons and custodial settings are part of a comprehensive response to COVID-19.', 'Related Articles Prisons and custodial settings are part of a comprehensive response to COVID 19 Lancet Public Health 2020 Mar 17 Authors Kinner SA Young JT Snow K Southalan L Lopez Acu a D Ferreira Borges C O Moore PMID 32197116 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32197116?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2021-01-04 12:07:12'),
(44, 'Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal.', 'Related Articles Managing Cancer Care During the COVID 19 Pandemic Agility and Collaboration Toward a Common Goal J Natl Compr Canc Netw 2020 Mar 20 1 4 Authors Ueda M Martins R Hendrie PC McDonnell T Crews JR Wong TL McCreery B Jagels B Crane A Byrd DR Pergam SA Davidson NE Liu C Stewart FM Abstract The first confirmed case of coronavirus disease 2019 COVID 19 in the United States was reported on January 20 2020 in Snohomish County Washington At the epicenter of COVID 19 in the United States the Seattle Cancer Care Alliance Fred Hutchinson Cancer Research Center and University of Washington are at the forefront of delivering care to patients with cancer during this public health crisis This Special Feature highlights the unique circumstances and challenges of cancer treatment amidst this global pandemic and the importance of organizational structure preparation agility and a shared vision for continuing to provide cancer treatment to patients in the face of uncertainty and rapid change PMID 32197238 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32197238?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:04:34'),
(45, 'COVID-19: Vulnerability and the power of privilege in a pandemic.', 'Related Articles COVID 19 Vulnerability and the power of privilege in a pandemic Health Promot J Austr 2020 Mar 20 Authors Smith JA Judd J PMID 32197274 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32197274?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:04:37'),
(46, 'Point-of-Care RNA-Based Diagnostic Device for COVID-19.', 'Related Articles Point of Care RNA Based Diagnostic Device for COVID 19 Diagnostics Basel 2020 Mar 18 10 3 Authors Yang T Wang YC Shen CF Cheng CM Abstract At the end of 2019 the novel coronavirus disease COVID 19 a fast spreading respiratory disease caused by severe acute respiratory syndrome coronavirus 2 SARS CoV 2 was reported in Wuhan China and has now affected over 123 countries globally PMID 32197339 PubMed', 'https://www.ncbi.nlm.nih.gov/pubmed/32197339?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:04:37'),
(47, 'Practical recommendations for the perioperative management of the patient with suspection or serious infection by coronavirus SARS-CoV.', 'Related Articles Practical recommendations for the perioperative management of the patient with suspection or serious infection by coronavirus SARS CoV Rev Esp Anestesiol Reanim 2020 Mar 17 Authors Montero Feijoo A Maseda E Adalia Bartolom R Aguilar G Gonz lez de Castro R G mez Herreras JI Garc a Palenciano C Pereira J Ramasco Rueda F Samso E Su rez de la Rica A Tamayo Medel G Varela Dur n M en nombre del Grupo de Trabajo de Infecci n Perioperatoria de la Sociedad Espa ola de Anestesiolog a y Reanimaci n GTIPO SEDAR Abstract In December 2019 the Wuhan Municipal Health and health Commission Hubei Province China reported a series of cases of pneumonia of unknown etiology On January 7 2020 the Chinese authorities identified as a causative agent of the outbreak a new type of virus of the Coronaviridiae family called SARS CoV 2 Since then thounsands of cases have been reported with global dissemination Infections in humans cause a broad clinical spectrum ranging from mild upper respiratory tract infection to severe acute respiratory distress syndrome and sepsis There is not specific treatment for SARS CoV 2 which is why the fundamental aspects are to establish adequate prevention measures and support treatment and management of complications PMID 32197787 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32197787?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:04:38'),
(48, 'What Should Gastroenterologists and Patients Know About COVID-19?', 'Related Articles What Should Gastroenterologists and Patients Know About COVID 19 Clin Gastroenterol Hepatol 2020 Mar 17 Authors Ungaro RC Sullivan T Colombel JF Patel G PMID 32197957 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32197957?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:06:04'),
(49, 'A case of COVID-19 and pneumonia returning from Macau in Taiwan: Clinical course and anti-SARS-CoV-2 IgG dynamic.', 'Related Articles A case of COVID 19 and pneumonia returning from Macau in Taiwan Clinical course and anti SARS CoV 2 IgG dynamic J Microbiol Immunol Infect 2020 Mar 10 Authors Lee NY Li CW Tsai HP Chen PL Syue LS Li MC Tsai CS Lo CL Hsueh PR Ko WC Abstract A 46 year old woman presented to the emergency department with 2 day fever and cough at seven days after returning from Macau COVID 19 and pneumonia was diagnosed based on the positive real time RT PCR tests for oropharyngeal swab samples and the presence of anti SARS COV 2 IgG starting from the illness day 11 and post exposure 18 21 days PMID 32198005 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198005?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:04:41'),
(50, 'Advance of promising targets and agents against 2019-nCoV in China.', 'Related Articles Advance of promising targets and agents against 2019 nCoV in China Drug Discov Today 2020 Mar 17 Authors Duan Y Zhu HL Zhou C PMID 32198066 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198066?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:04:43'),
(51, 'Transmission potential and severity of COVID-19 in South Korea.', 'Related Articles Transmission potential and severity of COVID 19 in South Korea Int J Infect Dis 2020 Mar 17 Authors Shim E Tariq A Choi W Lee Y Chowell G Abstract OBJECTIVES Since the first case of 2019 novel coronavirus COVID 19 identified on Jan 20 2020 in South Korea the number of cases rapidly increased resulting in 6 284 cases including 42 deaths as of March 6 2020 To examine the growth rate of the outbreak we aimed to present the first study to report the reproduction number of COVID 19 in South Korea METHODS The daily confirmed cases of COVID 19 in South Korea were extracted from publicly available sources By using the empirical reporting delay distribution and simulating the generalized growth model we estimated the effective reproduction number based on the discretized probability distribution of the generation interval RESULTS We identified four major clusters and estimated the reproduction number at 1 5 95 CI 1 4 1 6 In addition the intrinsic growth rate was estimated at 0 6 95 CI 0 6 0 7 and the scaling of growth parameter was estimated at 0 8 95 CI 0 7 0 8 indicating sub exponential growth dynamics of COVID 19 The crude case fatality rate is higher among males 1 1 compared to females 0 4 and increases with older age CONCLUSIONS Our results indicate early sustained transmission of COVID 19 in South Korea and support the implementation of social distancing measures to rapidly control the outbreak PMID 32198088 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198088?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:05:03'),
(52, 'Covid-19: control measures must be equitable and inclusive.', 'Related Articles Covid 19 control measures must be equitable and inclusive BMJ 2020 03 20 368 m1141 Authors Berger ZD Evans NG Phelan AL Silverman RD PMID 32198146 PubMed in process', 'https://www.ncbi.nlm.nih.gov/pubmed/32198146?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:05:15'),
(53, 'Evidence informing the UK\'s COVID-19 public health response must be transparent.', 'Related Articles Evidence informing the UK s COVID 19 public health response must be transparent Lancet 2020 Mar 17 Authors Alwan NA Bhopal R Burgess RA Colburn T Cuevas LE Smith GD Egger M Eldridge S Gallo V Gilthorpe MS Greenhalgh T Griffiths C Hunter PR Jaffar S Jepson R Low N Martineau A McCoy D Orcutt M Pankhania B Pikhart H Pollock A Scally G Smith J Sridhar D Taylor S Tennant PWG Themistocleous Y Wilson A 36 signatories PMID 32197104 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32197104?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:05:23'),
(54, 'Covid-19: GPs can stop health checks for over 75s and routine medicine reviews.', 'Related Articles Covid 19 GPs can stop health checks for over 75s and routine medicine reviews BMJ 2020 Mar 20 368 m1157 Authors Rimmer A PMID 32198147 PubMed', 'https://www.ncbi.nlm.nih.gov/pubmed/32198147?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:05:36'),
(55, 'COVID-19 in gastroenterology: a clinical perspective.', 'Related Articles COVID 19 in gastroenterology a clinical perspective Gut 2020 Mar 20 Authors Ong J Young BE Ong S PMID 32198152 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198152?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:05:48'),
(56, 'Covid-19: 15 000 deregistered doctors are told, \"Your NHS needs you\".', 'Related Articles Covid 19 15 000 deregistered doctors are told Your NHS needs you BMJ 2020 03 20 368 m1152 Authors Dyer C PMID 32198153 PubMed', 'https://www.ncbi.nlm.nih.gov/pubmed/32198153?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:21:13'),
(57, 'Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection.', 'Related Articles Hiding in Plain Sight an Approach to Treating Patients with Severe COVID 19 Infection mBio 2020 Mar 20 11 2 Authors Fedson DS Opal SM Rordam OM Abstract Patients with COVID 19 infection are at risk of acute respiratory disease syndrome ARDS and death The tissue receptor for COVID 19 is ACE2 and higher levels of ACE2 can protect against ARDS Angiotensin receptor blockers and statins upregulate ACE2 Clinical trials are needed to determine whether this drug combination might be used to treat patients with severe COVID 19 infection PMID 32198163 PubMed in process', 'https://www.ncbi.nlm.nih.gov/pubmed/32198163?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:05:57'),
(58, 'Novel Coronavirus: What Neuroradiologists as Citizens of the World Need to Know.', 'Related Articles Novel Coronavirus What Neuroradiologists as Citizens of the World Need to Know AJNR Am J Neuroradiol 2020 Mar 20 Authors Mahajan A Hirsch JA PMID 32198164 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198164?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:06:13'),
(59, 'Challenges for NHS hospitals during covid-19 epidemic.', 'Related Articles Challenges for NHS hospitals during covid 19 epidemic BMJ 2020 Mar 20 368 m1117 Authors Willan J King AJ Jeffery K Bienz N PMID 32198166 PubMed in process', 'https://www.ncbi.nlm.nih.gov/pubmed/32198166?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:06:19'),
(60, 'Covid-19: experts question the evidence behind closing London Underground and city metros during the pandemic.', 'Related Articles Covid 19 experts question the evidence behind closing London Underground and city metros during the pandemic BMJ 2020 Mar 20 368 m1154 Authors Coombes R PMID 32198178 PubMed', 'https://www.ncbi.nlm.nih.gov/pubmed/32198178?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:06:23'),
(61, 'Covid-19: cases grow in US as Trump pushes promise of a malaria drug.', 'Related Articles Covid 19 cases grow in US as Trump pushes promise of a malaria drug BMJ 2020 Mar 20 368 m1155 Authors Tanne JH PMID 32198179 PubMed', 'https://www.ncbi.nlm.nih.gov/pubmed/32198179?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:06:31'),
(62, 'Covid-19: medical students to be employed by NHS as part of epidemic response.', 'Related Articles Covid 19 medical students to be employed by NHS as part of epidemic response BMJ 2020 Mar 20 368 m1156 Authors Mahase E PMID 32198184 PubMed', 'https://www.ncbi.nlm.nih.gov/pubmed/32198184?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:41:08'),
(63, 'Practical laboratory considerations amidst the COVID-19 outbreak: early experience from Singapore.', 'Related Articles Practical laboratory considerations amidst the COVID 19 outbreak early experience from Singapore J Clin Pathol 2020 Mar 20 Authors Tan SS Yan B Saw S Lee CK Chong AT Jureen R Sethi S Abstract The coronavirus disease 2019 COVID 19 is a zoonotic viral infection originating from Wuhan China in December 2019 The World Health Organization has classified this pandemic as a global health emergency due to its virulent nature of transmission which may lead to acute respiratory distress syndrome Singapore s health ministry has responded with enhanced surveillance of COVID 19 for all suspected pneumonia cases further increasing the volume of testing via real time reverse transcription PCR as well as samples necessitating stringent infectious control Collectively this has implications on the total testing process laboratory operations and its personnel due to biosafety concerns Turnaround time for routine testing may also be affected The aim of this article is to present our tertiary institution s early experience with managing this emerging crisis and offer practical considerations for the preanalytical analytical and postanalytical phases of laboratory testing in this cohort of patients PMID 32198190 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198190?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:41:18'),
(64, 'Clinical course and mortality risk of severe COVID-19.', 'Related Articles Clinical course and mortality risk of severe COVID 19 Lancet 2020 Mar 17 Authors Weiss P Murdoch DR PMID 32197108 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32197108?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:41:26'),
(65, 'COVID-19: towards controlling of a pandemic.', 'Related Articles COVID 19 towards controlling of a pandemic Lancet 2020 Mar 17 Authors Bedford J Enria D Giesecke J Heymann DL Ihekweazu C Kobinger G Lane HC Memish Z Oh MD Sall AA Schuchat A Ungchusak K Wieler LH WHO Strategic and Technical Advisory Group for Infectious Hazards PMID 32197103 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32197103?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:41:33'),
(66, 'Covid-19 fatality is likely overestimated.', 'Related Articles Covid 19 fatality is likely overestimated BMJ 2020 03 20 368 m1113 Authors Niforatos JD Melnick ER Faust JS PMID 32198267 PubMed in process', 'https://www.ncbi.nlm.nih.gov/pubmed/32198267?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:41:48'),
(67, 'Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection.', 'Related Articles Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus COVID 19 infection Int J Gynaecol Obstet 2020 Mar 20 Authors Chen D Yang H Cao Y Cheng W Duan T Fan C Fan S Feng L Gao Y He F He J Hu Y Jiang Y Li Y Li J Li X Li X Lin K Liu C Liu J Liu X Pan X Pang Q Pu M Qi H Shi C Sun Y Sun J Wang X Wang Y Wang Z Wang Z Wang C Wu S Xin H Yan J Zhao Y Zheng J Zhou Y Zou L Zeng Y Zhang Y Guan X Eppes CS Fox K Belfort MA Abstract OBJECTIVE To provide clinical management guidelines for novel coronavirus COVID 19 in pregnancy METHODS On February 5 2020 a multidisciplinary teleconference comprising Chinese physicians and researchers was held and medical management strategies of COVID 19 infection in pregnancy were discussed RESULTS Ten key recommendations were provided for the management of COVID 19 infections in pregnancy CONCLUSION Currently there is no clear evidence regarding optimal delivery timing the safety of vaginal delivery or whether cesarean delivery prevents vertical transmission at the time of delivery therefore route of delivery and delivery timing should be individualized based on obstetrical indications and maternal fetal status PMID 32196655 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32196655?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:41:59'),
(68, 'Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres.', 'Related Articles Recommendations for the prevention mitigation and containment of the emerging SARS CoV 2 COVID 19 pandemic in haemodialysis centres Nephrol Dial Transplant 2020 Mar 20 Authors Basile C Combe C Pizzarelli F Covic A Davenport A Kanbay M Kirmizis D Schneditz D van der Sande F Mitra S Abstract COVID 19 a disease caused by a novel coronavirus is a major global human threat that has turned into a pandemic This novel coronavirus has specifically high morbidity in the elderly and in comorbid populations Uraemic patients on dialysis combine an intrinsic fragility and a very frequent burden of comorbidities with a specific setting in which many patients are repeatedly treated in the same area haemodialysis centres Moreover if infected the intensity of dialysis requiring specialized resources and staff is further complicated by requirements for isolation control and prevention putting healthcare systems under exceptional additional strain Therefore all measures to slow if not to eradicate the pandemic and to control unmanageably high incidence rates must be taken very seriously The aim of the present review of the European Dialysis EUDIAL Working Group of ERA EDTA is to provide recommendations for the prevention mitigation and containment in haemodialysis centres of the emerging COVID 19 pandemic The management of patients on dialysis affected by COVID 19 must be carried out according to strict protocols to minimize the risk for other patients and personnel taking care of these patients Measures of prevention protection screening isolation and distribution have been shown to be efficient in similar settings They are essential in the management of the pandemic and should be taken in the early stages of the disease PMID 32196116 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32196116?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:41:39'),
(69, 'Strategies to Inform Allocation of Stockpiled Ventilators to Healthcare Facilities During a Pandemic.', 'Related Articles Strategies to Inform Allocation of Stockpiled Ventilators to Healthcare Facilities During a Pandemic Health Secur 2020 Mar 19 Authors Koonin LM Pillai S Kahn EB Moulia D Patel A Abstract During a severe pandemic especially one causing respiratory illness many people may require mechanical ventilation Depending on the extent of the outbreak there may be insufficient capacity to provide ventilator support to all of those in need As part of a larger conceptual framework for determining need for and allocation of ventilators during a public health emergency this article focuses on the strategies to assist state and local planners to allocate stockpiled ventilators to healthcare facilities during a pandemic accounting for critical factors in facilities ability to make use of additional ventilators These strategies include actions both in the pre pandemic and intra pandemic stages As a part of pandemic preparedness public health officials should identify and query healthcare facilities in their jurisdiction that currently care for critically ill patients on mechanical ventilation to determine existing inventory of these devices and facilities ability to absorb additional ventilators Facilities must have sufficient staff space equipment and supplies to utilize allocated ventilators adequately At the time of an event jurisdictions will need to verify and update information on facilities capacity prior to making allocation decisions Allocation of scarce life saving resources during a pandemic should consider ethical principles to inform state and local plans for allocation of ventilators In addition to ethical principles decisions should be informed by assessment of need determination of facilities ability to use additional ventilators and facilities capacity to ensure access to ventilators for vulnerable populations eg rural inner city and uninsured and underinsured individuals or high risk populations that may be more susceptible to illness PMID 32196387 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32196387?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:42:06'),
(70, 'Telehealth for global emergencies: Implications for coronavirus disease 2019 (COVID-19).', 'Related Articles Telehealth for global emergencies Implications for coronavirus disease 2019 COVID 19 J Telemed Telecare 2020 Mar 20 1357633X20916567 Authors Smith AC Thomas E Snoswell CL Haydon H Mehrotra A Clemensen J Caffery LJ PMID 32196391 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32196391?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:42:12'),
(71, 'COVID-19 (Coronavirus).', 'Related Articles COVID 19 Coronavirus Lymphat Res Biol 2020 Mar 20 Authors Abstract This strain of coronavirus is a new one and scientists do not yet know all there is to know about it While these common sense points will always be helpful it is important that you keep up to date with the advice being given by the Centers for Disease Control and Prevention CDC and NHS England and how it might affect you personally These suggestions have been produced using the most up to date advice available to us from our Scientific and Medical Advisors and are not intended to replace or supersede advice you may have been given from your health care professional PMID 32196406 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32196406?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:42:18'),
(72, 'Hypothesis for potential pathogenesis of SARS-CoV-2 infection--a review of immune changes in patients with viral pneumonia.', 'Related Articles Hypothesis for potential pathogenesis of SARS CoV 2 infection a review of immune changes in patients with viral pneumonia Emerg Microbes Infect 2020 Mar 20 1 14 Authors Lin L Lu L Cao W Li T Abstract Coronavirus disease 2019 COVID 19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 SARS CoV 2 with droplets and contact as the main means of transmission Since the first case appeared in Wuhan China in December 2019 the outbreak has gradually spread nationwide Up to now according to official data released by the Chinese health commission the number of newly diagnosed patients has been declining and the epidemic is gradually being controlled Although most patients have mild symptoms and good prognosis after infection some patients developed severe and die from multiple organ complications The pathogenesis of SARS CoV 2 infection in humans remains unclear Immune function is a strong defense against invasive pathogens and there is currently no specific antiviral drug against the virus This article reviews the immunological changes of coronaviruses like SARS MERS and other viral pneumonia similar to SARS CoV 2 Combined with the published literature the potential pathogenesis of COVID 19 is inferred and the treatment recommendations for giving high doses intravenous immunoglobulin and low molecular weight heparin anticoagulant therapy to severe type patients are proposed PMID 32196410 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32196410?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:42:25'),
(73, 'Laboratory Diagnosis of Emerging Human Coronavirus Infections - The State of the Art.', 'Related Articles Laboratory Diagnosis of Emerging Human Coronavirus Infections The State of the Art Emerg Microbes Infect 2020 Mar 20 1 26 Authors Loeffelholz MJ Tang YW Abstract The three unprecedented outbreaks of emerging human coronavirus HCoV infections at the beginning of 21st century have highlighted the necessity for readily available accurate and fast diagnostic testing methods The laboratory diagnostic methods for human coronavirus infections have evolved substantially with the development of novel assays as well as the availability of updated tests for emerging ones Newer laboratory methods are fast highly sensitive and specific and are gradually replacing the conventional gold standards This presentation reviews the current laboratory methods available for testing coronaviruses by focusing on the coronavirus disease 2019 COVID 19 outbreak going on in Wuhan Viral pneumonias typically do not result in the production of purulent sputum Thus a nasopharyngeal swab is usually the collection method used to obtain a specimen for testing Nasopharyngeal specimens may miss some infections a deeper specimen may need to be obtained by bronchoscopy Alternatively repeated testing can be used because over time the likelihood of the SARS CoV 2 being present in the nasal pharynx increases Several integrated random access point of care molecular devices are currently under development for fast and accurate diagnosis of SARS CoV 2 infections These assays are simple fast and safe and can be used in the local hospitals and clinics bearing the burden of identifying and treating patients PMID 32196430 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32196430?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 09:34:17'),
(74, 'Diagnostic Value of Chest CT in Coronavirus Disease 2019 (COVID-19).', 'Related Articles Diagnostic Value of Chest CT in Coronavirus Disease 2019 COVID 19 Curr Med Imaging 2020 Mar 20 Authors Sun Z PMID 32196453 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32196453?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 09:34:28'),
(75, 'Supporting Clinicians During the COVID-19 Pandemic.', 'Related Articles Supporting Clinicians During the COVID 19 Pandemic Ann Intern Med 2020 Mar 20 Authors Dewey C Hingle S Goelz E Linzer M PMID 32196544 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32196544?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 09:34:42'),
(76, 'Point-of-Care Lung Ultrasound findings in novel coronavirus disease-19 pnemoniae: a case report and potential applications during COVID-19 outbreak.', 'Related Articles Point of Care Lung Ultrasound findings in novel coronavirus disease 19 pnemoniae a case report and potential applications during COVID 19 outbreak Eur Rev Med Pharmacol Sci 2020 Mar 24 5 2776 2780 Authors Buonsenso D Piano A Raffaelli F Bonadia N de Gaetano Donati K Franceschi F Abstract An outbreak of a novel coronavirus disease 19 nCoV 19 infection began in December 2019 in Wuhan China and now involved the whole word Several health workers have been infected in different countries We report the case of a young man with documented nCoV 19 infection evaluated with lung ultrasound and discuss potential applications of lung ultrasound in this setting Lung ultrasound allowed the identification of nCoV 19 infection at bed side Moreover lung ultrasound can have several other advantages such as reduced health worker exposition to infected patients repeatability during follow up low costs and easier application in low resource settings PMID 32196627 PubMed in process', 'https://www.ncbi.nlm.nih.gov/pubmed/32196627?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 09:34:58'),
(77, 'Eleven Faces of Coronavirus Disease 2019.', 'Related Articles Eleven Faces of Coronavirus Disease 2019 Allergy 2020 Mar 20 Authors Dong X Cao YY Lu XX Zhang JJ Du H Yan YQ Akdis CA Gao YD Abstract BACKGROUND AND AIMS The outbreak of coronavirus disease 2019 COVID 19 caused by severe acute respiratory syndrome coronavirus 2 SARS CoV 2 infection has recently spread worldwide and been declared a pandemic We aim to describe here the various clinical presentations of this disease by examining eleven cases METHODS Electronic medical records of 11 patients with COVID 19 were collected and demographics clinical manifestations outcomes key laboratory results and radiological images are discussed RESULTS The clinical course of the eleven cases demonstrated the complexity of the COVID 19 profile with different clinical presentations Clinical manifestations range from asymptomatic cases to patients with mild and severe symptoms with or without pneumonia Laboratory detection of the viral nucleic acid can yield false negative results and serological testing of virus specific IgG and IgM antibodies should be used as an alternative for diagnosis Patients with common allergic diseases did not develop distinct symptoms and severe courses Cases with a pre existing condition of chronic obstructive pulmonary disease or complicated with a secondary bacterial pneumonia were more severe CONCLUSION All different clinical characteristics of COVID 19 should be taken into consideration to identify patients that need to be in strict quarantine for the efficient containment of the pandemic PMID 32196678 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32196678?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 09:35:17'),
(78, 'COVID-19 in pregnant women.', 'Related Articles COVID 19 in pregnant women Lancet Infect Dis 2020 Mar 17 Authors Schmid MB Fontijn J Ochsenbein K lble N Berger C Bassler D PMID 32197098 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32197098?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 09:36:16'),
(79, 'Will COVID-19 be a litmus test for post-Ebola Sub-Saharan Africa?', 'Related Articles Will COVID 19 be a litmus test for post Ebola Sub Saharan Africa J Med Virol 2020 Mar 20 Authors Agyeman AA Laar A Ofori Asenso R Abstract In 2014 the worst outbreak of Ebola virus disease EVD emerged in sub Saharan Africa SSA causing fear and panic The outbreak which started in Guinea quickly moved across to Sierra Leone and Liberia With an average EVD case fatality rate of around 50 range 25 90 there were many casualties and the number of recorded deaths exceeded 11 300 by June 2016 1 This article is protected by copyright All rights reserved PMID 32196700 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32196700?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 09:36:23'),
(80, 'The clinical characteristics of pneumonia patients co-infected with 2019 novel coronavirus and influenza virus in Wuhan, China.', 'Related Articles The clinical characteristics of pneumonia patients co infected with 2019 novel coronavirus and influenza virus in Wuhan China J Med Virol 2020 Mar 20 Authors Ding Q Lu P Fan Y Xia Y Liu M Abstract The outbreak of 2019 novel coronavirus COVID 19 infection emerged in Wuhan China on December 2019 Since then the novel coronavirus pneumonia disease has been spreading quickly and many countries and territories have been affected with major outbreaks in China South Korea Italy and Iran Influenza virus has been known as a common pathogen in winter and it can cause pneumonia It was found clinically that very few patients were diagnosed with both COVID 19 and influenza virus 5 out of the 115 patients confirmed with COVID 19 were also diagnosed with influenza virus infection with three cases being influenza A and two cases being influenza B In this study we describe the clinical characteristics of those patients who got infected with COVID 19 as well as influenza virus Common symptoms at onset of illness included fever 5 100 patients Cough 5 100 patients shortness of breath 5 100 patients nasal tampon 3 60 patients pharyngalgia 3 60 patients myalgia 2 40 patients fatigue 2 40 patients headache 2 40 patients and expectoration 2 40 patients The laboratory results showed that compared to the normal values the patients lymphocytes were reduced 4 80 patients and liver function ALT and AST 2 40 patients 2 40 patients and C reactive protein 4 80 patients were increased when admitted to hospital They stayed in hospital for 14 30 17 12 and 19 days 28 4 7 02 respectively The main complications for the patients were acute respiratory distress syndrome ARDS 1 20 patients acute liver injury 3 60 patients and diarrhea 2 40 patients All patients were given antiviral therapy including oseltamivir oxygen inhalation and antibiotics Three patients were treated with glucocorticoids including two treated with oral glucocorticoids One of the five patients had transient hemostatic medication for hemoptysis Fortunately all patients did not need ICU care and were discharged from hospital without death In conclusion those patients with both COVID 19 and influenza virus infection did not appear to show a more severe condition because based on the laboratory findings imaging studies and patient prognosis they showed similar clinical characteristics as those patients with COVID 19 infection only However it is worth noting that the symptoms of nasal tampon and pharyngalgia may be more prone to appear for those co infection patients This article is protected by copyright All rights reserved PMID 32196707 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32196707?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 09:36:29'),
(81, 'Coronaviruses and immunosuppressed patients. The facts during the third epidemic.', 'Related Articles Coronaviruses and immunosuppressed patients The facts during the third epidemic Liver Transpl 2020 Mar 20 Authors D Antiga L Abstract Following the outbreak in China the Lombardy region of Italy has become one of the areas of highest incidence of severe acute respiratory syndrome Coronavirus 2 SARS CoV 2 As the outbreak grew to a pandemic many centres worldwide raised the concern that immunocompromised patients may be at high risk of developing a severe respiratory disease called COVID 19 Unlike common viral agents such as Adenovirus Rhinovirus Norovirus Influenza Respiratory Syncytial Virus Coronaviruses have not shown to cause a more severe disease in immunosuppressed patients For this family of viruses the host innate immune response appears the main driver of lung tissue damage during infection PMID 32196933 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32196933?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 09:36:33'),
(82, 'Navigating Coronavirus Disease 2019 (Covid-19) in Physiatry: A CAN report for Inpatient Rehabilitation Facilities.', 'Related Articles Navigating Coronavirus Disease 2019 Covid 19 in Physiatry A CAN report for Inpatient Rehabilitation Facilities PM R 2020 Mar 20 Authors McNeary L Maltser S Verduzco Gutierrez M Abstract We are facing a global pandemic in relation to coronavirus disease 2019 Covid 19 Emergency preparedness plans often do not consider issues specific to inpatient rehabilitation facilities The CAN model can be used to prepare for natural disasters including the COVID 19 pandemic This report was created to aid specialists in acute Inpatient Rehabilitation Facilities This article is protected by copyright All rights reserved PMID 32196983 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32196983?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 09:36:39'),
(83, 'Clinical features in pediatric COVID-19.', 'Related Articles Clinical features in pediatric COVID 19 Pediatr Pulmonol 2020 Mar 20 Authors Yasri S Wiwanitkit V PMID 32196995 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32196995?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 09:36:50'),
(84, 'Covid-19 and the Stiff Upper Lip - The Pandemic Response in the United Kingdom.', 'Related Articles Covid 19 and the Stiff Upper Lip The Pandemic Response in the United Kingdom N Engl J Med 2020 Mar 20 Authors Hunter DJ PMID 32197002 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32197002?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 09:36:57'),
(85, 'Early Introduction of Severe Acute Respiratory Syndrome Coronavirus 2 into Europe.', 'Related Articles Early Introduction of Severe Acute Respiratory Syndrome Coronavirus 2 into Europe Emerg Infect Dis 2020 Mar 20 26 7 Authors Olsen SJ Chen MY Liu YL Witschi M Ardoin A Calba C Mathieu P Masserey V Maraglino F Marro S Penttinen P Robesyn E Pukkila J European COVID 19 Work Group Abstract Early infections with severe acute respiratory syndrome coronavirus 2 in Europe were detected in travelers from Wuhan China in January 2020 In 1 tour group 5 of 30 members were ill 3 cases were laboratory confirmed In addition a healthcare worker was infected This event documents early importation and subsequent spread of the virus in Europe PMID 32197059 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32197059?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 09:37:06'),
(86, 'Rhabdomyolysis as Potential Late Complication Associated with COVID-19.', 'Related Articles Rhabdomyolysis as Potential Late Complication Associated with COVID 19 Emerg Infect Dis 2020 Mar 20 26 7 Authors Jin M Tong Q Abstract We describe a patient in Wuhan China with severe acute respiratory syndrome coronavirus 2 infection who had progressive pulmonary lesions and rhabdomyolysis with manifestations of lower limb pain and fatigue Rapid clinical recognition of rhabdomyolysis symptoms in patients with severe acute respiratory syndrome coronavirus 2 infection can be lifesaving PMID 32197060 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32197060?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:13:29'),
(87, 'Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak.', 'Related Articles Probable Pangolin Origin of SARS CoV 2 Associated with the COVID 19 Outbreak Curr Biol 2020 Mar 13 Authors Zhang T Wu Q Zhang Z Abstract An outbreak of coronavirus disease 2019 COVID 19 caused by the 2019 novel coronavirus SARS CoV 2 began in the city of Wuhan in China and has widely spread worldwide Currently it is vital to explore potential intermediate hosts of SARS CoV 2 to control COVID 19 spread Therefore we reinvestigated published data from pangolin lung samples from which SARS CoV like CoVs were detected by Liu et al 1 We found genomic and evolutionary evidence of the occurrence of a SARS CoV 2 like CoV named Pangolin CoV in dead Malayan pangolins Pangolin CoV is 91 02 and 90 55 identical to SARS CoV 2 and BatCoV RaTG13 respectively at the whole genome level Aside from RaTG13 Pangolin CoV is the most closely related CoV to SARS CoV 2 The S1 protein of Pangolin CoV is much more closely related to SARS CoV 2 than to RaTG13 Five key amino acid residues involved in the interaction with human ACE2 are completely consistent between Pangolin CoV and SARS CoV 2 but four amino acid mutations are present in RaTG13 Both Pangolin CoV and RaTG13 lost the putative furin recognition sequence motif at S1 S2 cleavage site that can be observed in the SARS CoV 2 Conclusively this study suggests that pangolin species are a natural reservoir of SARS CoV 2 like CoVs PMID 32197085 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32197085?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:13:51'),
(88, 'COVID-19 in pregnant women - Authors\' reply.', 'Related Articles COVID 19 in pregnant women Authors reply Lancet Infect Dis 2020 Mar 17 Authors Baud D Giannoni E Pomar L Qi X Nielsen Saines K Musso D Favre G PMID 32197096 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32197096?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:13:36'),
(89, 'Autopsy in suspected COVID-19 cases.', 'Related Articles Autopsy in suspected COVID 19 cases J Clin Pathol 2020 Mar 20 Authors Hanley B Lucas SB Youd E Swift B Osborn M Abstract The severe acute respiratory syndrome SARS coronavirus 2 CoV 2 outbreak in Wuhan China has now spread to many countries across the world including the UK with over 3000 deaths as of early March 2020 This will inevitably lead to an increase in the number of suspected coronavirus disease 2019 COVID 19 related deaths at autopsy The Royal College of Pathologists has responded to this concern with the release of guidelines on autopsy practice relating to COVID 19 The following article is a summary and interpretation of these guidelines It includes a description of hazard group 3 organisms to which SARS CoV 2 has been assigned a brief description of what is currently known about the pathological and autopsy findings in COVID 19 a summary of the recommendations for conducting autopsies in suspected COVID 19 cases and the techniques for making the diagnosis at autopsy It concludes by considering the clinicopathological correlation and notification of such cases PMID 32198191 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198191?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:13:41'),
(90, 'Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.', 'Related Articles Crystal structure of SARS CoV 2 main protease provides a basis for design of improved ketoamide inhibitors Science 2020 Mar 20 Authors Zhang L Lin D Sun X Curth U Drosten C Sauerhering L Becker S Rox K Hilgenfeld R Abstract The COVID 19 pandemic caused by SARS CoV 2 is a global health emergency An attractive drug target among coronaviruses is the main protease Mpro 3CLpro due to its essential role in processing the polyproteins that are translated from the viral RNA We report the X ray structures of the unliganded SARS CoV 2 Mpro and its complex with an ketoamide inhibitor This was derived from a previously designed inhibitor but with the P3 P2 amide bond incorporated into a pyridone ring to enhance the half life of the compound in plasma Based on the structure we developed the lead compound into a potent inhibitor of the SARS CoV 2 Mpro The pharmacokinetic characterization of the optimized inhibitor reveals a pronounced lung tropism and suitability for administration by the inhalative route PMID 32198291 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198291?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:13:45'),
(91, 'Mental Health Strategies to Combat the Psychological Impact of COVID-19 Beyond Paranoia and Panic.', 'Related Articles Mental Health Strategies to Combat the Psychological Impact of COVID 19 Beyond Paranoia and Panic Ann Acad Med Singapore 2020 Jan 49 1 1 3 Authors Ho CS Chee CY Ho RC PMID 32200399 PubMed in process', 'https://www.ncbi.nlm.nih.gov/pubmed/32200399?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:14:52'),
(92, 'Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses.', 'Related Articles Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses Biochem Biophys Res Commun 2020 Mar 18 Authors Qi F Qian S Zhang S Zhang Z Abstract The new coronavirus SARS CoV 2 outbreak from December 2019 in Wuhan Hubei China has been declared a global public health emergency Angiotensin I converting enzyme 2 ACE2 is the host receptor by SARS CoV 2 to infect human cells Although ACE2 is reported to be expressed in lung liver stomach ileum kidney and colon its expressing levels are rather low especially in the lung SARS CoV 2 may use co receptors auxiliary proteins as ACE2 partner to facilitate the virus entry To identify the potential candidates we explored the single cell gene expression atlas including 119 cell types of 13 human tissues and analyzed the single cell co expression spectrum of 51 reported RNA virus receptors and 400 other membrane proteins Consistent with other recent reports we confirmed that ACE2 was mainly expressed in lung AT2 liver cholangiocyte colon colonocytes esophagus keratinocytes ileum ECs rectum ECs stomach epithelial cells and kidney proximal tubules Intriguingly we found that the candidate co receptors manifesting the most similar expression patterns with ACE2 across 13 human tissues are all peptidases including ANPEP DPP4 and ENPEP Among them ANPEP and DPP4 are the known receptors for human CoVs suggesting ENPEP as another potential receptor for human CoVs We also conducted CellPhoneDB analysis to understand the cell crosstalk between CoV targets and their surrounding cells across different tissues We found that macrophages frequently communicate with the CoVs targets through chemokine and phagocytosis signaling highlighting the importance of tissue macrophages in immune defense and immune pathogenesis PMID 32199615 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32199615?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:15:01'),
(93, 'The global community needs to swiftly ramp up the response to contain COVID-19.', 'Related Articles The global community needs to swiftly ramp up the response to contain COVID 19 Lancet 2020 Mar 19 Authors Fisher D Wilder Smith A PMID 32199470 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32199470?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:15:15'),
(94, 'COVID-19 and the consequences of isolating the elderly.', 'Related Articles COVID 19 and the consequences of isolating the elderly Lancet Public Health 2020 Mar 19 Authors Armitage R Nellums LB PMID 32199471 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32199471?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:15:28'),
(95, 'COVID-19: protecting health-care workers.', 'Related Articles COVID 19 protecting health care workers Lancet 2020 Mar 21 395 10228 922 Authors The Lancet PMID 32199474 PubMed in process', 'https://www.ncbi.nlm.nih.gov/pubmed/32199474?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:15:43'),
(96, 'Offline: COVID-19-a reckoning.', 'Related Articles Offline COVID 19 a reckoning Lancet 2020 Mar 21 395 10228 935 Authors Horton R PMID 32199478 PubMed in process', 'https://www.ncbi.nlm.nih.gov/pubmed/32199478?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:15:59'),
(97, 'Canada and COVID-19: learning from SARS.', 'Related Articles Canada and COVID 19 learning from SARS Lancet 2020 Mar 21 395 10228 936 937 Authors Webster P PMID 32199479 PubMed in process', 'https://www.ncbi.nlm.nih.gov/pubmed/32199479?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:14:21'),
(98, 'Viral dynamics in mild and severe cases of COVID-19.', 'Related Articles Viral dynamics in mild and severe cases of COVID 19 Lancet Infect Dis 2020 Mar 19 Authors Liu Y Yan LM Wan L Xiang TX Le A Liu JM Peiris M Poon LLM Zhang W PMID 32199493 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32199493?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:14:33'),
(99, 'Estimation of COVID-19 outbreak size in Italy.', 'Related Articles Estimation of COVID 19 outbreak size in Italy Lancet Infect Dis 2020 Mar 19 Authors Tuite AR Ng V Rees E Fisman D PMID 32199494 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32199494?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:14:13'),
(100, 'Patients with mental health disorders in the COVID-19 epidemic.', 'Related Articles Patients with mental health disorders in the COVID 19 epidemic Lancet Psychiatry 2020 Apr 7 4 e21 Authors Yao H Chen JH Xu YF PMID 32199510 PubMed in process', 'https://www.ncbi.nlm.nih.gov/pubmed/32199510?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:14:01'),
(101, 'Mental health care for international Chinese students affected by the COVID-19 outbreak.', 'Related Articles Mental health care for international Chinese students affected by the COVID 19 outbreak Lancet Psychiatry 2020 Apr 7 4 e22 Authors Zhai Y Du X PMID 32199511 PubMed in process', 'https://www.ncbi.nlm.nih.gov/pubmed/32199511?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:21:38');
INSERT INTO `rss_articles` (`id`, `title`, `body`, `href`, `rss_id`, `status`, `created_at`, `updated_at`) VALUES
(102, 'The characteristics and clinical value of chest CT images of novel coronavirus pneumonia.', 'Related Articles The characteristics and clinical value of chest CT images of novel coronavirus pneumonia Clin Radiol 2020 Mar 19 Authors Zhao X Liu B Yu Y Wang X Du Y Gu J Wu X Abstract AIM To investigate the characteristics and clinical value of chest computed tomography CT images of novel coronavirus pneumonia NCP MATERIALS AND METHODS Clinical data and CT images of 80 cases of NCP were collected The clinical manifestations and laboratory test results of the patients were analysed The lesions in each lung segment of the patient s chest CT images were characterised Lesions were scored according to length and diffusivity RESULTS The main clinical manifestations were fever dry cough fatigue a little white sputum or diarrhoea A total of 1 702 scored lesions were found in the first chest CT images of 80 patients The lesions were located mainly in the subpleural area of the lungs 92 4 Most of the lesions were ground glass opacity and subsequent fusions could increase in range and spread mainly in the subpleural area Pulmonary consolidation accounted for 44 1 of all of the lesions Of the 80 cases 76 patients 95 had bilateral lung disease four 5 patients had unilateral lung disease and eight 10 patients had cord shadow CONCLUSION The chest CT of NCP patients is characterised by the onset of bilateral ground glass lesions located in the subpleural area of the lung and progressive lesions that result in consolidation with no migratory lesions Pleural effusions and mediastinal lymphadenopathy are rare As patients can have inflammatory changes in the lungs alongside a negative early nucleic acid test chest CT in combination with epidemiological and laboratory tests is a useful examination to evaluate the disease and curative effect PMID 32199619 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32199619?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:23:43'),
(103, 'Responding to the COVID-19 pandemic in complex humanitarian crises.', 'Related Articles Responding to the COVID 19 pandemic in complex humanitarian crises Int J Equity Health 2020 Mar 21 19 1 41 Authors Poole DN Escudero DJ Gostin LO Leblang D Talbot EA PMID 32199457 PubMed in process', 'https://www.ncbi.nlm.nih.gov/pubmed/32199457?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:18:17'),
(104, 'The outbreak of Coronavirus Disease 2019 (COVID-19)-An emerging global health threat.', 'Related Articles The outbreak of Coronavirus Disease 2019 COVID 19 An emerging global health threat J Infect Public Health 2020 Mar 18 Authors Arshad Ali S Baloch M Ahmed N Arshad Ali A Iqbal A Abstract The outbreak of Coronavirus Disease 2019 COVID 19 causing novel coronavirus infected pneumonia NCIP has affected the lives of 71 429 people globally Originating in China the disease has a rapid progression to other countries Research suggests remarkable genomic resemblance of 2019 nCoV with Severe Acute Respiratory Syndrome SARS which has a history of a pandemic in 2002 With evidence of nosocomial spread a number of diligent measures are being employed to constrain its propagation Hence the Public Health Emergency of International Concern PHEIC has been established by the World Health Organization WHO with strategic objectives for public health to curtail its impact on global health and economy PMID 32199792 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32199792?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:20:23'),
(105, 'Clinical characteristics of novel coronavirus disease 2019 (COVID-19) in newborns, infants and children.', 'Related Articles Clinical characteristics of novel coronavirus disease 2019 COVID 19 in newborns infants and children Pediatr Neonatol 2020 Mar 10 Authors Hong H Wang Y Chung HT Chen CJ PMID 32199864 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32199864?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:20:19'),
(106, 'Global epidemiology of coronavirus disease 2019: disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status.', 'Related Articles Global epidemiology of coronavirus disease 2019 disease incidence daily cumulative index mortality and their association with country healthcare resources and economic status Int J Antimicrob Agents 2020 Mar 18 105946 Authors Lai CC Wang CY Wang YH Hsueh SC Ko WC Hsueh PR Abstract It has been 2 months since the first case of coronavirus disease 2019 COVID 19 was reported in Wuhan So far COVID 19 has affected 84 503 patients in 57 countries territories and caused 2 924 deaths in nine countries However the epidemiology data differ across countries Although China had higher morbidity and mortality than other sites the number of new cases per day in China is lesser than that outside of China since February 26 2020 The incidence ranged from 61 4 per 1 000 000 people in Republic of Korea to 0 0002 per 1 000 000 people in India The daily cumulative index DCI of COVID 19 cumulative cases no of days between the first reported case and February 29 2020 was greatest in China 1 320 85 per day followed by Republic of Korea 78 78 per day Iran 43 11 per day and Italy 30 62 per day However the DCI in other countries territories were less than 10 per day Several effective measures including restricting travel from China controlling the distribution of masks extensive investigation of COVID 19 spread and at once daily press conference by government to inform and educate people were aggressively conducted in Taiwan This is probably the reason why there was only 39 cases as of February 29 2020 with a DCI of 1 case per day in Taiwan which was much lower than that of nearby countries such as Republic of Korea and Japan Additionally the incidence and mortality were correlated with DCI However further study and continued monitoring are needed to better understand the underlying mechanism of COVID 19 PMID 32199877 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32199877?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:20:58'),
(107, 'Effect of gastrointestinal symptoms on patients infected with COVID-19.', 'Related Articles Effect of gastrointestinal symptoms on patients infected with COVID 19 Gastroenterology 2020 Mar 18 Authors Zhou Z Zhao N Shu Y Han S Chen B Shu X PMID 32199880 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32199880?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:20:28'),
(108, 'Should biologics for psoriasis be interrupted in the era of COVID-19?', 'Related Articles Should biologics for psoriasis be interrupted in the era of COVID 19 J Am Acad Dermatol 2020 Mar 18 Authors Lebwohl M Rivera Oyola R Murrell DF PMID 32199889 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32199889?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:22:33'),
(109, 'Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From ACC\'s Interventional Council and SCAI.', 'Related Articles Catheterization Laboratory Considerations During the Coronavirus COVID 19 Pandemic From ACC s Interventional Council and SCAI J Am Coll Cardiol 2020 Mar 16 Authors Welt FGP Shah PB Aronow HD Bortnick AE Henry TD Sherwood MW Young MN Davidson LJ Kadavath S Mahmud E Kirtane AJ American College of Cardiology s ACC Interventional Council and the Society of Cardiovascular Angiography and Intervention SCAI PMID 32199938 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32199938?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:21:53'),
(110, 'COVID-19 OUTBREAK IN NORTHERN ITALY: FIRST PRACTICAL INDICATIONS FOR RADIOTHERAPY DEPARTMENTS.', 'Related Articles COVID 19 OUTBREAK IN NORTHERN ITALY FIRST PRACTICAL INDICATIONS FOR RADIOTHERAPY DEPARTMENTS Int J Radiat Oncol Biol Phys 2020 Mar 18 Authors Filippi AR Russi E Magrini SM Corv R PMID 32199941 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32199941?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:21:51'),
(111, '[Infection with SARS-CoV-2 in pregnancy. Information and proposed care. CNGOF.]', 'Related Articles Infection with SARS CoV 2 in pregnancy Information and proposed care CNGOF Gynecol Obstet Fertil Senol 2020 Mar 18 Authors Peyronnet V Sibiude J Deruelle P Huissoud C Lescure X Lucet JC Mandelbrot L Nisand I Vayssi re C Yazpandanah Y Luton D Picone O Abstract A new coronavirus SARS CoV 2 highlighted at the end of 2019 in China is spreading across all continents Most often at the origin of a mild infectious syndrome associating mild symptoms fever cough myalgia headache and possible digestive disorders to different degrees SARS Covid 2 can cause serious pulmonary pathologies and sometimes death Data on the consequences during pregnancy are limited The first Chinese data published seem to show that the symptoms in pregnant women are the same as those of the general population There are no cases of intrauterine maternal fetal transmission but cases of newborns infected early suggest that there could be vertical perpartum or neonatal transmission Induced prematurity and cases of respiratory distress in newborns of infected mothers have been described Pregnancy is known as a period at higher risk for the consequences of respiratory infections as for influenza so it seems important to screen for Covid 19 in the presence of symptoms and to monitor closely pregnant women In this context of the SARS Covid 2 epidemic the societies of gynecology obstetrics infectious diseases and neonatalogy have proposed a French protocol for the management of possible and proven cases of SARS Covid 2 in pregnant women These proposals may evolve on a daily basis with the advancement of the epidemic and knowledge in pregnant women Subsequently an in depth analysis of cases in pregnant women will be necessary in order to improve knowledge on the subject PMID 32199996 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32199996?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:21:50'),
(112, 'SARS-CoV-2 turned positive in a discharged patient with COVID-19 arouses concern regarding the present standard for discharge.', 'Related Articles SARS CoV 2 turned positive in a discharged patient with COVID 19 arouses concern regarding the present standard for discharge Int J Infect Dis 2020 Mar 18 Authors Zhang JF Yan K Ye HH Lin J Zheng JJ Cai T Abstract An outbreak of COVID 19 in Wuhan China caused by SARS CoV 2 has led to a serious epidemic in China and other countries resulting in worldwide concern With the active efforts from prevention and control the quantity of discharged patients is escalating How to manage these patients normatively is still challenging We hereby reported an asymptomatic discharged patient with COVID 19 who was retested positive for SARS CoV 2 which arouses concern regarding the present discharge standard of COVID 19 PMID 32200109 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32200109?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:22:45'),
(113, 'The Novel Coronavirus (SARS-CoV-2) Epidemic.', 'Related Articles The Novel Coronavirus SARS CoV 2 Epidemic Ann Acad Med Singapore 2020 Jan 49 1 1 3 Authors Hsu LY Chia PY Lim JF PMID 32200398 PubMed in process', 'https://www.ncbi.nlm.nih.gov/pubmed/32200398?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:22:17'),
(114, 'Use of antiviral drugs to reduce COVID-19 transmission.', 'Related Articles Use of antiviral drugs to reduce COVID 19 transmission Lancet Glob Health 2020 Mar 19 Authors Mitj O Clotet B PMID 32199468 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32199468?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:22:00'),
(115, 'The emotional impact of Coronavirus 2019-nCoV (new Coronavirus disease).', 'Related Articles The emotional impact of Coronavirus 2019 nCoV new Coronavirus disease Psychiatry Res 2020 Mar 12 287 112915 Authors Lima CKT Carvalho PMM Lima IAAS Nunes JVAO Saraiva JS de Souza RI da Silva CGL Neto MLR Abstract BACKGROUND A novel form of Coronavirus 2019 nCoV in Wuhan has created a confused and rapidly evolving situation In this situational framework patients and front line healthcare workers are vulnerable METHOD Studies were identified using large circulation international journals found in two electronic databases Scopus and Embase RESULTS Populations of patients that may require tailored interventions are older adults and international migrant workers Older adults with psychiatric conditions may be experiencing further distress The COVID 19 epidemic has underscored potential gaps in mental health services during emergencies CONCLUSIONS Most health professionals working in isolation units and hospitals do not receive any training for providing mental health care Fear seems more certainly a consequence of mass quarantine PMID 32199182 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32199182?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:21:40'),
(116, 'Misguided drug advice for COVID-19.', 'Related Articles Misguided drug advice for COVID 19 Science 2020 Mar 20 Authors FitzGerald GA PMID 32198292 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198292?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:21:34'),
(117, 'COVID-19: a fast evolving pandemic.', 'Related Articles COVID 19 a fast evolving pandemic Trans R Soc Trop Med Hyg 2020 Mar 21 Authors Whitworth J PMID 32198918 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198918?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:22:29'),
(118, 'Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19).', 'Related Articles Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease COVID 19 Clin Infect Dis 2020 Mar 21 Authors Guo L Ren L Yang S Xiao M Chang Yang F Dela Cruz CS Wang Y Wu C Xiao Y Zhang L Han L Dang S Xu Y Yang Q Xu S Zhu H Xu Y Jin Q Sharma L Wang L Wang J Abstract BACKGROUND Emergence of coronavirus disease 2019 COVID 19 is a major healthcare threat Current method of detection involves qPCR based technique which identifies the viral nucleic acids when present in sufficient quantity False negative results can be achieved and failure to quarantine the infected patient would be a major setback in containing the viral transmission We here aim to describe the time kinetics of various antibodies produced against the 2019 novel coronavirus SARS CoV 2 and evaluate the potential of antibody testing to diagnose COVID 19 METHODS The host humoral response against SARS CoV 2 including IgA IgM and IgG response were examined by using an ELISA based assay on the recombinant viral nucleocapsid protein Total 208 plasma samples were collected from 82 confirmed and 58 probable cases qPCR negative but had typical manifestation The diagnostic value of IgM was evaluated in this cohort RESULTS The median duration of IgM and IgA antibody detection were 5 days IQR 3 6 while IgG was detected on 14 days IQR 10 18 after symptom onset with a positive rate of 85 4 92 7 and 77 9 respectively In confirmed and probable cases the positive rates of IgM antibodies were 75 6 and 93 1 respectively The detection efficiency by IgM ELISA is higher than that of qPCR method after 5 5 days of symptom onset The positive detection rate is significantly increased 98 6 when combined IgM ELISA assay with PCR for each patient compare with a single qPCR test 51 9 CONCLUSIONS Humoral response to SARS CoV 2 can aid to the diagnosis of COVID 19 including subclinical cases PMID 32198501 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198501?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:21:41'),
(119, 'The potential added value of FDG PET/CT for COVID-19 pneumonia.', 'Related Articles The potential added value of FDG PET CT for COVID 19 pneumonia Eur J Nucl Med Mol Imaging 2020 Mar 21 Authors Deng Y Lei L Chen Y Zhang W PMID 32198615 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198615?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:21:48'),
(120, '2019 novel Coronavirus outbreak: a quiz or final exam?', 'Related Articles 2019 novel Coronavirus outbreak a quiz or final exam Front Med 2020 Mar 20 Authors Xu J Chen Y Chen H Cao B Abstract The 2019 novel Coronavirus 2019 nCoV is an emerging pathogen and is threatening the global health Strikingly more than 28 000 cases and 550 deaths have been reported within two months from disease emergence Armed with experience from previous epidemics in the last two decades clinicians scientists officials and citizens in China are all contributing to the prevention of further 2019 nCoV transmission Efficient preliminary work has enabled us to understand the basic characteristics of 2019 nCoV but there are still many unanswered questions It is too early now to judge our performance in this outbreak Continuous and strengthened efforts should be made not only during the epidemic but also afterwards in order to prepare for any incoming challenges PMID 32198708 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198708?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:20:53'),
(121, 'A Unique Protease Cleavage Site Predicted in the Spike Protein of the Novel Pneumonia Coronavirus (2019-nCoV) Potentially Related to Viral Transmissibility.', 'Related Articles A Unique Protease Cleavage Site Predicted in the Spike Protein of the Novel Pneumonia Coronavirus 2019 nCoV Potentially Related to Viral Transmissibility Virol Sin 2020 Mar 20 Authors Wang Q Qiu Y Li JY Zhou ZJ Liao CH Ge XY PMID 32198713 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198713?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:21:47'),
(122, 'Prepare to adapt: Blood supply and transfusion support during the first 2 weeks of the 2019 Novel Coronavirus (COVID-19) pandemic affecting Washington State.', 'Related Articles Prepare to adapt Blood supply and transfusion support during the first 2 weeks of the 2019 Novel Coronavirus COVID 19 pandemic affecting Washington State Transfusion 2020 Mar 21 Authors Pagano MB Hess JR Tsang HC Staley E Gernsheimer T Sen N Clark C Nester T Bailey C Alcorn K Abstract BACKGROUND The first coronavirus COVID 19 case was reported in United States US in the state of Washington approximately three months after the outbreak in Wuhan China Three weeks later the US federal government declared the pandemic a national emergency The number of confirmed COVID 19 positive cases increased rather rapidly and changed routine daily activities of the community STUDY DESIGN AND METHODS This brief report describes the response from the hospital the regional blood center and the hospital based transfusion services to the events that took place in the community during the initial phases of the pandemic RESULTS In Washington State the first week of March started with 4 confirmed cases and ended with 150 by the end of the second week of March there were more than 700 cases of confirmed COVID 19 During the first week blood donations dropped significantly Blood units provided from blood centers of non affected areas of the country helped keep inventory stable and allow for routine hospital operations The hospital based transfusion service began prospective triaging of blood orders to monitor and prioritize blood utilization In the second week blood donations recovered and the hospital postponed elective procedures to ensure staff and personal protective equipment were appropriate for the care of critical patients CONCLUSION As community activities are disrupted and hospital activities switch from routine operations to pandemic focused and urgent care oriented the blood supply and utilization requires a number of transformations PMID 32198754 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198754?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:21:57'),
(123, 'Is there a role for lung ultrasound during the COVID-19 pandemic?', 'Related Articles Is there a role for lung ultrasound during the COVID 19 pandemic J Ultrasound Med 2020 Mar 20 Authors Soldati G Smargiassi A Inchingolo R Buonsenso D Perrone T Briganti DF Perlini S Torri E Mariani A Mossolani EE Tursi F Mento F Demi L PMID 32198775 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198775?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:21:56'),
(124, 'Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing.', 'Related Articles Clinical Features and Treatment of COVID 19 Patients in Northeast Chongqing J Med Virol 2020 Mar 21 Authors Wan S Xiang Y Fang W Zheng Y Li B Hu Y Lang C Huang D Sun Q Xiong Y Huang X Lv J Luo Y Shen L Yang H Huang G Yang R Abstract BACKGROUND The outbreak of the novel coronavirus in China SARS CoV 2 that began in December 2019 presents a significant and urgent threat to global health This study was conducted to provide the international community with a deeper understanding of this new infectious disease METHODS Epidemiological clinical features laboratory findings radiological characteristics treatment and clinical outcomes of 135 patients in northeast Chongqing were collected and analyzed in this study RESULTS A total of 135 hospitalized patients with COVID 19 were enrolled The median age was 47 years IQR 36 55 and there was no significant gender difference 53 3 men The majority of patients had contact with people from the Wuhan area Forty three 31 9 patients had underlying disease primarily hypertension 13 9 6 diabetes 12 8 9 cardiovascular disease 7 5 2 and malignancy 4 3 0 Common symptoms included fever 120 88 9 cough 102 76 5 and fatigue 44 32 5 Chest CT scans showed bilateral patchy shadows or ground glass opacity in the lungs of all of the patients All of the patients received antiviral therapy 135 100 Kaletra and interferon were both used antibacterial therapy 59 43 7 and corticosteroids 36 26 7 In addition many patients received traditional Chinese medicine 124 91 8 It is suggested that patients should receive Kaletra early and should be treated by a combination of western and Chinese medicine Compared with the mild cases the severe cases had lower lymphocyte counts and higher plasma levels of Pt APTT D dimer LDH PCT ALB CRP and AST CONCLUSION In this study the clinic features and therapies of 135 COVID 19 patients were demonstrated Kaletra and traditional Chinese medicine played an important role in the treatment of the viral pneumonia Further studies are required to explore the role of Kaletra and traditional Chinese medicine in the treatment of COVID 19 This article is protected by copyright All rights reserved PMID 32198776 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198776?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:22:37'),
(125, 'COVID-19: A Singapore Orthopedic resident\'s musings in the Emergency Department.', 'Related Articles COVID 19 A Singapore Orthopedic resident s musings in the Emergency Department Acad Emerg Med 2020 Mar 21 Authors Liang ZC Ooi SBS Abstract I felt my heart skip a beat as I took off my lead gown preparing to put in my post operative orders A transient wave of apprehension and I daresay fear swept past me that very moment It has been a good 8 years since I ve graduated medical school with nary an exposure to emergency medicine since my intern days I wasn t sure I could remember how to read an EKG accurately much less manage a patient in respiratory failure PMID 32198801 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198801?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:23:18'),
(126, 'Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation?', 'Related Articles Case report of COVID 19 in a kidney transplant recipient Does immunosuppression alter the clinical presentation Am J Transplant 2020 Mar 20 Authors Guillen E Pineiro GJ Revuelta I Rodriguez D Bodro M Moreno A Campistol JM Diekmann F Ventura Aguiar P Abstract COVID 19 is novel infectious disease with an evolving understanding of its epidemiology and clinical manifestations Immunocompromised patients often present atypical presentations of viral diseases Herein we report a case of a COVID 19 infection in a solid organ transplant recipient in which the first clinical symptoms were of gastrointestinal viral disease and fever which further progressed to respiratory symptoms in 48h In these high risk populations protocols for screening for SARS Cov2 may be needed to be re evaluated PMID 32198834 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198834?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:21:19'),
(127, '[When COVID-19 encounters interstitial lung disease: challenges and management].', 'Related Articles When COVID 19 encounters interstitial lung disease challenges and management Zhonghua Jie He He Hu Xi Za Zhi 2020 Mar 21 43 0 E039 Authors Ren YH Wang SY Liu M Guo YM Dai HP Abstract In December 2019 a new type of coronavirus pneumonia COVID 19 emerged in Wuhan Hubei and spread rapidly to China and over 100 countries around the world The lung injury and repair caused by COVID 19 has many similarities with the onset and progression of interstitial lung disease ILD Therefore it is difficult to distinguish between COVID 19 and some types of new onset ILD or other causes leading to acute exacerbation of ILD Clinicians need to comprehensively analyze the epidemic history disease onset characteristics clinical manifestations image characteristics serological andpathogenic microorganism test results to confirm diagnosis Because of this the article will discuss the issues related to the differential diagnosis and management of COVID 19 and ILD and try to provide reasonable suggestions PMID 32198915 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198915?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:23:35'),
(128, 'Guide to the Forensic Pathology Practice on Death Cases Related to Corona Virus Disease 2019 （COVID-19） （Trial Draft）.', 'Related Articles Guide to the Forensic Pathology Practice on Death Cases Related to Corona Virus Disease 2019 COVID 19 Trial Draft Fa Yi Xue Za Zhi 2020 Feb 25 36 1 6 5 Authors Mao DM Zhou N Zheng D Le JC Zhao QH Luo B Guan DW Zhou YW Hu BJ Cheng JD Abstract Abstract Autopsy is of great significance to the elucidation of the pathological changes pathogenesis and cause of death of corona virus disease 2019 COVID 19 and can provide theoretical basis for more scientific and accurate prevention and control of the outbreak Based on related laws and regulations such as Law of the People s Republic of China on Prevention and Control of Infectious Diseases the clinical manifestations and epidemiological characteristics of COVID 19 and the related guidelines on the prevention and control of the outbreak combined with the practical work of forensic pathology examination the Guide to the Forensic Pathology Practice on Death Cases Related to Corona Virus Disease 2019 COVID 19 Trial Draft has been developed This guide includes information on the background investigation of the cases autopsy room requirements personal prevention and protections external examinations autopsy auxiliary examinations and so on This guide can be used as a reference by forensic and pathological examination institutions as well as examination staff PMID 32198985 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198985?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:21:26'),
(129, 'Deciphering the power of isolation in controlling COVID-19 outbreaks.', 'Related Articles Deciphering the power of isolation in controlling COVID 19 outbreaks Lancet Glob Health 2020 Apr 8 4 e452 e453 Authors Niud Y Xu F PMID 32199105 PubMed in process', 'https://www.ncbi.nlm.nih.gov/pubmed/32199105?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:21:43'),
(130, 'Review and Prospect of Pathological Features of Corona Virus Disease.', 'Related Articles Review and Prospect of Pathological Features of Corona Virus Disease Fa Yi Xue Za Zhi 2020 Feb 25 36 1 16 20 Authors Wang HJ Du SH Yue X Chen CX Abstract Abstract Since 2003 coronavirus has caused multiple major public health events that resulted in global epidemics such as severe acute respiratory syndrome SARS Middle East respiratory syndrome MERS and corona virus disease 2019 COVID 19 Especially since COVID 19 has outbroken in Wuhan Hubei in December 2019 coronavirus has had a significant impact on people s health and lives But so far the pathological diagnosis of COVID 19 has been relatively deficient it is still confined to the pathological findings of punctured organs and the majority of medical workers have poor awareness of its pathological characteristics The COVID 19 as same as SARS and MERS is caused by coronaviruses and can cause viral pneumonia They have certain similarities This article comprehensively reviews the pathological features observed in the autopsies of the aforementioned three diseases in order to provide reference to the analysis of pathological changes of COVID 19 PMID 32198986 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198986?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:20:46'),
(131, 'Gross examination report of a COVID-19 death autopsy.', 'Related Articles Gross examination report of a COVID 19 death autopsy Fa Yi Xue Za Zhi 2020 Feb 25 36 1 21 23 Authors Liu Q Wang RS Qu GQ Wang YY Liu P Zhu YZ Fei G Ren L Zhou YW Liu L Abstract Abstract PMID 32198987 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198987?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:20:35'),
(132, 'Safety protection of forensic examination during the epidemic of COVID-19.', 'Related Articles Safety protection of forensic examination during the epidemic of COVID 19 Fa Yi Xue Za Zhi 2020 Feb 25 36 1 24 28 Authors Qiu H Wang HJ Chen QL Yue X Abstract Abstract PMID 32198988 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198988?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:20:39'),
(133, 'Protection of forensic scene investigation and postmortem examination during the epidemic period of COVID-19.', 'Related Articles Protection of forensic scene investigation and postmortem examination during the epidemic period of COVID 19 Fa Yi Xue Za Zhi 2020 Feb 25 36 1 29 34 Authors Pang HB Xu LM Niu Y Abstract Abstract PMID 32198989 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198989?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:20:42'),
(134, 'COVID-19 in Italy: momentous decisions and many uncertainties.', 'Related Articles COVID 19 in Italy momentous decisions and many uncertainties Lancet Glob Health 2020 Mar 18 Authors Lazzerini M Putoto G PMID 32199072 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32199072?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:23:00'),
(135, 'COVID-19 battle during the toughest sanctions against Iran.', 'Related Articles COVID 19 battle during the toughest sanctions against Iran Lancet 2020 Mar 18 Authors Takian A Raoofi A Kazempour Ardebili S PMID 32199073 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32199073?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 11:22:39'),
(136, 'Will COVID-19 generate global preparedness?', 'Related Articles Will COVID 19 generate global preparedness Lancet 2020 Mar 18 Authors Jacobsen KH PMID 32199074 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32199074?dopt=Abstract', 21, 'published', '2020-03-24 07:00:06', '2020-03-24 11:20:32'),
(137, 'Health security capacities in the context of COVID-19 outbreak: an analysis of International Health Regulations annual report data from 182 countries.', 'Related Articles Health security capacities in the context of COVID 19 outbreak an analysis of International Health Regulations annual report data from 182 countries Lancet 2020 Mar 18 Authors Kandel N Chungong S Omaar A Xing J Abstract BACKGROUND Public health measures to prevent detect and respond to events are essential to control public health risks including infectious disease outbreaks as highlighted in the International Health Regulations IHR In light of the outbreak of 2019 novel coronavirus disease COVID 19 we aimed to review existing health security capacities against public health risks and events METHODS We used 18 indicators from the IHR State Party Annual Reporting SPAR tool and associated data from national SPAR reports to develop five indices 1 prevent 2 detect 3 respond 4 enabling function and 5 operational readiness We used SPAR 2018 data for all of the indicators and categorised countries into five levels across the indices in which level 1 indicated the lowest level of national capacity and level 5 the highest We also analysed data at the regional level using the six geographical WHO regions FINDINGS Of 182 countries 52 28 had prevent capacities at levels 1 or 2 and 60 33 had response capacities at levels 1 or 2 81 45 countries had prevent capacities and 78 43 had response capacities at levels 4 or 5 indicating that these countries were operationally ready 138 76 countries scored more highly in the detect index than in the other indices 44 24 countries did not have an effective enabling function for public health risks and events including infectious disease outbreaks 7 4 at level 1 and 37 20 at level 2 102 56 countries had level 4 or level 5 enabling function capacities in place 32 18 countries had low readiness 2 1 at level 1 and 30 17 at level 2 and 104 57 countries were operationally ready to prevent detect and control an outbreak of a novel infectious disease 66 36 at level 4 and 38 21 at level 5 INTERPRETATION Countries vary widely in terms of their capacity to prevent detect and respond to outbreaks Half of all countries analysed have strong operational readiness capacities in place which suggests that an effective response to potential health emergencies could be enabled including to COVID 19 Findings from local risk assessments are needed to fully understand national readiness capacities in relation to COVID 19 Capacity building and collaboration between countries are needed to strengthen global readiness for outbreak control FUNDING None PMID 32199075 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32199075?dopt=Abstract', 21, 'published', '2020-03-24 07:00:06', '2020-03-24 11:22:23'),
(138, 'COVID-19 cacophony: is there any orchestra conductor?', 'Related Articles COVID 19 cacophony is there any orchestra conductor Lancet 2020 Mar 18 Authors Flahault A PMID 32199076 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32199076?dopt=Abstract', 21, 'published', '2020-03-24 07:00:06', '2020-03-24 11:21:58'),
(139, 'The resilience of the Spanish health system against the COVID-19 pandemic.', 'Related Articles The resilience of the Spanish health system against the COVID 19 pandemic Lancet Public Health 2020 Mar 18 Authors Legido Quigley H Mateos Garc a JT Campos VR Gea S nchez M Muntaner C McKee M PMID 32199083 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32199083?dopt=Abstract', 21, 'published', '2020-03-24 07:00:06', '2020-03-24 11:22:27'),
(140, 'SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?', 'Related Articles SARS CoV2 should inhibitors of the renin angiotensin system be withdrawn in patients with COVID 19 Eur Heart J 2020 Mar 20 Authors Kuster GM Pfister O Burkard T Zhou Q Twerenbold R Haaf P Widmer AF Osswald S PMID 32196087 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32196087?dopt=Abstract', 21, 'published', '2020-03-24 07:00:06', '2020-03-24 11:21:14'),
(141, 'New WHO recommendations to prevent tuberculosis aim to save millions of lives', 'Geneva New World Health Organization WHO guidance will help countries accelerate efforts to stop people with tuberculosis TB infection becoming sick with TB by giving them preventive treatment A quarter of the world s population is estimated to be infected with TB bacteria These people are neither sick nor contagious However they are at greater risk of developing TB disease especially those with weakened immunity Offering them TB preventive treatment will not only protect them from becoming sick but also cut down on the risk of transmission in the community As we mark World TB Day 2020 the disease remains the world s top infectious killer In 2018 10 million people fell ill with TB worldwide and 1 5 million people lost their lives to this disease COVID 19 is highlighting just how vulnerable people with lung diseases and weakened immune systems can be said Dr Tedros Adhanom Ghebreyesus WHO Director General The world committed to end TB by 2030 improving prevention is key to making this happen Millions of people need to be able to take TB preventive treatment to stop the onset of disease avert suffering and save lives Dr Tedros highlighted the importance to continue efforts to tackle longstanding health problems including TB during global outbreaks such as COVID 19 At the same time programmes already in place to combat TB and other major infectious diseases can be leveraged to make the response to COVID 19 more effective and rapid Although some progress has been made towards targets set at the UN high level Meeting on TB in 2018 TB preventive treatment has been largely neglected Global leaders committed to ensuring access to TB preventive treatment to at least 24 million contacts of people with active TB and 6 million people living with HIV by 2022 To date only a fraction of that target has been reached with countries putting less than 430 000 contacts and 1 8 million people on TB preventive treatment in 2018 TB remains the top cause of death among people with HIV TB preventive treatment works synergistically with antiretroviral therapy to prevent TB and save lives Reinvigorated efforts by governments health services partners donors and civil society will be needed to increase access to TB preventive treatment to the levels targeted The new consolidated guidelines recommend a range of innovative approaches to scale up access to TB preventive treatment WHO recommends a scale up of TB preventive treatment among populations at highest risk including household contacts of TB patients people living with HIV and other people at risk with lowered immunity or living in crowded settings WHO recommends an integration of TB preventive treatment services into ongoing case finding efforts for active TB All household contacts of TB patients and people living with HIV are recommended to be screened for active TB If active TB is ruled out they should be initiated on TB preventive treatment WHO recommends that either a tuberculin skin test or interferon gamma release assay IGRA be used to test for TB infection Both tests are helpful to find people more likely to benefit from TB preventive treatment but should not become a barrier to scale up access Testing for TB infection is not required before starting TB preventive treatment in people living with HIV and children under 5 years who are contacts of people with active TB WHO recommends new shorter options for preventive treatment in addition to the widely used 6 months of daily isoniazid The shorter options that are now recommended range from a 1 month daily regimen of rifapentine plus isoniazid to 3 months weekly rifapentine plus isoniazid 3 months daily rifampicin plus isoniazid or 4 months of daily rifampicin alone As people around the globe come together to commemorate World TB Day WHO is calling on governments affected communities civil society organizations health care providers donors partners and the industry to unite forces and step up the TB response notably for TB preventive treatment to ensure no one is left behind said Dr Tereza Kasaeva Director of WHO s Global TB Programme The new WHO guidance shows the way forward for millions to rapidly access new tools and shorter safer options for preventive treatment The time for action is now TB preventive treatment is an affordable intervention that can prevent families from sliding into poverty and preserve the health and economy of whole communities WHO anticipates that as new and safer drugs come onto the markets and as prices fall it will become a highly cost effective way to save millions of lives NOTES FOR EDITORS WORK BY WHO AND PARTNERS WHO works closely with Member States including the US Government and technical and funding partners such as UNITAID to enhance access to shorter TB preventive treatment regimens UNITAID supported projects such as IMPAACT4TB and Cap TB projects enabled by WHO with partners in Brazil Cambodia Cameroon C te d Ivoire Democratic Republic of Congo Ethiopia Ghana India Indonesia Kenya Lesotho Malawi Mozambique South Africa Uganda United Republic of Tanzania and Zimbabwe are leading the way The new treatment options are also now more affordable thanks to the significant price drop of rifapentine a key drug facilitated recently by UNITAID the Global Fund to Fight AIDS Tuberculosis and Malaria and global biopharmaceutical company Sanofi along with forthcoming arrangements underway with generic manufacturers MORE ABOUT THE GUIDELINES The new consolidated WHO guidelines come with an operational handbook to help guide countries step by step as they take TB preventive treatment to scale This includes guidance on how to prioritize and invest from demand creation for TB prevention to supervision and monitoring of the programme The guidelines and operational handbook are also accompanied by an innovative mobile application Prevent TB to help health care workers manage TB preventive treatment in their communities Its online dashboard allows programme managers to visualize and monitor data in real time The application can be customized by countries to suit their specific settings and is currently being adopted in India and Philippines WORLD TB DAY The new guidelines and tools are being released ahead of World TB Day World TB Day is observed on March 24 each year to raise public awareness and understanding about the world s deadliest infectious killer TB and its devastating health social and economic impact on people around the world Under the theme It s Time the spotlight this year is on urgently accelerating the TB response to save lives and end suffering', 'https://www.who.int/news-room/detail/24-03-2020-new-who-recommendations-to-prevent-tuberculosis-aim-to-save-millions-of-lives', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:03:19'),
(142, 'Pass the message: Five steps to kicking out coronavirus', 'Geneva 23 March 2020 FIFA the international governing body of football and the World Health Organization WHO have teamed up to combat the coronavirus COVID 19 by launching a new awareness campaign led by world renowned footballers who are calling on all people around the world to follow five key steps to stop the spread of the disease The Pass the message to kick out coronavirus campaign promotes five key steps for people to follow to protect their health in line with WHO guidance focused on hand washing coughing etiquette not touching your face physical distance and staying home if feeling unwell FIFA and its President Gianni Infantino have been actively involved in passing the message against this pandemic since the very beginning said WHO Director General Dr Tedros Adhanom Ghebreyesus at the virtual launch of the campaign at WHO headquarters in Geneva Switzerland Be it through campaigns or funding FIFA has stood up to the coronavirus and I am delighted that world football is supporting WHO to kick out the coronavirus I have no doubt with this type of support that together we will win We need teamwork to combat the coronavirus said FIFA President Gianni Infantino FIFA has teamed up with WHO because health comes first I call upon the football community worldwide to join us in supporting this campaign to pass the message even further Some of the greatest players to have played the beautiful game have put their names to the campaign and are united in their desire to pass the message to kick out COVID 19 Twenty eight players are involved in the video campaign which is being published in 13 languages Sami Al Jaber KSA Alisson Becker BRA Emre Bel zo lu TUR Jared Borgetti MEX Gianluigi Buffon ITA Iker Casillas ESP Sunil Chhetri IND Youri Djorkaeff FRA Han Duan CHN Samuel Eto o CMR Radamel Falcao COL Laura Georges FRA Valeri Karpin RUS Miroslav Klose GER Philipp Lahm GER Gary Lineker ENG Carli Lloyd USA Lionel Messi ARG Mido EGY Michael Owen ENG Park Ji sung KOR Carles Puyol ESP C lia a i GER Asako Takakura JPN Yaya Tour CIV Juan Sebasti n Ver n ARG Sun Wen CHN and Xavi Hern ndez ESP A video campaign which will be published on player and FIFA digital channels is also being provided as individual localized files to the 211 FIFA member associations and media agencies together with a graphics toolkit for implementation on social media to further pass the message Hands It starts with your hands says Alisson Becker WHO Goodwill ambassador for health promotion Liverpool FC and Brazil goalkeeper and The Best FIFA Men s Goalkeeper 2019 Please wash your hands frequently with soap and water or an alcohol based solution Such frequent washing with soap and water or preferably with an alcohol based hand solution kills viruses that may be on your hands It is simple but it is very important Elbows Cover your nose and mouth with a bent elbow or tissue when you sneeze or cough says Carli Lloyd two time FIFA Women s World Cup winner from the United States Dispose of tissue immediately and wash your hands Droplets spread the coronavirus By following respiratory hygiene you protect the people around you from contracting viruses such as cold flu and coronavirus Face Avoid touching your face particularly your eyes nose or mouth to prevent the virus from entering your body adds FC Barcelona and Argentina forward Lionel Messi The Best FIFA Men s Player in 2019 and a multiple FIFA Ballon d Or winner Hands touch too many surfaces and can quickly pick up viruses Once contaminated hands can transfer the virus to your face from where the virus can move inside your body making you feel unwell Distance In terms of social interaction take a step back says Han Duan who represented China PR 188 times in an international career that spanned 11 years Stay at least one metre distance from others By maintaining such social distancing you are helping to avoid breathing in any droplets from someone who sneezes or coughs in close proximity Feel know your symptoms If you feel unwell stay home concludes Samuel Eto o former FC Barcelona and Cameroon striker who represented his country 114 times Please follow all instructions provided by your local health authorities If you have a fever cough and difficulty breathing seek medical attention and call in advance Keep informed as local health authorities provide the latest information on the situation in your area Please follow their specific instructions and call in advance to allow them to direct you to the appropriate local health facility This serves to protect you and to help prevent the spread of virus and other infections FIFA have also pledged 10 million to support the COVID 19 Solidarity Response Fund for WHO For more information please consult WHO and follow the latest information online', 'https://www.who.int/news-room/detail/23-03-2020-pass-the-message-five-steps-to-kicking-out-coronavirus', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:03:39'),
(143, 'Dracunculiasis eradication: intensifying surveillance amid continued zero human cases in Ethiopia and Mali', 'In 2019 Ethiopia and Mali reported zero human cases of dracunculiasis guinea worm disease although the total number of human cases reported to the World Health Organization WHO last year peaked at 54 cases While surveillance activities have been stepped up in countries reporting cases hundreds more field workers and volunteers are being trained and cross border vigilance are being carried out to prevent transmission', 'https://www.who.int/news-room/detail/19-03-2020-dracunculiasis-eradication-intensifying-surveillance-amid-continued-zero-human-cases-in-ethiopia-and-mali', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:04:07'),
(144, 'CND accepts all WHO recommendations on the control of several psychoactive substances from the 42nd ECDD meeting', 'During its 63rd session the Commission on Narcotic Drugs CND accepted all recommendations from the 42nd meeting of the WHO Expert Committee on Drug Dependence ECDD', 'https://www.who.int/news-room/detail/18-03-2020-c-n-d-accepts-all-w-h-o-recommendations-from-42nd-e-c-d-d', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:05:04');
INSERT INTO `rss_articles` (`id`, `title`, `body`, `href`, `rss_id`, `status`, `created_at`, `updated_at`) VALUES
(145, 'Water and Climate Change', 'World Water Day 2020 is about water and climate change and how the two are inextricably linked This year s campaign shows how our use of water will help reduce floods droughts scarcity and pollution and will help fight climate change itself By adapting to the water effects of climate change we will protect health and save lives And by using water more efficiently we will reduce greenhouse gases Our key messages are clear We cannot afford to wait Climate policy makers must put water at the heart of action plans Climate change effects water supplies and human health Health systems need to prepare for more water related disease associated with climate change Water can help fight climate change and protect health There are sustainable affordable and scalable water and sanitation solutions Everyone has a role to play In our daily lives there are surprisingly easy steps we can all take to address climate change and protect health', 'https://www.who.int/news-room/detail/17-03-2020-water-and-climate-change', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:05:33'),
(146, 'ICC-WHO Joint Statement: An unprecedented private sector call to action to tackle COVID-19', 'In a coordinated effort to combat the coronavirus COVID 19 pandemic the International Chamber of Commerce ICC and the World Health Organization WHO have agreed to work closely to ensure the latest and most reliable information and tailored guidance reaches the global business community The COVID 19 pandemic is a global health and societal emergency that requires effective immediate action by governments individuals and businesses All businesses have a key role to play in minimising the likelihood of transmission and impact on society Early bold and effective action will reduce short term risks to employees and long term costs to businesses and the economy To aid this collective effort ICC will regularly send updated advice to its network of over 45 million businesses so that businesses everywhere can take informed and effective action to protect their workers customers and local communities and contribute to the production and distribution of essential supplies ICC will also contribute to enhancing information flows on the coronavirus outbreak by surveying its global private sector network to map the global business response This will both encourage businesses to adopt appropriate precautionary approaches and generate new data and insights to support national and international government efforts As an immediate priority businesses should be developing or updating readying or implementing business continuity plans Business continuity plans should aim to reduce transmission including by promoting understanding of the disease its symptoms and appropriate behavior among employees setting up a reporting system for any cases and contacts preparing essentials limiting travel and physical connectivity and planning for measures such as teleworking when necessary Calls to Action ICC strongly endorses WHO s call on national governments everywhere to adopt a whole of government and whole of society approach in responding to the COVID 19 pandemic Reducing the further spread of COVID 19 and mitigating its impact should be a top priority for Heads of State and Government Political action should be coordinated with actors in the private sector and civil society to maximize reach of messaging and effectiveness Governments should commit to making available all necessary resources to combat COVID 19 with the minimum of delay and to ensure that cross border medical and other essential goods supply chains are able to function effectively and efficiently ICC and the WHO encourage national chambers of commerce to work closely with UN country teams including WHO country offices where they exist and to designate mutual focal points to coordinate this collaboration ICC encourages its members to support their country s national response efforts and to contribute to the global response efforts coordinated by the WHO through www covid19responsefund org As the pandemic evolves ICC Secretary General John W H Denton AO and WHO Director General Dr Tedros Adhanom Ghebreyesus will continue to coordinate their efforts Essential information on the COVID 19 pandemic can be found on the WHO s dedicated site', 'https://www.who.int/news-room/detail/16-03-2020-icc-who-joint-statement-an-unprecedented-private-sector-call-to-action-to-tackle-covid-19', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:06:03'),
(147, 'WHO, UN Foundation and partners launch first-of-its-kind COVID-19 Solidarity Response Fund', 'A new coronavirus disease COVID 19 Solidarity Response Fund will raise money from a wide range of donors to support the work of the World Health Organization WHO and partners to help countries respond to the COVID 19 pandemic The fund the first of its kind enables private individuals corporations and institutions anywhere in the world to come together to directly contribute to global response efforts and has been created by the United Nations Foundation and the Swiss Philanthropy Foundation together with WHO', 'https://www.who.int/news-room/detail/13-03-2020-who-un-foundation-and-partners-launch-first-of-its-kind-covid-19-solidarity-response-fund', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:06:22'),
(148, 'Mid-term review of the UN Decade of Action on Nutrition', 'The joint FAO WHO Nutrition Decade Secretariat has developed the Mid term Review Foresight paper which will serve as the background paper for the consultation process Reflecting on the broader development in nutrition globally this paper develops a vision on actions to be taken in the different areas of the Work Programme of the Nutrition Decade considering specific advances and opportunities in individual policy areas', 'https://www.who.int/news-room/detail/12-03-2020-mid-term-review-of-the-un-decade-of-action-on-nutrition', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:10:51'),
(149, 'COVID-19: IFRC, UNICEF and WHO issue guidance to protect children and support safe school operations', 'GENEVA NEW YORK The International Federation of the Red Cross IFRC UNICEF and the World Health Organization WHO today issued new guidance to help protect children and schools from transmission of the COVID 19 virus The guidance provides critical considerations and practical checklists to keep schools safe It also advises national and local authorities on how to adapt and implement emergency plans for educational facilities In the event of school closures the guidance includes recommendations to mitigate against the possible negative impacts on children s learning and wellbeing This means having solid plans in place to ensure the continuity of learning including remote learning options such as online education strategies and radio broadcasts of academic content and access to essential services for all children These plans should also include necessary steps for the eventual safe reopening of schools Where schools remain open and to make sure that children and their families remain protected and informed the guidance calls for Providing children with information about how to protect themselves Promoting best handwashing and hygiene practices and providing hygiene supplies Cleaning and disinfecting school buildings especially water and sanitation facilities and Increasing airflow and ventilation The guidance while specific to countries that have already confirmed the transmission of COVID 19 is still relevant in all other contexts Education can encourage students to become advocates for disease prevention and control at home in school and in their community by talking to others about how to prevent the spread of viruses Maintaining safe school operations or reopening schools after a closure requires many considerations but if done well can promote public health For example safe school guidelines implemented in Guinea Liberia and Sierra Leone during the outbreak of Ebola virus disease from 2014 to 2016 helped prevent school based transmissions of the virus UNICEF is urging schools whether open or helping students through remote learning to provide students with holistic support Schools should provide children with vital information on handwashing and other measures to protect themselves and their families facilitate mental health support and help to prevent stigma and discrimination by encouraging students to be kind to each other and avoid stereotypes when talking about the virus The new guidance also offers helpful tips and checklists for parents and caregivers as well as children and students themselves These actions include Monitoring children s health and keeping them home from school if they are ill Encouraging children to ask questions and express their concerns and Coughing or sneezing into a tissue or your elbow and avoid touching your face eyes mouth and nose', 'https://www.who.int/news-room/detail/10-03-2020-covid-19-ifrc-unicef-and-who-issue-guidance-to-protect-children-and-support-safe-school-operations', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:10:35'),
(150, 'The unmet need for social context in family planning', 'New evidence on the relationship between sexual health and social context finds a strong association between gender equality education and family planning', 'https://www.who.int/news-room/detail/10-03-2020-the-unmet-need-for-social-context-in-family-planning', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:10:58'),
(151, 'Nigeria targets nearly 12 million in Yellow fever vaccination across two high risk States', 'Read the full story', 'https://www.who.int/news-room/detail/28-02-2020-nigeria-targets-nearly-12-million-in-yellow-fever-vaccination-across-two-high-risk-states', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:11:06'),
(152, 'WHO statement on cases of COVID-19 surpassing 100 000', 'As of today s reports the global number of confirmed cases of COVID 19 has surpassed 100 000 As we mark this sombre moment the World Health Organization WHO reminds all countries and communities that the spread of this virus can be significantly slowed or even reversed through the implementation of robust containment and control activities', 'https://www.who.int/news-room/detail/07-03-2020-who-statement-on-cases-of-covid-19-surpassing-100-000', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:11:12'),
(153, 'Medical Product Alert N° 1/2020 (English version)', 'Falsified antimalarials in West and Central Africa displaying an outdated WHO Essential Drugs Programme logo This Medical Product Alert relates to a series of confirmed falsified antimalarials circulating in West and Central Africa Medicines subject of this alert display a similar logo to the outdated WHO Essential Drugs Programme logo Since 2013 different falsified medicines all displaying the outdated WHO Essential Drugs Programme logo have been reported to the WHO Global Surveillance and Monitoring System by various stakeholders The continued and widespread availability of these falsified medicines highlights a strong need for additional vigilance WHO previously published two alerts on this issue No 132 in Oct 2014 and No 131 in March 2014 This WHO medical product alert N 1 2020 refers to falsified Quinine Sulphate 300mg presented in six different combinations of batch numbers expiry and manufacturing dates see Table 1 The fraudulent use of the outdated WHO Essential Drugs Programme logo may create a false sense of product quality Table 1 List of identified falsified Quinine Sulphate 300mg subject of WHO Alert N 1 2020 Recently received results of analysed samples show they do not contain any of the expected active ingredients Quinine sulphate is referenced on the WHO Model List of Essential Medicines to manage and treat severe malaria At this stage no adverse reactions attributed to these falsified products have been reported to WHO All the above falsified products claim to be manufactured by REMEDICA LTD Cyprus and to contain 300mg of quinine sulphate Remedica Ltd has confirmed that they did not manufacture the above falsified products and the variable data batch number and dates on the above products has never been used by Remedica These falsified medicines display the following common characteristics please see photographs grey or white plastic containers which contain 1000 loose circular tablets each display the outdated WHO Essential Drugs Programme logo English and French labelling with mistakes and inconsistencies and discovered at patient level in both regulated and unregulated outlets Product details photographs and advice to the public are available on the following pages Outdated WHO Essential Drugs Programme logo Photographs of confirmed falsified Quinine Sulphate 300mg tablets subject of Medical Product Alert N 1 2020 1 Falsified Quinine Sulphate Tablets B P 300mg identified in Chad Batch 44680 2 Falsified Quinine Sulphate Tablets B P 300mg identified in Nigeria and Cameroon Batch 44680 WHO requests increased vigilance within the supply chains of countries likely to be affected by these falsified products Increased vigilance should include hospitals clinics health centres wholesalers distributors pharmacies and any other suppliers of medical products If you are in possession of the above products please do not use If you have used these falsified products or if you suffer an adverse event having used these products please seek immediate advice from a qualified healthcare professional and ensure they report the incident to your local Ministry of Health National Medicines Regulatory Authorities National Pharmacovigilance Centre All medical products must be obtained from authentic and reliable sources Their authenticity and condition should be carefully checked Seek advice from a healthcare professional in case of doubt National health authorities are asked to immediately notify WHO if these falsified products are discovered in their country If you have any information concerning the manufacture distribution or supply of these products please contact rapidalert who int WHO Global Surveillance and Monitoring System for Substandard and Falsified Medical Products For further information please visit our website www who int medicines regulation ssffc en', 'https://www.who.int/news-room/detail/09-03-2020-medical-product-alert-n-1-2020-english-version', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:11:19'),
(154, 'COVID 19: Occupational Health', 'WHO resources for protection of health workers and emergency responders The protection of health workers is one of the priorities for the response to COVID19 outbreaks Occupational health services in health care facilities have an important role for protecting health workers and ensuring the business continuity of health care services Corona Virus Disease COVID 19 Outbreak Rights roles and responsibilities of health workers including key considerations for occupational safety and health English only Health workers exposure risk assessment and management in the context of COVID 19 virus Rational use of personal protective equipment for coronavirus disease COVID 19 WHO ePROTECT respiratory occupational health and safety The COVID 19 risk communication package for healthcare facilities WHO and ILO Occupational safety and health in public health emergencies A manual for protecting health workers and responders English Chinese ILO and WHO Work improvement in health services English French Spanish Portuguese Arab Chinese WHO resources for non healthcare workplaces Non healthcare workplaces such as businesses and enterprises have also the responsibility to protect the health and safety of their workers and those affected by their operations Getting your workplace ready for COVID 19 Business and employees Coronavirus disease COVID 19 technical guidance Points of entry and mass gatherings Coronavirus disease COVID 19 advice for the public Coping with stress during the COVID 19 outbreak Travel and tourism COVID 19 website WHO Travel Advice Infographics Prevention COVID 19 at the workplace', 'https://www.who.int/news-room/detail/09-03-2020-covid-19-occupational-health', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:11:30'),
(155, 'Women\'s health and rights: 25 years of progress?', 'The 1995 Beijing Declaration and Platform for Action remains the world s most progressive blueprint for advancing gender equality worldwide Twenty five years after it was affirmed by 189 countries what progress has been made in raising this blueprint off the page', 'https://www.who.int/news-room/detail/08-03-2020-women-s-health-and-rights-25-years-of-progress', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:11:40'),
(156, 'End in sight, but flare-ups likely in the Ebola outbreak in the Democratic Republic of the Congo', 'Remarks by Dr Ibrahima Soc Fall World Health Organization Assistant Director General Emergency Response Good afternoon I hope that your busy week was interrupted like mine with a moment of joy on Tuesday That moment was the celebration of a woman being discharged from an Ebola treatment centre in Beni Her name is Masika She was the last person in the Democratic Republic of the Congo confirmed to have Ebola Health workers and other responders sacrificed a lot to get to this point Since the outbreak was declared in August 2018 there have been 420 attacks on health facilities in DRC resulting in 11 deaths and 86 injuries among health care workers and patients It s been a huge amount of work At the peak of the outbreak more than 120 cases were being reported each week 28 health zones were affected with cases appearing 1200 kilometres apart In response 11 labs have been set up to test around 3500 samples each week 11 Ebola treatment centres were set up to care for people with Ebola 300 000 people have been vaccinated 250 000 contacts have been registered 26 000 safe and dignified burials have been conducted More than 3000 health facilities were identified for infection prevention and control support More than 1000 metric tonnes of supplies have been delivered An Ebola vaccine has been licensed and two treatments found to be highly effective Almost 160 million people have been screened for Ebola symptoms at borders or other points of control This work is continuing The outbreak isn t over WHO recommends waiting two full incubation periods that s 42 days after the last person tests negative a second time before declaring the end of the outbreak We must stay in active response mode to get us over that finish line We have to be prepared for other cases emerging It s is a very real risk Remember that during the Ebola outbreak in West Africa flare ups of new cases occurred after the end of the outbreak There are four reasons why new cases may emerge during this 42 day period or even after the end of the outbreak First because of the complex security environment Ebola transmission outside of groups under monitoring is possible Second Ebola virus can persist in used needles syringes or vials for several weeks Third Ebola virus can persist in the body fluids of survivors for many months and can be transmitted well after recovery or in rare cases can result in relapse as we ve already seen during this outbreak Finally Ebola virus is present in an animal reservoir in the region and there is always a risk of a new spillover to humans This is why it s critical to maintain surveillance and rapid response capacities And that s what we are doing We re still in full response mode In addition to the activities I already mentioned I have to underline how critical it is to continue supporting the Survivor Programme which provides follow up care for almost all of the 1169 survivors in 26 health areas in North Kivu and Ituri The programme also helps reduce the risks of re introduction events We need to continue this work until the end of the outbreak to keep the capacity in place to rapidly respond to flare ups to keep supporting survivors after the outbreak and to transition the capacities built in this response toward building a stronger health system But to be very frank right now the world risks dropping the baton at the finish line WHO faces an immediate US 20 million funding gap If no new resources are received we will run out of money before the end of the outbreak We appreciate the generosity of donors who have supported the response since August 2018 Now we need to get over the finish line WHO is calling on the international community to help us end this outbreak and keep our promises to communities to build a stronger health system If we are forced to scale back operations because of a lack of funds and then a new case emerges we might not have the people and resources on the ground that we need to shut down transmission quickly Just a single case could re ignite the epidemic That would be a tragedy An avoidable tragedy It is important that the global community doesn t only focus efforts when there is an immediate threat then walk away when the threat subsides The health system has to be strong to stop much more than Ebola It has to stop malaria measles cholera and now COVID 19 There is a lot more work to do Thank you', 'https://www.who.int/news-room/detail/06-03-2020-end-in-sight-but-flare-ups-likely-in-the-ebola-outbreak-in-the-democratic-republic-of-the-congo', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:11:48'),
(157, 'Shortage of personal protective equipment endangering health workers worldwide', 'WHO calls on industry and governments to increase manufacturing by 40 per cent to meet rising global demand The World Health Organization has warned that severe and mounting disruption to the global supply of personal protective equipment PPE caused by rising demand panic buying hoarding and misuse is putting lives at risk from the new coronavirus and other infectious diseases Healthcare workers rely on personal protective equipment to protect themselves and their patients from being infected and infecting others But shortages are leaving doctors nurses and other frontline workers dangerously ill equipped to care for COVID 19 patients due to limited access to supplies such as gloves medical masks respirators goggles face shields gowns and aprons Without secure supply chains the risk to healthcare workers around the world is real Industry and governments must act quickly to boost supply ease export restrictions and put measures in place to stop speculation and hoarding We can t stop COVID 19 without protecting health workers first said WHO Director General Dr Tedros Adhanom Ghebreyesus Since the start of the COVID 19 outbreak prices have surged Surgical masks have seen a sixfold increase N95 respirators have trebled and gowns have doubled Supplies can take months to deliver and market manipulation is widespread with stocks frequently sold to the highest bidder WHO has so far shipped nearly half a million sets of personal protective equipment to 47 countries but supplies are rapidly depleting Based on WHO modelling an estimated 89 million medical masks are required for the COVID 19 response each month For examination gloves that figure goes up to 76 million while international demand for goggles stands at 1 6 million per month Recent WHO guidance calls for the rational and appropriate use of PPE in healthcare settings and the effective management of supply chains WHO is working with governments industry and the Pandemic Supply Chain Network to boost production and secure allocations for critically affected and at risk countries To meet rising global demand WHO estimates that industry must increase manufacturing by 40 per cent Governments should develop incentives for industry to ramp up production This includes easing restrictions on the export and distribution of personal protective equipment and other medical supplies Every day WHO is providing guidance supporting secure supply chains and delivering critical equipment to countries in need NOTE TO EDITORS Since the start of the COVID 19 outbreak countries that have received WHO PPE supplies include Western Pacific region Cambodia Fiji Kiribati Lao People s Democratic Republic Mongolia Nauru Papua New Guinea Samoa Solomon Islands Tonga Vanuatu and the Philippines Southeast Asia region Bangladesh Bhutan Maldives Myanmar Nepal and Timor Leste Eastern Mediteranean region Afghanistan Djibouti Lebanon Somalia Pakistan Sudan Jordan Morocco and Iran Africa region Senegal Algeria Ethiopia Togo Ivory Coast Mauritius Nigeria Uganda Tanzania Angola Ghana Kenya Zambia Equatorial Guinea Gambia Madagascar Mauritania Mozambique Seychelles and Zimbabwe', 'https://www.who.int/news-room/detail/03-03-2020-shortage-of-personal-protective-equipment-endangering-health-workers-worldwide', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:11:56'),
(158, 'UN releases US$15 million to help vulnerable countries battle the spread of the coronavirus', 'UN Humanitarian Chief Mark Lowcock today released US 15 million from the Central Emergency Response Fund CERF to help fund global efforts to contain the COVID 19 virus The announcement came as the World Health Organization WHO upgraded the global risk of the coronavirus outbreak to very high its top level of risk assessment The WHO has said there is still a chance of containing the virus if its chain of transmission is broken The sudden increases of cases in Italy the Islamic Republic of Iran and the Republic of Korea are deeply concerning There are now cases linked to Iran in Bahrain Iraq Kuwait and Oman along with cases linked to Italy in Algeria Austria Croatia Germany Spain and Switzerland The UN funding has been released to the WHO and the United Nations Children s Fund UNICEF It will fund essential activities including monitoring the spread of the virus investigating cases and the operation of national laboratories The WHO has called for US 675 million to fund the fight against coronavirus There is a window of opportunity to contain the spread of the virus if countries take robust measures to detect cases early isolate and care for patients and trace contacts Emergency Relief Coordinator and Under Secretary General for Humanitarian Affairs Mark Lowcock said We do not yet see evidence that the virus is spreading freely As long as that s the case we still have a chance of containing it But swift and robust action must be taken to detect cases early isolate and care for patients and trace contacts We must act now to stop this virus from putting more lives at risk This grant from the UN s Emergency Fund will help countries with fragile health systems boost their detection and response operations It has the potential to save the lives of millions of vulnerable people This is a critical juncture in the outbreak The focus is on containing COVID 19 by strengthening surveillance conducting thorough outbreak investigations to identify contacts and applying appropriate measures to prevent further spread Tedros Adhanom Ghebreyesus WHO Director General said The potential spread of the virus to countries with weaker health systems is one of our biggest concerns These funds will help support these countries get ready for detecting and isolating cases protecting their health workers and treating patients with dignity and appropriate care This will help us save lives and push back the virus UNICEF is leading on preventative actions in communities across the affected countries with risk communication providing hygiene and medical kits to schools and health clinics and monitoring the impact of the outbreak to support continuity of care education and social services At this pivotal moment every effort must be made to push back against the outbreak said UNICEF Executive Director Henrietta Fore These crucial funds will support our global efforts to bolster weaker health systems and inform children pregnant women and families about how to protect themselves Since it was launched in 2006 CERF has provided more than 6 billion to over 100 countries and helped hundreds of millions of people', 'https://www.who.int/news-room/detail/01-03-2020-un-releases-us-15-million-to-help-vulnerable-countries-battle-the-spread-of-the-coronavirus', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:12:07'),
(159, 'Guideline on parent training to prevent child maltreatment and promote the positive development of children aged 0-17 years', 'WHO is developing a guideline on parent training to prevent child maltreatment and promote the positive development of children aged 0 17 years Part of the guideline development process involves constitution of a Guideline Development Group GDG which should represent a broad spectrum of perspectives constituencies and relevant expertise The biographies of individuals proposed for membership of the GDG are provided below for public review and comment Any comment or concern about the individuals listed should be sent to Dr Alexander Butchart butcharta who int Liane Alampay Rose Apondi Stephen Blight Ida Ferdinandi Frances Gardner Daisy Kisyombe Wadih Maalouf Harriet MacMillan Joseph Murray Mark Tomlinson Catherine Ward', 'https://www.who.int/news-room/detail/01-03-2020-guideline-on-parent-training-to-prevent-child-maltreatment-and-promote-the-positive-development-of-children-aged-0-17-years', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:12:21'),
(160, 'WHO launches a digital version of its Model list of Essential Medicines (EML)', 'The World Health Organization has launched a new easy to access digital version of its Model list of Essential Medicines EML The move will revolutionize the way this core WHO reference tool is used', 'https://www.who.int/news-room/detail/27-02-2020-who-launch-e-eml', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:12:28'),
(161, 'WHO steps up action to improve access to safe blood', 'The World Health Organization s new action plan to speed up universal access to safe blood and blood products pulls together existing recommendations and recommends new improved ways of working It s the start of a four year collaborative effort to improve blood transfusion and blood based therapies in all countries Safe blood saves lives in all sorts of circumstances not least in emergency and epidemic settings Blood transfusion and blood products are critical for birth delivery for both the mother and baby the survival and quality of life of patients suffering from life threatening conditions such as haemophilia thalassemia immune deficiency and cancer treating severe injuries and carrying out medical and surgical procedures But progress in blood safety and availability has been slow in many parts of the world placing patients safety at risk and putting undue pressure on health workers Progress is also mostly restricted to developed countries Out of the approximate 118 million blood donations collected globally 42 are collected in high income countries home to 16 of the world s population And one out of four low income countries do not test all donated blood while 54 of countries do not have surveillance systems to securitise the supply chain from blood donor to patient Challenges include slow implementation of national blood policies and weak blood regulatory systems insufficient number of voluntary blood donors who are considered the safest donors poor quality management of screening tests blood grouping and compatibility testing inappropriate clinical use of blood insufficient national funding for blood safety To address these WHO has set out six key objectives for all countries and in particular those with weak blood systems appropriately structured well coordinated and sustainably resourced national blood systems regulatory capacity to ensure the quality and safety of blood functioning and efficiently managed blood services effective implementation of patient blood management to optimize transfusion practices effective surveillance haemovigilance and pharmacovigilance supported by comprehensive and accurate data collection systems partnerships collaboration and information exchange to achieve key priorities and jointly address challenges and emerging threats at global regional and national levels The Organization looks forward to working with partners worldwide to implement the plan improve blood supply particularly in the low and middle income countries where this is so urgently needed and save lives The plan will run from 2020 2024', 'https://www.who.int/news-room/detail/26-02-2020-who-steps-up-action-to-improve-access-to-safe-blood', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:12:36'),
(162, 'A Joint Statement on Tourism and COVID-19 - UNWTO and WHO Call for Responsibility and Coordination', 'As the current outbreak of the Coronavirus Disease COVID 19 continues to develop the World Health Organization WHO and the World Tourism Organization UNWTO are committed to working together in guiding the travel and tourism sectors response to COVID 19 On 30 January 2020 the Director General of the World Health Organization WHO declared the outbreak of COVID 19 to be a Public Health Emergency of International Concern and issued a set of Temporary Recommendations WHO did not recommend any travel or trade restriction based on the current information available WHO is working closely with global experts governments and partners to rapidly expand scientific knowledge on this new virus to track the spread and virulence of the virus and to provide advice to countries and the global community on measures to protect health and prevent the spread of this outbreak Cooperation is key The tourism sector is fully committed to putting people and their well being first International cooperation is vital for ensuring the sector can effectively contribute to the containment of COVID 19 UNWTO and WHO are working in close consultation and with other partners to assist States in ensuring that health measures be implemented in ways that minimize unnecessary interference with international traffic and trade Tourism s response needs to be measured and consistent proportionate to the public health threat and based on local risk assessment involving every part of the tourism value chain public bodies private companies and tourists in line with WHO s overall guidance and recommendations UNWTO and WHO stand ready to work closely with all those communities and countries affected by the current health emergency to build for a better and more resilient future Travel restrictions going beyond these may cause unnecessary interference with international traffic including negative repercussions on the tourism sector At this challenging time UNWTO and WHO join the international community in standing in solidarity with affected countries', 'https://www.who.int/news-room/detail/27-02-2020-a-joint-statement-on-tourism-and-covid-19---unwto-and-who-call-for-responsibility-and-coordination', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:12:41'),
(163, 'France pledges US$100 million (€90 million) for WHO Academy', 'Geneva France s Minister for Europe and Foreign Affairs Mr Jean Yves Le Drian and Dr Tedros Adhanom Ghebreyesus Director General of WHO today met at the Permanent Mission of France to the United Nations in Geneva to discuss the WHO Academy which will be the world s largest and most innovative lifelong learning platform in global health The WHO Academy aims to reach millions of people worldwide offering high tech learning environments at a hub in Lyon with spokes in the six WHO regions The Academy will provide learning opportunities for leaders educators researchers health workers WHO staff and the broader public and will deliver high quality multilingual learning both online and in person alongside a cutting edge simulation centre for health emergencies The discussion today follows a Declaration of Intent signed by Emmanuel Macron President of the French Republic and Dr Tedros on 11 June 2019 and a pledge by France in the amount of US 100 million 90 million to WHO to support the creation of the WHO Academy which will be established as an internal division within WHO Technology and innovation in learning are creating exciting new opportunities to accelerate progress towards health for all in every country said Dr Tedros Adhanom Ghebreyesus Director General of WHO The WHO Academy will support millions of learners to maximize health impacts with the best evidence adult learning approaches and state of the art technologies By propelling and strengthening digital innovations and lifelong learning opportunities around the world the WHO Academy will play an instrumental role towards achieving WHO s triple billion goal by 2023 and the health Sustainable Development Goals 1 billion more people will benefit from universal health coverage 1 billion more will be better protected in health emergencies and 1 billion more will enjoy improved health and wellbeing The funding from France represents a commitment to accelerate the development of the WHO Academy and confirms the engagement of France a longstanding partner of WHO and a key actor in global health and its strong support to the ambitions of 13th WHO General Programme of Work to ensure healthy lives and well being for all ages', 'https://www.who.int/news-room/detail/24-02-2020-france-pledges-us100-million-for-who-academy', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:12:48'),
(164, 'Key dates for nursing and midwifery discussions in May 2020', 'WHO has declared 2020 as the International Year of the Nurse and the Midwife to mark the bicentenary of the birth of the founder of modern nursing Florence Nightingale and to recognize the critical contribution both professions make to global health May is a key moment to catalyse high level dialogue and collaborative engagements for moving forward the findings of The State of the World s Nursing Report which will be launched on World Health Day 7 April 2020 as part of the activities of the International Year of the Nurse and the Midwife Key dates for May 2020 Ninth WHO Global Forum for Government Chief Nursing and Midwifery Officers GCNMOs and the Eighth Triad Meeting 13 15 May Geneva organized jointly by WHO the International Confederation of Midwives and the International Council of Nurses The meetings will be held at the Centre International de Conf rence CICG immediately prior to the Seventy third World Health Assembly by invitation only The GCNMO Forum and the ICM ICN WHO Triad Meeting have heightened importance during the International Year of the Nurse and the Midwife Occurring at almost the mid point of 2020 the meetings will focus on pivoting from advocacy to action Participants will learn how to leverage the findings from The State of the World s Nursing 2020 and anticipated reports on midwifery to make evidence based arguments for national policy reforms and investment in nursing and midwifery to improve primary healthcare strengthen emergency response and resilience and achieve UHC Health for All Film Festival 16 May PM Geneva special focus on nursing and midwifery film submission Walk the Talk 17 May AM Geneva special focus will be given to nurses and midwives in celebration of the International Year of the Nurse and Midwife We encourage you to register at https www who int news room events detail 2020 05 17 default calendar walk the talk the health for all challenge World Health Assembly 17 20 May Geneva', 'https://www.who.int/news-room/detail/20-02-2020-key-dates-for-nursing-and-midwifery-discussions-in-may-2020', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:12:59'),
(165, 'Cervical cancer elimination initiative updates', 'February Garnering international support on the path to eliminate cervical cancer', 'https://www.who.int/news-room/detail/04-03-2020-cervical-cancer-elimination-initiative-updates-december-2019', 22, 'published', '2020-03-24 11:01:53', '2020-03-24 11:13:07'),
(166, '1.4 million vaccines from global stockpile support yellow fever control in Nigeria', 'The International Coordinating Group ICG on vaccine provision for yellow fever has provided 1 4 million vaccine doses for an immunization campaign that starts on Saturday 2 December to help control an ongoing yellow fever outbreak in Nigeria', 'http://www.who.int/entity/mediacentre/news/releases/2017/vaccine-stockpile-yellowfever-nigeria/en/index.html', 23, 'published', '2020-03-25 06:25:05', '2020-03-25 06:28:18'),
(167, 'WHO supports the immunization of 874 000 people against yellow fever in Nigeria', 'WHO supports the immunization of 874 000 people against yellow fever in Nigeria', 'http://www.who.int/entity/mediacentre/news/releases/2017/immunization-yellowfever-nigeria/en/index.html', 23, 'published', '2020-03-25 06:25:05', '2020-03-25 06:28:07'),
(168, 'WHO provides 1.2 million antibiotics to fight plague in Madagascar', 'WHO provides 1 2 million antibiotics to fight plague in Madagascar', 'http://www.who.int/entity/mediacentre/news/releases/2017/antibiotics-plague-madagascar/en/index.html', 23, 'published', '2020-03-25 06:25:05', '2020-03-25 06:28:10'),
(169, 'Partners commit to reduce cholera deaths by 90% by 2030', 'An ambitious new strategy to reduce deaths from cholera by 90 by 2030 will be launched tomorrow by the Global Task Force on Cholera Control GTFCC a diverse network of more than 50 UN and international agencies academic institutions and NGOs that supports countries affected by the disease', 'http://www.who.int/entity/mediacentre/news/releases/2017/partners-reduce-cholera/en/index.html', 23, 'published', '2020-03-25 06:25:05', '2020-03-25 06:28:17'),
(170, 'World hunger again on the rise, driven by conflict and climate change, new UN report says', 'After steadily declining for over a decade global hunger is on the rise again affecting 815 million people in 2016 or 11 per cent of the global population says a new edition of the annual United Nations report on world food security and nutrition released today At the same time multiple forms of malnutrition are threatening the health of millions worldwide The increase 38 million more people than the previous year is largely due to the proliferation of violent conflicts and climate related shocks according to The State of Food Security and Nutrition in the World 2017', 'http://www.who.int/entity/mediacentre/news/releases/2017/world-hunger-report/en/index.html', 23, 'published', '2020-03-25 06:25:05', '2020-03-25 06:28:22'),
(171, 'Sierra Leone to begin cholera vaccination drive in disaster-affected areas', 'Half a million people in Sierra Leone will be able to access the life saving cholera vaccine within weeks the country s Ministry of Health and Sanitation announced on Tuesday', 'http://www.who.int/entity/mediacentre/news/releases/2017/sierra-leone-cholera-vaccination/en/index.html', 23, 'published', '2020-03-25 06:25:05', '2020-03-25 06:28:09'),
(172, 'Cholera count reaches 500 000 in Yemen', 'The total number of suspected cholera cases in Yemen this year hit the half a million mark on Sunday and nearly 2000 people have died since the outbreak began to spread rapidly at the end of April The overall caseload nationwide has declined since early July particularly in the worst affected areas But suspected cases of the deadly waterborne disease continue to rage across the country infecting an estimated 5000 people per day', 'http://www.who.int/entity/mediacentre/news/releases/2017/cholera-yemen-mark/en/index.html', 23, 'published', '2020-03-25 06:25:05', '2020-03-25 06:28:27'),
(173, 'WHO calls for immediate action to save lives in Somalia', 'WHO is concerned by the chronic shortage of funding for life saving work in Somalia in response to the ongoing drought that has plunged the country further towards famine disease and health insecurity', 'http://www.who.int/entity/mediacentre/news/releases/2017/save-lives-somalia/en/index.html', 23, 'published', '2020-03-25 06:25:05', '2020-03-25 06:28:24'),
(174, 'Challenges and hope in delivering health in South Sudan', 'In South Sudan the World Health Organization WHO supports the Ministry of Health and works with 67 Health Cluster partners to provide health services within a country disrupted by conflict Since December 2013 conflict has displaced some 2 3 million people including 1 6 million internally displaced persons South Sudan is a country that is affected by complex emergencies resulting from prolonged conflict climate change a broken health system and outbreaks of communicable diseases said Dr Abdulmumini Usman WHO Representative in South Sudan', 'http://www.who.int/entity/hac/crises/ssd/features/photo_story_ssd/en/index.html', 23, 'published', '2020-03-25 06:25:05', '2020-03-25 06:28:26'),
(175, 'Stop the violence. Protect health care', 'In the last few months a number of attacks against health care workers medical transports and facilities have taken place in several countries like Afghanistan Syria and Yemen to mention a few These incidents are taking place in countries with fragile health care systems that are already struggling to treat the numbers of people affected by the ongoing conflicts there In some cases the situation is made yet worse by the restrictions placed on aid workers preventing them from getting to the people who need them', 'http://www.who.int/entity/mediacentre/news/statements/2015/stop-violence/en/index.html', 23, 'published', '2020-03-25 06:25:05', '2020-03-25 06:28:19'),
(176, 'Ensuring continuity of TB services during the COVID-19 pandemic', 'GENEVA As the world comes together to tackle the COVID 19 pandemic it is important to ensure that essential health services and operations are continued to protect the lives of people with TB and other diseases or health conditions Health services including national programmes to combat TB need to be actively engaged in ensuring an effective and rapid response to COVID 19 while ensuring that TB services are maintained In the lead up to World TB Day Dr Tedros Adhanom Ghebreyesus WHO Director General emphasized in a news release COVID 19 is highlighting just how vulnerable people with lung diseases and weakened immune systems can be The world committed to end TB by 2030 improving prevention is key to making this happen The World Health Organization WHO Global TB Programme along with WHO regional and country offices has developed an information note in collaboration with stakeholders This note is intended to assist national TB programmes and health personnel to urgently maintain continuity of essential services for people affected with TB during the COVID 19 pandemic driven by innovative people centred approaches as well as maximizing joint support to tackle both diseases We stand in solidarity with those affected by COVID 19 and those at the frontlines of the fight to combat the disease said Dr Tereza Kasaeva Director of the WHO Global TB Programme We need to act with urgency to ensure that in line with our vision of Health for All no one with TB COVID 19 or any health condition will miss out on the prevention and care they need It s time for action', 'https://www.who.int/news-room/detail/24-03-2020-ensuring-continuity-of-tb-services-during-the-covid-19-pandemic', 22, 'published', '2020-03-25 06:27:26', '2020-03-25 06:28:15'),
(177, 'World TB Day 2020: It’s Time for solidarity', 'WHO calls for continued collaboration in countries across health programmes for harmonized and integrated policies and service delivery and engagement with communities and other sectors', 'https://www.who.int/news-room/detail/24-03-2020-world-tb-day-2020-it-s-time-for-solidarity', 22, 'published', '2020-03-25 06:27:26', '2020-03-25 06:28:11'),
(178, 'WHO Information Note: Ensuring continuity of TB services during the COVID-19 pandemic', 'WHO Global TB Programme along with WHO regional and country offices has developed an information note in collaboration with stakeholders to assist national TB programmes and health personnel to urgently maintain continuity of essential services for people affected with TB during the COVID 19 pandemic', 'https://www.who.int/news-room/detail/20-03-2020-who-information-note-ensuring-continuity-of-tb-services-during-the-covid-19-pandemic', 22, 'published', '2020-03-25 06:27:26', '2020-03-25 06:28:02'),
(180, 'Middle East respiratory syndrome coronavirus (MERS-CoV) – Qatar', 'On 18 February 2020 the National IHR Focal Point for Qatar reported one laboratory confirmed case of Middle East Respiratory Syndrome coronavirus infection MERS CoV to WHO', 'http://www.who.int/entity/csr/don/12-march-2020-mers-qatar/en/index.html', 24, 'published', '2020-03-25 06:33:40', '2020-03-25 06:34:28'),
(182, 'Dengue fever – French Territories of the Americas – French Guiana, Guadeloupe, Martinique, Saint-Martin, and Saint-Barthélemy', 'On 12 February 2020 the European Centre for Disease Prevention and Control ECDC reported an increase in the number of cases of dengue infection in French Guiana Guadeloupe Martinique and Saint Martin In January 2020 health authorities in the region declared a dengue epidemic in Guadeloupe and Saint Martin and indicated that Martinique is also at risk of an epidemic Dengue epidemics in these territories usually occur when there is a shift in the predominant circulating DENV serotype and non immune populations e g tourists new immigrants or people not previously exposed to the circulating serotypes are exposed to the new serotype through human movements within the territories or across neighboring countries Local transmission occurs through the Aedes mosquito vector present on the islands and in French Guiana', 'http://www.who.int/entity/csr/don/10-March-2020-dengue-fever-french-territories-of-the-americas/en/index.html', 24, 'published', '2020-03-25 06:33:40', '2020-03-25 06:34:25');
INSERT INTO `rss_articles` (`id`, `title`, `body`, `href`, `rss_id`, `status`, `created_at`, `updated_at`) VALUES
(184, 'Measles -  Central African Republic', 'The Central African Republic CAR has experienced an upsurge in measles cases as a result of outbreaks since 2019', 'http://www.who.int/entity/csr/don/04-march-2020-measles-car/en/index.html', 24, 'published', '2020-03-25 06:33:40', '2020-03-25 06:34:21'),
(186, 'Middle East respiratory syndrome coronavirus (MERS-CoV) – The Kingdom of Saudi Arabia', 'From 1 December 2019 through 31 January 2020 the National IHR Focal Point of Saudi Arabia reported 19 additional cases of MERS CoV infection including 8 associated deaths', 'http://www.who.int/entity/csr/don/24-february-2020-mers-saudi-arabia/en/index.html', 24, 'published', '2020-03-25 06:33:40', '2020-03-25 06:34:30'),
(187, 'Dengue fever – Chile', 'On 7 February 2020 the Chile IHR National Focal Point informed the Pan American Health Organization World Health Organization PAHO WHO of the detection of three confirmed cases of autochthonous dengue fever reported on Easter Island', 'http://www.who.int/entity/csr/don/22-february-2020-dengue-chile/en/index.html', 24, 'published', '2020-03-25 06:33:40', '2020-03-25 06:34:20'),
(188, 'Yellow fever – Uganda', 'From 4 November through 14 February 2020 eight laboratory confirmed cases of yellow fever in Buliisa 3 Maracha 1 and Moyo 4 including four deaths CFR 50 were detected through the national surveillance system', 'http://www.who.int/entity/csr/don/21-february-2020-yellow-fever-uganda/en/index.html', 24, 'published', '2020-03-25 06:33:40', '2020-03-25 06:34:23'),
(189, 'Lassa Fever – Nigeria', 'From 1 January through 9 February 2020 472 laboratory confirmed cases including 70 deaths case fatality ratio 14 8 have been reported in 26 out of 36 Nigerian states and the Federal Capital Territory', 'http://www.who.int/entity/csr/don/20-february-2020-lassa-fever-nigeria/en/index.html', 24, 'published', '2020-03-25 06:33:40', '2020-03-25 06:34:47'),
(193, 'Middle East respiratory syndrome coronavirus (MERS-CoV) – United Arab Emirates', 'On 9 and 13 January 2020 the National IHR Focal Point of the United Arab Emirates UAE reported an additional two 2 laboratory confirmed cases of Middle East respiratory syndrome Coronavirus MERS CoV to WHO The link below provides details of the 2 reported cases', 'http://www.who.int/entity/csr/don/31-january-2020-mers-united-arab-emirates/en/index.html', 24, 'published', '2020-03-25 06:33:40', '2020-03-25 06:34:45'),
(196, 'Novel Coronavirus – Republic of Korea (ex-China)', 'On 20 January 2020 National IHR Focal Point NFP for Republic of Korea reported the first case of novel coronavirus in the Republic of Korea The case is a 35 year old female Chinese national residing in Wuhan Hubei province in China The case patient had developed fever chill and muscle pain on 18 January while in Wuhan She visited a local hospital in Wuhan and was initially diagnosed with a cold On 19 January the case patient was detected with fever 38 3 C upon arrival at the Incheon International Airport The case patient was transferred to a national designated isolation hospital for testing and treatment She was tested positive for pancoronavirus reverse transcriptase polymerase chain reaction RT PCR assay and subsequently was confirmed positive for novel coronavirus 2019 nCoV on 20 January by sequencing at the Korea Centers for Disease Control and Prevention KCDC Upon detection the patient had chills runny nose and muscle pain', 'http://www.who.int/entity/csr/don/21-january-2020-novel-coronavirus-republic-of-korea-ex-china/en/index.html', 24, 'published', '2020-03-25 06:33:40', '2020-03-25 06:34:38'),
(198, 'Novel Coronavirus – Japan (ex-China)', 'The Japanese Ministry of Health Labour and Welfare today informed the World Health Organization WHO of a confirmed case of a novel coronavirus 2019 nCoV in a person who travelled to Wuhan China This is the second confirmed case of 2019 nCoV that has been detected outside of China following confirmation of a case in Thailand on 13 January Considering global travel patterns additional cases in other countries are likely Coronaviruses are a large family of viruses that cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome 2019 nCoV is a new strain that has not been previously identified in humans', 'http://www.who.int/entity/csr/don/16-january-2020-novel-coronavirus-japan-ex-china/en/index.html', 24, 'published', '2020-03-25 06:33:40', '2020-03-25 06:34:16'),
(199, 'Information Note Nitrosamine impurities', 'Medicine Regulatory Authorities first became aware of the presence of the nitrosamine impurity Nnitrosodimethylamine NDMA in products containing valsartan in July 2018 Valsartan is an Angiotensin II Receptor Blocker ARB and belongs to a family of analogue compounds commonly referred to as the sartans Further nitrosamine impurities were subsequently detected in other medicines belonging to the sartan family including N nitrosodiethylamine NDEA N nitrosodiisopropylamine NDIPA N nitrosoethylisopropylamine NEIPA and N nitroso N methyl 4 aminobutyric acid NMBA', 'http://www.who.int/entity/medicines/publications/drugalerts/InformationNote_Nitrosamine-impurities/en/index.html', 25, 'published', '2020-03-25 06:38:30', '2020-03-25 08:10:18'),
(200, 'Medical Product Alert N° 11/2019 (English version)', 'Falsified Amoxicillin Clavulanic Acid products circulating in Haiti', 'http://www.who.int/entity/medicines/publications/drugalerts/drug_alert-11-2019/en/index.html', 25, 'published', '2020-03-25 06:38:30', '2020-03-25 08:10:26'),
(201, 'Medical Product Alert N° 10/2019 (English version)', 'This Medical Product Alert relates to four confirmed falsified products quinine sulphate circulating in Central African Republic and Chad and quinine bisulphate circulating in Uganda It should be noted that this is the second WHO Medical Product Alert issued on the same batch number of falsified quinine bisulphate circulating in the African region Please refer to the previous WHO Medical Product Alert N 2 2017 issued 27 July 2017 Quinine bisulphate and quinine sulphate are listed on the WHO Model List of Essential Medicines for management of severe malaria This alert compiles details of four different falsified products that have been discovered at different times and locations over the past year This repeated occurrence highlights the need for additional vigilance in Central and East Africa for such products that display common characteristics and distribution patterns WHO was informed by a non governmental organization NGO that this falsified quinine sulphate was found at patient level in the Central African Republic At this stage testing has not yet been conducted Product details are listed in Table 1 below', 'http://www.who.int/entity/medicines/publications/drugalerts/drug_alert-10-2019/en/index.html', 25, 'published', '2020-03-25 06:38:30', '2020-03-25 08:10:28'),
(202, 'Medical Product Alert N° 9/2019 (English version)', 'Falsified Augmentin found in Uganda and Kenya', 'http://www.who.int/entity/medicines/publications/drugalerts/drug_alert-9-2019/en/index.html', 25, 'published', '2020-03-25 06:38:30', '2020-03-25 08:10:35'),
(203, 'Medical Product Alert N° 8/2019 (English version)', 'This Medical Product Alert relates to 3 different falsified rabies vaccines Verorab Speeda and Rabipur and 1 falsified anti rabies serum Equirab circulating in the Philippines It is linked to the WHO Medical Product Alert N 1 2019 issued on 30 January 2019 regarding falsified Verorab rabies vaccines circulating in the Philippines Rabies is a vaccine preventable viral disease that is almost always fatal following the onset of clinical symptoms Rabies is present worldwide with over 95 of human deaths occurring in the Asia and Africa regions Genuine Verorab Speeda and Rabipur vaccines are used for pre exposure vaccination or post exposure prophylaxis Genuine Equirab anti rabies serum provides passive immunization against rabies WHO recently received confirmation that falsified batches of Verorab Speeda Rabipur and Equirab were available at patient level in the Philippines Investigations are ongoing and laboratory analyses are being facilitated for available samples to determine their contents and better assess the risk to public health At this stage no adverse reactions attributed to the below mentioned falsified products have been reported to WHO A rabies vaccine shortage is ongoing in the Philippines', 'http://www.who.int/entity/medicines/publications/drugalerts/drug_alert-8-2019/en/index.html', 25, 'published', '2020-03-25 06:38:30', '2020-03-25 08:10:41'),
(204, 'Medical Product Alert N° 7/2019 (English version)', 'Falsified meglumine antimoniate ampoules in Iran and Pakistan', 'http://www.who.int/entity/medicines/publications/drugalerts/drug_alert-7-2019/en/index.html', 25, 'published', '2020-03-25 06:38:30', '2020-03-25 08:10:44'),
(205, 'Medical Product Alert N° 6/2019 (English version)', 'This Medical Product Alert relates to confirmed falsified hydrochlorothiazide that has been found to contain glibenclamide instead of hydrochlorothiazide circulating in the WHO region of Africa Adverse effects attributed to these products have been reported Genuine hydrochlorothiazide is used as an antihypertensive and diuretic medicine whereas glibenclamide is an antidiabetic medicine In March 2019 WHO was informed by a nongovernmental organization in Cameroon that a medicine presenting as hydrochlorothiazide 50mg had caused hypoglycaemia in patients Preliminary testing indicated that the product did not contain any of the stated active ingredient hydrochlorothiazide and glibenclamide had instead been identified Verification with the stated manufacturer confirmed this product to be falsified The local health authorities were informed of this incident', 'http://www.who.int/entity/medicines/publications/drugalerts/drug_alert-6-2019/en/index.html', 25, 'published', '2020-03-25 06:38:30', '2020-03-25 08:10:27'),
(206, 'Medical Product Alert N° 5/2019 (English version)', 'This Medical Product Alert relates to the circulation of confirmed falsified Mencevax ACWY in the WHO region of Africa Genuine Mencevax ACWY is used to prevent meningitis types A C W and Y On 15 March 2019 the Ministry of Public Health in Niger issued a call for vigilance regarding the circulation of falsified Mencevax ACWY vaccines This WHO medical product alert provides the details of those products which have been confirmed as falsified to date Inquiries indicate that the supply chain route of these falsified vaccines includes other countries in West Africa as such increased vigilance is requested in all countries of the region at all levels of the supply chain', 'http://www.who.int/entity/medicines/publications/drugalerts/drug_alert-5-2019/en/index.html', 25, 'published', '2020-03-25 06:38:30', '2020-03-25 08:10:29'),
(207, 'Medical Product Alert N° 4/2019 (English version)', 'This Medical Product Alert relates to the circulation of confirmed falsified DUKORAL in the WHO region of South East Asia Genuine Dukoral is a WHO pre qualified oral cholera vaccine WHO was recently informed by the manufacturer Valneva that 8000 falsified packs of the oral cholera vaccine Dukoral were distributed in Bangladesh WHO country office and health authorities in Bangladesh have quarantined the falsified vaccines identified to date', 'http://www.who.int/entity/medicines/publications/drugalerts/drug_alert-4-2019/en/index.html', 25, 'published', '2020-03-25 06:38:30', '2020-03-25 08:10:48'),
(208, 'Medical Product Alert N° 3/2019 (English version)', 'This Medical Product Alert relates to confirmed falsified versions of ICLUSIG 45mg circulating in the WHO Region of the Western Pacific This is linked to the WHO Medical Product Alert N 2 2019 issued on 31 January 2019 regarding falsified ICLUSIG traded globally Genuine ICLUSIG the active pharmaceutical ingredient of which is Ponatinib Hydrochloride is used to treat different forms of leukaemia On 18 February 2019 WHO was informed that a wholesaler based in Malaysia had purchased the product ICLUSIG 45mg with batch number PR072875 presented in English language packaging This specific product is referenced in the previous WHO Medical Product Alert N 2 2019 and is confirmed falsified', 'http://www.who.int/entity/medicines/publications/drugalerts/drug_alert-3-2019/en/index.html', 25, 'published', '2020-03-25 06:38:30', '2020-03-25 08:10:53'),
(209, 'Do PCSK9 inhibitors do anything more than reduce LDL cholesterol?', 'Byrne and colleagues point out the lack of reliable evidence on cardiovascular risk with inclisiran and the omens are not good 1Inclisiran undoubtedly has a marked lowering effect on low density', 'http://feeds.bmj.com/~r/bmj/recent/~3/kKbNnSRnvpQ/bmj.m1159.short', 26, 'published', '2020-03-25 08:00:57', '2020-03-25 08:10:43'),
(210, 'Covid-19: trials of four potential treatments to generate &amp;#x201C;robust data&amp;#x201D; of what works', 'The World Health Organization WHO is to coordinate an international study of treatments for covid 19 that will focus on four potential treatment strategies Tedros Ghebreyesus WHO director general', 'http://feeds.bmj.com/~r/bmj/recent/~3/uxwhkGyAIjY/bmj.m1206.short', 26, 'published', '2020-03-25 08:00:57', '2020-03-25 08:10:46'),
(211, 'Covid-19: doctors are given new guidelines on when to admit patients to critical care', 'Decisions about whether to admit patients with covid 19 to critical care should consider the medical benefit including the patient s likelihood of recovery the National Institute for Health and Care', 'http://feeds.bmj.com/~r/bmj/recent/~3/x3yRvvXH2rg/bmj.m1189.short', 26, 'published', '2020-03-25 08:00:57', '2020-03-25 08:10:38'),
(212, 'Covid-19: US testing ramps up as early response draws harsh criticism', 'Daily testing for coronavirus infection in the United States is finally approaching levels seen in other developed countries This follows nearly two months in which tests were difficult to obtain', 'http://feeds.bmj.com/~r/bmj/recent/~3/iNPjliZIf94/bmj.m1167.short', 26, 'published', '2020-03-25 08:00:57', '2020-03-25 08:10:37'),
(213, 'Sixty seconds on . . . covid kindness', 'Kindness We have more pressing needs than that Yes you do But this column is going to focus on the nice things that people are offering to do for NHS staff during this time Okay like what Well', 'http://feeds.bmj.com/~r/bmj/recent/~3/t8Gj40bYKCU/bmj.m1169.short', 26, 'published', '2020-03-25 08:00:57', '2020-03-25 08:10:32'),
(214, 'Covid-19: European drugs agency to review safety of ibuprofen', 'Debate over the safety of non steroidal anti inflammatory drugs NSAIDs in treating covid 19 has continued with the European Medicines Agency saying that the drugs could be considered for treating', 'http://feeds.bmj.com/~r/bmj/recent/~3/_lXNsKc62LQ/bmj.m1168.short', 26, 'published', '2020-03-25 08:00:57', '2020-03-25 08:01:52'),
(215, 'Interpreting test results: don&amp;#x2019;t blame the tools', 'McCormack and Holmes discuss the imprecision of medical measurements and suggest a method for estimating variation in test results 1 Byron s paraphrased proverb Good workmen never quarrel with', 'http://feeds.bmj.com/~r/bmj/recent/~3/E5E_dzxBKoc/bmj.m1162.short', 26, 'published', '2020-03-25 20:32:38', '2020-03-25 20:37:57'),
(216, 'Covid-19: Trump declares intention to &amp;#x201C;re-open economy&amp;#x201D; within weeks against experts&amp;#x2019; advice', 'President Donald Trump growing increasingly impatient with social distancing measures urged by US public health officials has said that he wants people back at work and packed churches all over', 'http://feeds.bmj.com/~r/bmj/recent/~3/oHBo_9oBuIk/bmj.m1217.short', 26, 'published', '2020-03-25 20:32:38', '2020-03-25 20:38:02'),
(217, 'Covid-19: experts question analysis suggesting half UK population has been infected', 'Experts have criticised an unpublished modelling study released to the media on Tuesday 24 March that suggested that half the UK population might already have been infected with covid 19 1They', 'http://feeds.bmj.com/~r/bmj/recent/~3/NZLgB3qc_Zo/bmj.m1216.short', 26, 'published', '2020-03-25 20:32:38', '2020-03-25 20:37:54'),
(218, 'Covid-19 risks and response in South Asia', 'Over the past few weeks we have seen political leaders policy makers and health managers grapple with the reality of a novel coronavirus outbreak and its potential for global spread 12 From what', 'http://feeds.bmj.com/~r/bmj/recent/~3/-jE52IVCaRE/bmj.m1190.short', 26, 'published', '2020-03-25 20:32:38', '2021-01-04 12:41:28'),
(219, 'David Oliver: Covid-19&amp;#x2014;recriminations and political point scoring must wait', 'Now is surely not the time for premature post mortems on our response to covid 19 for party political point scoring or for reheating of historical resentments Nor is it the time for attacks on', 'http://feeds.bmj.com/~r/bmj/recent/~3/nzFSXz6zV5A/bmj.m1153.short', 26, 'published', '2020-03-25 20:32:38', '2020-03-25 20:37:49'),
(220, 'Where there&amp;#x2019;s life . . .', 'bmj 368 mar25 2 m1200 FAF1faGetty ImagesA nurse in a protective suit attends to a baby in an isolation ward at Wuhan Children s Hospital China has announced that it will lift the lockdown on Wuhan', 'http://feeds.bmj.com/~r/bmj/recent/~3/RVrpX5l_bHE/bmj.m1200.short', 26, 'published', '2020-03-25 20:32:38', '2020-03-25 20:37:46'),
(221, 'COVID-19 pandemic: palliative care for elderly and frail patients at home and in residential and nursing homes.', 'Related Articles COVID 19 pandemic palliative care for elderly and frail patients at home and in residential and nursing homes Swiss Med Wkly 2020 Mar 23 150 w20235 Authors Kunz R Minder M PMID 32208497 PubMed in process', 'https://www.ncbi.nlm.nih.gov/pubmed/32208497?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:03:20'),
(222, 'More awareness is needed for severe acute respiratory syndrome coronavirus 2019 transmission through exhaled air during non-invasive respiratory support: experience from China.', 'Related Articles More awareness is needed for severe acute respiratory syndrome coronavirus 2019 transmission through exhaled air during non invasive respiratory support experience from China Eur Respir J 2020 03 55 3 Authors Guan L Zhou L Zhang J Peng W Chen R PMID 32198275 PubMed indexed for MEDLINE', 'https://www.ncbi.nlm.nih.gov/pubmed/32198275?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:03:23'),
(223, 'Community pharmacist in public health emergencies: Quick to action against the coronavirus 2019-nCoV outbreak.', 'Related Articles Community pharmacist in public health emergencies Quick to action against the coronavirus 2019 nCoV outbreak Res Social Adm Pharm 2020 04 16 4 583 586 Authors Ung COL Abstract The 2019 nCoV infection that is caused by a novel strain of coronavirus was first detected in China in the end of December 2019 and declared a public health emergency of international concern by the World Health Organization on January 30 2020 Community pharmacists in one of the first areas that had confirmed cases of the viral infection Macau joined the collaborative force in supporting the local health emergency preparedness and response arrangements This paper aimed to improve the understanding of community pharmacists role in case of 2019 CoV outbreak based on the practical experiences in consultation with the recommendations made by the International Pharmaceutical Federation on the Coronavirus 2019 nCoV outbreak PMID 32081569 PubMed indexed for MEDLINE', 'https://www.ncbi.nlm.nih.gov/pubmed/32081569?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:03:49'),
(224, 'Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.', 'Related Articles Severe acute respiratory syndrome coronavirus 2 SARS CoV 2 and coronavirus disease 2019 COVID 19 The epidemic and the challenges Int J Antimicrob Agents 2020 Mar 55 3 105924 Authors Lai CC Shih TP Ko WC Tang HJ Hsueh PR Abstract The emergence of severe acute respiratory syndrome coronavirus 2 SARS CoV 2 previously provisionally named 2019 novel coronavirus or 2019 nCoV disease COVID 19 in China at the end of 2019 has caused a large global outbreak and is a major public health issue As of 11 February 2020 data from the World Health Organization WHO have shown that more than 43 000 confirmed cases have been identified in 28 countries regions with 99 of cases being detected in China On 30 January 2020 the WHO declared COVID 19 as the sixth public health emergency of international concern SARS CoV 2 is closely related to two bat derived severe acute respiratory syndrome like coronaviruses bat SL CoVZC45 and bat SL CoVZXC21 It is spread by human to human transmission via droplets or direct contact and infection has been estimated to have mean incubation period of 6 4 days and a basic reproduction number of 2 24 3 58 Among patients with pneumonia caused by SARS CoV 2 novel coronavirus pneumonia or Wuhan pneumonia fever was the most common symptom followed by cough Bilateral lung involvement with ground glass opacity was the most common finding from computed tomography images of the chest The one case of SARS CoV 2 pneumonia in the USA is responding well to remdesivir which is now undergoing a clinical trial in China Currently controlling infection to prevent the spread of SARS CoV 2 is the primary intervention being used However public health authorities should keep monitoring the situation closely as the more we can learn about this novel virus and its associated outbreak the better we can respond PMID 32081636 PubMed indexed for MEDLINE', 'https://www.ncbi.nlm.nih.gov/pubmed/32081636?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:03:51'),
(225, 'Mental health care for medical staff in China during the COVID-19 outbreak.', 'Related Articles Mental health care for medical staff in China during the COVID 19 outbreak Lancet Psychiatry 2020 04 7 4 e15 e16 Authors Chen Q Liang M Li Y Guo J Fei D Wang L He L Sheng C Cai Y Li X Wang J Zhang Z PMID 32085839 PubMed indexed for MEDLINE', 'https://www.ncbi.nlm.nih.gov/pubmed/32085839?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:02:17'),
(226, 'Online mental health services in China during the COVID-19 outbreak.', 'Related Articles Online mental health services in China during the COVID 19 outbreak Lancet Psychiatry 2020 04 7 4 e17 e18 Authors Liu S Yang L Zhang C Xiang YT Liu Z Hu S Zhang B PMID 32085841 PubMed indexed for MEDLINE', 'https://www.ncbi.nlm.nih.gov/pubmed/32085841?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:03:40'),
(227, 'The neglected health of international migrant workers in the COVID-19 epidemic.', 'Related Articles The neglected health of international migrant workers in the COVID 19 epidemic Lancet Psychiatry 2020 04 7 4 e20 Authors Liem A Wang C Wariyanti Y Latkin CA Hall BJ PMID 32085842 PubMed indexed for MEDLINE', 'https://www.ncbi.nlm.nih.gov/pubmed/32085842?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:03:44'),
(228, 'Mental health services for older adults in China during the COVID-19 outbreak.', 'Related Articles Mental health services for older adults in China during the COVID 19 outbreak Lancet Psychiatry 2020 04 7 4 e19 Authors Yang Y Li W Zhang Q Zhang L Cheung T Xiang YT PMID 32085843 PubMed indexed for MEDLINE', 'https://www.ncbi.nlm.nih.gov/pubmed/32085843?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:01:44'),
(229, 'Managing neonates with respiratory failure due to SARS-CoV-2 - Authors\' reply.', 'Related Articles Managing neonates with respiratory failure due to SARS CoV 2 Authors reply Lancet Child Adolesc Health 2020 04 4 4 e9 Authors Wang J Shi Y PMID 32151318 PubMed indexed for MEDLINE', 'https://www.ncbi.nlm.nih.gov/pubmed/32151318?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:01:46'),
(230, 'Managing neonates with respiratory failure due to SARS-CoV-2.', 'Related Articles Managing neonates with respiratory failure due to SARS CoV 2 Lancet Child Adolesc Health 2020 04 4 4 e8 Authors De Luca D PMID 32151320 PubMed indexed for MEDLINE', 'https://www.ncbi.nlm.nih.gov/pubmed/32151320?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:02:22'),
(231, 'Audio Interview: New Research on Possible Treatments for Covid-19.', 'Related Articles Audio Interview New Research on Possible Treatments for Covid 19 N Engl J Med 2020 03 19 382 12 e30 Authors Rubin EJ Baden LR Morrissey S PMID 32187489 PubMed indexed for MEDLINE', 'https://www.ncbi.nlm.nih.gov/pubmed/32187489?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:03:04'),
(232, 'Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China.', 'Related Articles Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan China PLoS One 2020 15 3 e0230548 Authors Yuan M Yin W Tao Z Tan W Hu Y Abstract Radiologic characteristics of 2019 novel coronavirus 2019 nCoV infected pneumonia NCIP which had not been fully understood are especially important for diagnosing and predicting prognosis We retrospective studied 27 consecutive patients who were confirmed NCIP the clinical characteristics and CT image findings were collected and the association of radiologic findings with mortality of patients was evaluated 27 patients included 12 men and 15 women with median age of 60 years IQR 47 69 17 patients discharged in recovered condition and 10 patients died in hospital The median age of mortality group was higher compared to survival group 68 IQR 63 73 vs 55 IQR 35 60 P 0 003 The comorbidity rate in mortality group was significantly higher than in survival group 80 vs 29 P 0 018 The predominant CT characteristics consisted of ground glass opacity 67 bilateral sides involved 86 both peripheral and central distribution 74 and lower zone involvement 96 The median CT score of mortality group was higher compared to survival group 30 IQR 7 13 vs 12 IQR 11 43 P 0 021 with more frequency of consolidation 40 vs 6 P 0 047 and air bronchogram 60 vs 12 P 0 025 An optimal cutoff value of a CT score of 24 5 had a sensitivity of 85 6 and a specificity of 84 5 for the prediction of mortality 2019 nCoV was more likely to infect elderly people with chronic comorbidities CT findings of NCIP were featured by predominant ground glass opacities mixed with consolidations mainly peripheral or combined peripheral and central distributions bilateral and lower lung zones being mostly involved A simple CT scoring method was capable to predict mortality PMID 32191764 PubMed indexed for MEDLINE', 'https://www.ncbi.nlm.nih.gov/pubmed/32191764?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:03:06'),
(233, 'COVID-19 epidemic in Switzerland: on the importance of testing, contact tracing and isolation.', 'Related Articles COVID 19 epidemic in Switzerland on the importance of testing contact tracing and isolation Swiss Med Wkly 2020 03 09 150 w20225 Authors Salath M Althaus CL Neher R Stringhini S Hodcroft E Fellay J Zwahlen M Senti G Battegay M Wilder Smith A Eckerle I Egger M Low N Abstract Switzerland is among the countries with the highest number of coronavirus disease 2019 COVID 19 cases per capita in the world There are likely many people with undetected SARS CoV 2 infection because testing efforts are currently not detecting all infected people including some with clinical disease compatible with COVID 19 Testing on its own will not stop the spread of SARS CoV 2 Testing is part of a strategy The World Health Organization recommends a combination of measures rapid diagnosis and immediate isolation of cases rigorous tracking and precautionary self isolation of close contacts In this article we explain why the testing strategy in Switzerland should be strengthened urgently as a core component of a combination approach to control COVID 19 PMID 32191813 PubMed indexed for MEDLINE', 'https://www.ncbi.nlm.nih.gov/pubmed/32191813?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:02:30'),
(234, 'COVID-19 pandemic: triage for intensive-care treatment under resource scarcity.', 'Related Articles COVID 19 pandemic triage for intensive care treatment under resource scarcity Swiss Med Wkly 2020 Mar 23 150 w20229 Authors Swiss Academy Of Medical Sciences PMID 32208495 PubMed in process', 'https://www.ncbi.nlm.nih.gov/pubmed/32208495?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:02:20'),
(235, 'COVID-19 &amp; Beyond: Micro-practices for Burnout Prevention and Emotional Wellness.', 'Related Articles COVID 19 Beyond Micro practices for Burnout Prevention and Emotional Wellness J Am Coll Radiol 2020 Mar 23 Authors Fessell D Cherniss C PMID 32208139 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32208139?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:02:28'),
(236, 'COVID-19: decision making and palliative care.', 'Related Articles COVID 19 decision making and palliative care Swiss Med Wkly 2020 Mar 23 150 w20233 Authors Borasio GD Gamondi C Obrist M Jox R For The Covid Task Force Of Palliative Ch Abstract Due to the current development around the COVID 19 pandemic palliative ch has created a Task Force to provide recommendations for health professionals on the treatment of palliative care patients in the various settings inpatient and outpatient PMID 32208494 PubMed in process', 'https://www.ncbi.nlm.nih.gov/pubmed/32208494?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:02:24'),
(237, 'Recommendations for the admission of patients with COVID-19 to intensive care and intermediate care units (ICUs and IMCUs).', 'Related Articles Recommendations for the admission of patients with COVID 19 to intensive care and intermediate care units ICUs and IMCUs Swiss Med Wkly 2020 Mar 23 150 w20227 Authors Swiss Society Of Intensive Care Medicine PMID 32208493 PubMed in process', 'https://www.ncbi.nlm.nih.gov/pubmed/32208493?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:02:27'),
(238, 'Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics.', 'Related Articles Treating COVID 19 Off Label Drug Use Compassionate Use and Randomized Clinical Trials During Pandemics JAMA 2020 Mar 24 Authors Kalil AC PMID 32208486 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32208486?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:02:13'),
(239, 'COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?', 'Related Articles COVID 19 and Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers What Is the Evidence JAMA 2020 Mar 24 Authors Patel AB Verma A PMID 32208485 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32208485?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:02:31'),
(240, 'Rapid Response to COVID-19: Health Informatics Support for Outbreak Management in an Academic Health System.', 'Related Articles Rapid Response to COVID 19 Health Informatics Support for Outbreak Management in an Academic Health System J Am Med Inform Assoc 2020 Mar 24 Authors Reeves JJ Hollandsworth HM Torriani FJ Taplitz R Abeles S Tai Seale M Millen M Clay BJ Longhurst CA Abstract OBJECTIVE To describe the implementation of technological support important for optimizing clinical management of the COVID 19 pandemic MATERIALS AND METHODS Our health system has confirmed prior and current cases of COVID 19 An Incident Command Center was established early in the crisis and helped identify electronic health record EHR based tools to support clinical care RESULTS We outline the design and implementation of EHR based rapid screening processes laboratory testing clinical decision support reporting tools and patient facing technology related to COVID 19 DISCUSSION The EHR is a useful tool to enable rapid deployment of standardized processes UC San Diego Health built multiple COVID 19 specific tools to support outbreak management including scripted triaging electronic check in standard ordering and documentation secure messaging real time data analytics and telemedicine capabilities Challenges included the need to frequently adjust build to meet rapidly evolving requirements communication and adoption and coordinating the needs of multiple stakeholders while maintaining high quality pre pandemic medical care CONCLUSION The EHR is an essential tool in supporting the clinical needs of a health system managing the COVID 19 pandemic PMID 32208481 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32208481?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:03:48'),
(241, 'The Battle Against Coronavirus Disease 2019 (COVID-19): Emergency Management and Infection Control in a Radiology Department.', 'Related Articles The Battle Against Coronavirus Disease 2019 COVID 19 Emergency Management and Infection Control in a Radiology Department J Am Coll Radiol 2020 Mar 21 Authors Huang Z Zhao S Li Z Chen W Zhao L Deng L Song B Abstract OBJECTIVE To describe the strategy and the emergency management and infection control procedures of our radiology department during the COVID 19 outbreak METHODS We set up emergency management and sensing control teams The team formulated various measures such as reconfiguration of the radiology department personal protection and staff training standardized imaging examination procedures for fever patients and common patients and so on RESULTS From January 21 to March 9 3 083 people underwent fever CT examinations Including the initial examination and reexamination the total number of fever CT examination is 3 340 As a result of our precautions none of the staff of the radiology department was infected with COVID 19 CONCLUSION Strategic planning and adequate protections can help protect patients and staff against a highly infectious disease while allow normal functioning at a high volume capacity PMID 32208140 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32208140?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:03:52'),
(242, 'Novel Screening and Triage Strategy in Iran During Deadly COVID-19 Epidemic; Value of Humanitarian Teleconsultation Service.', 'Related Articles Novel Screening and Triage Strategy in Iran During Deadly COVID 19 Epidemic Value of Humanitarian Teleconsultation Service J Am Coll Radiol 2020 Mar 20 Authors Davarpanah AH Mahdavi A Sabri A Langroudi TF Kahkouee S Haseli S Kazemi MA Mehrian P Mahdavi A Falahati F Tuchayi AM Bakhshayeshkaram M Taheri MS PMID 32208138 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32208138?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:03:09'),
(243, 'CT Findings of Coronavirus Disease (COVID-19) Severe Pneumonia.', 'Related Articles CT Findings of Coronavirus Disease COVID 19 Severe Pneumonia AJR Am J Roentgenol 2020 Mar 24 W1 W2 Authors Guan W Liu J Yu C PMID 32208010 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32208010?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:02:15'),
(244, 'Critical Organizational Issues for Cardiologists in the COVID-19 Outbreak: A Frontline Experience From Milan, Italy.', 'Related Articles Critical Organizational Issues for Cardiologists in the COVID 19 Outbreak A Frontline Experience From Milan Italy Circulation 2020 Mar 24 Authors Stefanini GG Azzolini E Condorelli G PMID 32207994 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32207994?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:03:22'),
(245, 'Covid-19 infection and mortality - A physiologist\'s perspective enlightening clinical features and plausible interventional strategies.', 'Related Articles Covid 19 infection and mortality A physiologist s perspective enlightening clinical features and plausible interventional strategies Am J Physiol Lung Cell Mol Physiol 2020 Mar 24 Authors Abassi ZA Skorecki K Heyman SN Kinaneh S Armaly Z PMID 32207983 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32207983?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:03:45'),
(246, 'Drug targets for corona virus: A systematic review.', 'Related Articles Drug targets for corona virus A systematic review Indian J Pharmacol 2020 Jan Feb 52 1 56 65 Authors Prajapat M Sarma P Shekhar N Avti P Sinha S Kaur H Kumar S Bhattacharyya A Kumar H Bansal S Medhi B Abstract The 2019 novel coronavirus nCoV is a major source of disaster in the 21th century However the lack of specific drugs to prevent treat an attack is a major need at this current point of time In this regard we conducted a systematic review to identify major druggable targets in coronavirus CoV We searched PubMed and RCSB database with keywords HCoV NCoV corona virus SERS CoV MERS CoV 2019 nCoV crystal structure X ray crystallography structure NMR structure target and drug target till Feb 3 2020 The search identified seven major targets spike protein envelop protein membrane protein protease nucleocapsid protein hemagglutinin esterase and helicase for which drug design can be considered There are other 16 nonstructural proteins NSPs which can also be considered from the drug design perspective The major structural proteins and NSPs may serve an important role from drug design perspectives However the occurrence of frequent recombination events is a major deterrent factor toward the development of CoV specific vaccines drugs PMID 32201449 PubMed indexed for MEDLINE', 'https://www.ncbi.nlm.nih.gov/pubmed/32201449?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:04:04'),
(247, 'Covid-19 mass testing facilities could end the epidemic rapidly.', 'Related Articles Covid 19 mass testing facilities could end the epidemic rapidly BMJ 2020 03 22 368 m1163 Authors Peto J PMID 32201376 PubMed indexed for MEDLINE', 'https://www.ncbi.nlm.nih.gov/pubmed/32201376?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:03:57'),
(248, 'SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients.', 'Related Articles SARS CoV 2 Viral Load in Upper Respiratory Specimens of Infected Patients N Engl J Med 2020 03 19 382 12 1177 1179 Authors Zou L Ruan F Huang M Liang L Huang H Hong Z Yu J Kang M Song Y Xia J Guo Q Song T He J Yen HL Peiris M Wu J PMID 32074444 PubMed indexed for MEDLINE', 'https://www.ncbi.nlm.nih.gov/pubmed/32074444?dopt=Abstract', 21, 'published', '2020-03-26 12:48:44', '2020-03-29 05:03:37'),
(249, 'Schistosomiasis elimination: refocusing on snail control to sustain progress', 'It is likely that countries endemic for schistosomiasis bilharzia and soil transmitted helminthiases intestinal worms will be able to treat 75 of school aged children by 2020 the target set by the NTD Roadmap developed by the World Health Organization WHO in 2012 In 2017 almost 99 million people were treated This includes 81 1 million school aged children representing 68 coverage worldwide For intestinal worms 598 1 million children were treated 188 million preschool aged and 410 1 million school aged children representing 69 coverage worldwide', 'https://www.who.int/news-room/detail/25-03-2020-schistosomiasis-elimination-refocusing-on-snail-control-to-sustain-progress', 22, 'published', '2020-03-26 12:48:45', '2020-03-29 05:03:12'),
(250, 'International working group on Ethics &amp; COVID-19', 'The response to the COVID 19 pandemic raises a number of difficult ethical issues related to e g clinical trials social distancing priority setting health care workers rights and obligations etc WHO has established an international Working Group on Ethics COVID 19 in order to develop advice on key ethical questions that Member States need to address Related document Distilling existing guidance to support COVID 19 Research Development pdf 263kb', 'https://www.who.int/news-room/detail/20-03-2020-who-has-established-an-international-working-group-on-ethics-covid-19', 22, 'published', '2020-03-26 12:48:45', '2020-03-29 05:03:19'),
(251, 'WHO urges countries to ensure the continuity of malaria services in the context of the COVID-19 pandemic', 'The COVID 19 pandemic is testing the resilience of robust health systems around the world Recognizing the heavy toll that malaria exacts on vulnerable populations in sub Saharan Africa as well as the region s fragile health infrastructure WHO underlines the critical importance of sustaining efforts to prevent detect and treat malaria As COVID 19 continues its rapid spread WHO would like to send a clear message to malaria affected countries in Africa said Dr Pedro Alonso Director of the WHO Global Malaria Programme Do not scale back your planned malaria prevention diagnostic and treatment activities If someone living in a place with malaria develops a fever he or she should seek diagnosis and care as soon as possible Ensuring access to core malaria prevention measures is an important strategy for reducing the strain on health systems these include vector control measures such as insecticide treated nets and indoor residual spraying as well as chemoprevention for pregnant women and young children intermittent preventive treatment in pregnancy intermittent preventive treatment in infants and seasonal malaria chemoprevention Additional special measures could ease the burden on health systems in the context of COVID 19 such as presumptive malaria treatment and mass drug administration Any interventions must consider the importance of both lowering malaria related mortality and ensuring the safety of communities and health workers WHO will provide guidance for countries to safely maintain essential health services in the context of the COVID 19 response About COVID 19 COVID 19 is the infectious disease caused by the most recently discovered coronavirus This new virus and disease were unknown before the outbreak began in Wuhan China in December 2019 Essential information on the COVID 19 pandemic can be found in a dedicated WHO site About malaria Malaria is a preventable and treatable disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes In 2018 there were an estimated 228 million cases of malaria worldwide and 405 000 malaria related deaths For more on malaria visit www who int malaria', 'https://www.who.int/news-room/detail/25-03-2020-who-urges-countries-to-ensure-the-continuity-of-malaria-services-in-the-context-of-the-covid-19-pandemic', 22, 'published', '2020-03-26 12:48:45', '2020-03-29 05:03:35'),
(252, 'Seven days in medicine: 18-24 March', 'Covid 19NHS strikes major deal with private hospitals to boost capacityThe NHS in England will benefit from an extra 8000 beds almost 1200 more ventilators and nearly 20 000 extra healthcare staff', 'http://feeds.bmj.com/~r/bmj/recent/~3/KGx3ripYozA/bmj.m1177.short', 26, 'published', '2020-03-26 12:48:45', '2020-03-29 05:03:32'),
(253, 'Covid-19: India imposes lockdown for 21 days and cases rise', 'The Indian government has announced a countrywide lockdown for three weeks starting at midnight on 24 March to slow the spread of covid 19 as the number of people testing positive in the country', 'http://feeds.bmj.com/~r/bmj/recent/~3/wtgwfr1YbQE/bmj.m1251.short', 26, 'published', '2020-03-26 12:48:45', '2020-03-29 05:03:26'),
(254, 'Nurses&amp;#x2019; professional &amp;#x0237;udgment: appropriate care for people according to their stage of life', 'The loss of a valuable nurse because of an irrational decision by the Nursing and Midwifery Council NMC is a shameful event I agree with Oliver that this will damage nurses confidence in the NMC', 'http://feeds.bmj.com/~r/bmj/recent/~3/VyMhwkwMrMU/bmj.m1191.short', 26, 'published', '2020-03-26 12:48:45', '2020-03-29 05:03:25'),
(255, 'Covid-19: what treatments are being investigated?', 'With no current specific treatment for covid 19 the race is on to develop or repurpose drugs to help end the epidemic The World Health Organization has now launched the SOLIDARITY trial to', 'http://feeds.bmj.com/~r/bmj/recent/~3/Vp9487JQxm0/bmj.m1252.short', 26, 'published', '2020-03-26 12:48:45', '2020-03-29 05:03:33'),
(256, 'Organ donation: educating the public about the &amp;#x201C;opt-out&amp;#x201D; system is crucial', 'The switch to an opt out system for organ donation is eagerly anticipated and represents a positive change 1 But it will not solve the organ donor deficit on its own The policy change has been', 'http://feeds.bmj.com/~r/bmj/recent/~3/moujEbMiRzg/bmj.m1207.short', 26, 'published', '2020-03-26 12:48:45', '2020-03-29 05:03:36'),
(257, 'WHO Director-General calls on G20 to Fight, Unite, and Ignite against COVID-19', 'Dr Tedros Adhanom Ghebreyesus Director General of the World Health Organization addressed Heads of State at today s extraordinary G20 Leaders Summit focused on COVID 19 He told them You have come together to confront the defining health crisis of our time We are at war with a virus that threatens to tear us apart if we let it He welcomed the G20 s initiative to find joint solutions and work together This is a global crisis that requires a global response Fight unite ignite Dr Tedros call was clear First he urged leaders to fight without excuses without regrets thanking countries who have already taken steps and urgently asking that they do more Second he encouraged them to unite stressing that no country can fight this alone and calling on all countries to build on the solidarity already sparked by the crisis Third he exhorted them to ignite a global movement to ensure this never happens again He welcomed G20 leaders commitment to do whatever it takes to overcome the pandemic to protect lives and livelihoods as well as restore confidence and shore up stability currently threatened in trade and other sectors and to commit to take all necessary health measures and seek to ensure adequate financing to contain the pandemic and protect people especially the most vulnerable The G20 committed to support and further strengthen WHO s mandate in coordinating the response and called for full funding of WHO s Strategic Preparedness and Response Plan G20 members pledged to work together to increase research and development funding for vaccines and medicines strengthen international scientific cooperation and leverage digital technologies In turn they tasked WHO and other relevant organizations with assessing gaps in pandemic preparedness and report the findings of this assessment to the G20 Finance and Health Ministers in order to establish a global initiative on pandemic preparedness and response together', 'https://www.who.int/news-room/detail/26-03-2020-who-s-director-general-calls-on-g20-to-fight-unite-and-ignite-against-covid-19', 22, 'published', '2020-03-26 18:57:48', '2020-03-29 05:03:42'),
(258, 'Ebola virus disease – Democratic Republic of the Congo', 'No new cases have been reported in the ongoing Ebola virus disease EVD outbreak in the Democratic Republic of the Congo since 17 February 2020 Figure 1', 'http://www.who.int/entity/csr/don/26-March-2020-ebola-drc/en/index.html', 24, 'published', '2020-03-26 18:57:48', '2020-03-29 05:04:14'),
(259, 'Unilateral bloodstained nasal discharge', 'A man in his 40s presented with six months of bloodstained nasal discharge from his right nostril Nasal endoscopy showed purulent bloodstained nasal discharge in the right nasal cavity and a mass', 'http://feeds.bmj.com/~r/bmj/recent/~3/KWkvfOj4QG8/bmj.m9.short', 26, 'published', '2020-03-26 18:57:49', '2020-03-29 05:04:21'),
(260, 'Covid-19: Don&amp;#x2019;t forget the impact on US family physicians', 'As covid 19 continues its exponential growth in parts of the United States we have heard a great deal in the media about brave exhausted emergency room doctors and staff 1 2 Very little that I have', 'http://feeds.bmj.com/~r/bmj/recent/~3/xuW0v13Cvr4/bmj.m1260.short', 26, 'published', '2020-03-26 18:57:49', '2020-03-29 05:04:31'),
(261, 'Covid-19: Gilead withdraws orphan drug designation from potential treatment after criticism', 'The US Food and Drug Administration FDA has withdrawn orphan drug designation from a potential covid 19 treatment after criticism that treating covid 19 as a rare disease was', 'http://feeds.bmj.com/~r/bmj/recent/~3/7yacMuqZlcA/bmj.m1259.short', 26, 'published', '2020-03-26 18:57:49', '2020-03-29 05:04:24'),
(262, 'Europe&amp;#x2019;s migrant containment policies threaten the response to covid-19', 'The world has watched the growing global health crisis caused by covid 19 with alarm fear and desperation One after another governments healthcare systems and individuals are adopting', 'http://feeds.bmj.com/~r/bmj/recent/~3/kv5zQGectrA/bmj.m1213.short', 26, 'published', '2020-03-26 18:57:49', '2020-03-29 05:04:25'),
(263, 'Covid-19: FDA approves use of convalescent plasma to treat critically ill patients', 'The US Food and Drug Administration has approved the use of plasma from recovered patients to treat people who are critically ill with covid 19 provided that doctors get approval over the', 'http://feeds.bmj.com/~r/bmj/recent/~3/Rdq0vdsqmlo/bmj.m1256.short', 26, 'published', '2020-03-26 18:57:49', '2020-03-29 05:04:22');
INSERT INTO `rss_articles` (`id`, `title`, `body`, `href`, `rss_id`, `status`, `created_at`, `updated_at`) VALUES
(264, 'The world&amp;#x2019;s largest refugee camp prepares for covid-19', 'Bangladesh with its 168 million inhabitants is one of the poorest and most densely populated countries in the world Millions live cheek by jowl in slums where 10 or more households share a', 'http://feeds.bmj.com/~r/bmj/recent/~3/fDRzBbn455A/bmj.m1205.short', 26, 'published', '2020-03-26 18:57:49', '2020-03-29 05:04:01'),
(265, 'Covid-19: weathering the storm', 'The UK is at last in near lockdown While further measures may be needed the government s announcement on Monday 23 March has brought the country nearly into step with its European neighbours If we', 'http://feeds.bmj.com/~r/bmj/recent/~3/7sLmpWdXbrc/bmj.m1199.short', 26, 'published', '2020-03-26 20:02:50', '2020-03-29 05:03:50'),
(266, 'Global, regional, and national burden of neck pain in the general population, 1990-2017: systematic analysis of the Global Burden of Disease Study 2017', 'AbstractObjectiveTo use data from the Global Burden of Disease Study between 1990 and 2017 to report the rates and trends of point prevalence annual incidence and years lived with disability for', 'http://feeds.bmj.com/~r/bmj/recent/~3/TsG18aXZqvk/bmj.m791.short', 26, 'published', '2020-03-26 20:02:50', '2020-03-29 05:04:50'),
(267, '\"2019-ncov\" OR nCov OR (coronavirus AND wuhan[TIAB]) OR \"novel coronavirus\" OR (pneumonia AND wuhan[TIAB]) OR COVID-19[TW] OR 2019ncov[TW] AND ( ( \"2019/12/01\"[PDat] : \"3000/12/31\"[PDat] ) ); +152 new citations', '152 new pubmed citations were retrieved for your search Click on the search hyperlink below to display the complete search results 2019 ncov OR nCov OR coronavirus AND wuhan TIAB OR novel coronavirus OR pneumonia AND wuhan TIAB OR COVID 19 TW OR 2019ncov TW AND 2019 12 01 PDat 3000 12 31 PDat These pubmed results were generated on 2020 04 02 PubMed comprises more than millions of citations for biomedical literature from MEDLINE life science journals and online books Citations may include links to full text content from PubMed Central and publisher web sites', 'https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Search&amp;db=pubmed&amp;term=%28%20%28%222019-ncov%22%20OR%20nCov%20OR%20%28coronavirus%20AND%20wuhan%5BTIAB%5D%29%20OR%20%22novel%20coronavirus%22%20OR%20%28pneumonia%20AND%20wuhan%5BTIAB%5D%29%20OR%20COVID-19%5BTW%5D%20OR%202019ncov%5BTW%5D%20AND%20%28%20%28%20%222019%2F12%2F01%22%5BPDat%5D%20%3A%20%223000%2F12%2F31%22%5BPDat%5D%20%29%20%29%29%20AND%20%222020%2F04%2F01%2007.10%22%5BMHDA%5D%3A%222020%2F04%2F02%2008.01%22%5BMHDA%5D%29', 21, 'pending', '2020-04-02 15:10:05', NULL),
(268, 'World Health Worker Week - April  5 - 11, 2020', 'The COVID 19 pandemic and other global emergencies show us once again the heroic efforts health workers on the front lines make every day to keep their communities and the world safe and healthy The WHO and the Global Health Workforce Network is pleased to partner with civil society partners the Frontline Health Workers Coalition and its members to honor health workers during World Health Worker Week April 5 11 2020 The Eighth Annual World Health Worker Week is yet another opportunity to mobilize communities partners and policymakers to increase support of health workers worldwide The 2020 theme is Leaders on the Front Line This theme highlights the need to provide greater leadership opportunities for frontline health workers particularly women health workers who make up more than 70 of the global health workforce At the same time this theme emphasizes how health workers often put themselves on the line often at great personal risk to themselves and their families to save and improve lives We invite all health workforce stakeholders to join us by raising public awareness and engaging on health workforce issues and recognize the lifesaving contribution of the health workforce All activities will be filtered through a World Health Worker Week portal hosted by the Frontline Health Workers Coalition secretariat at IntraHealth International Some key ways to get involved Add your voice to the WHWWeek conversation on social media Use the WHWW Social Media Guide with key messages graphics and suggested tweets Participate in the WHWW Video Testimonial Series and tell health policymakers why frontline health workers are Leaders on the Line and how we can better support them It s easy to take part see the guidance and upload your video Celebrate World Health Day on Tuesday April 7 In this International Year of the Nurse and the Midwife World Health Day will shine a light on the vital role nurses and midwives play in providing health care around the world and call for a strengthening of the nursing and midwifery workforce Share and promote World Health Day assets here', 'https://www.who.int/news-room/detail/02-04-2020-world-health-worker-week-2020', 22, 'pending', '2020-04-02 15:10:05', NULL),
(269, 'WHO to accelerate action to reduce the harmful use of alcohol', 'The harmful use of alcohol causes approximately 3 million deaths every year and the overall burden of disease and injuries attributable to alcohol consumption remains unacceptably high The pace of development and implementation of alcohol policies has been uneven in WHO regions and resources and capacities for implementation of the WHO Global strategy to reduce the harmful use of alcohol 10 years after its endorsement do not correspond to the magnitude of the problems On this basis the WHO Executive Board in its decision EB146 14 called for accelerated action to reduce the harmful use of alcohol The Board considered the report on the political declaration of the third high level meeting of the General Assembly on the prevention and control of non communicable diseases particularly Annex 3 entitled Implementation of the global strategy to reduce the harmful use of alcohol and the report on the findings of the consultative process on implementation of the global strategy to reduce the harmful use of alcohol and the way forward The Board in its decision EB146 14 requested the WHO Director General inter alia to develop an action plan 2022 2030 to effectively implement the Global strategy to reduce the harmful use of alcohol as a public health priority in consultation with Member States and relevant stakeholders for consideration by the 75th World Health Assembly through the 150th session of the WHO Executive Board in 2022 and to develop a technical report on the harmful use of alcohol related to cross border alcohol marketing advertising and promotional activities including targeting youth and adolescents before the 150th session of the WHO Executive Board which could contribute to the development of the action plan as well as to adequately resource the work on the harmful use of alcohol In response to decision EB146 14 the WHO Secretariat will implement the following March April 2020 Commissioning of the scoping review on the harmful use of alcohol related to cross border alcohol marketing advertising and promotional activities including targeting youth and adolescents Commissioning background papers for the report development April May 2020 Producing zero draft of the working document for development of an action plan 2022 2030 to effectively implement the Global strategy to reduce the harmful use with proposed essential elements and components June 2020 Technical expert meetings organized by WHO headquarters to discuss zero draft of the working document for development of the action plan and the content of the technical report on the harmful use of alcohol related to cross border alcohol marketing advertising and promotional activities July September 2020 Finalization of the working document for subsequent consultation process Web based consultation on the working document for development of the action plan open to Member States UN organizations and other international organizations and non State actors All relevant feedback received will be published on WHO website October 2020 March 2021 Regional technical consultations with Member States on the working document for development of the action plan 2022 2030 March April 2021 Development of the first draft of the action plan based on the input received on the working document in the process of the regional consultations April June 2021 The web based consultation on the first draft of the action plan open to Member States UN organizations and other international organizations and non State actors All relevant feedback received will be published on WHO website Discussion of the first draft at the Third WHO Forum on alcohol drugs and addictive behaviours attended by technical focal points from Member States representatives of UN entities civil society organizations WHO collaborating centres and academia Consultation with economic operators in alcohol production and trade on their contribution to reducing the harmful use of alcohol within their core roles An informal consultation with Member States on the first draft of the action plan July August 2021 Development of the second draft of the action plan based on the feedback received on the first draft during the previous stages of the consultation process August November 2021 Briefings on the second draft of the action plan organized at the Regional Committee meetings Release of the technical report on the harmful use of alcohol related to cross border alcohol marketing advertising and promotional activities including targeting youth and adolescents with a summary of main findings and conclusions available in six languages A formal meeting of Member States for consideration of the second draft of the action plan Finalization of the draft action plan taken into consideration feedback and inputs received from Member States and other stakeholders during the consultation process in April October 2021 Development and submission of the report by the Secretariat to 150th session of the Executive Board January February 2022 The 150th session of the WHO Executive Board will consider the report of the WHO Director General containing the draft action plan 2022 2030 to effectively implement the Global strategy to reduce the harmful use of alcohol', 'https://www.who.int/news-room/detail/28-03-2020-who-to-accelerate-action-to-reduce-the-harmful-use-of-alcohol', 22, 'pending', '2020-04-02 15:10:06', NULL),
(270, 'IPA, WHO and UNICEF launch Read the World on International Children’s Book Day to support children and young people in isolation', 'Geronimo Stilton author to kickstart exclusive children s book reading initiative amid COVID 19 pandemic Much loved children s authors are joining an initiative to read extracts of their books to millions of children and young people currently living in isolation amid the COVID 19 pandemic Read the World is a collaboration between the International Publishers Association IPA the World Health Organization WHO and UNICEF It kicks off today on International Children s Book Day at 15 00 GMT 17 00 CET with Italian author Elisabetta Dami creator of the popular character Geronimo Stilton These are uncharted waters for us all and the psycho social effects of prolonged isolation and social distancing are yet to be seen and understood said IPA President Hugo Setzer All of us should take particular care of our mental health at the moment and especially that of young minds The IPA wanted to do something positive to bring children and their favourite writers closer to stimulate their interest in books and to create a carefree moment for families to share during this difficult period of confinement Children s lives and routines have been turned upside down in just a few short weeks said UNICEF Executive Director Henrietta Fore Even when the outside world is out of bounds for now reading can remind children and young people that the transportive power of books is unlimited WHO is committed to fighting the COVID 19 pandemic on all fronts especially when it comes to protecting young people said WHO Director General Dr Tedros Adhanom Ghebreyesus We understand the fear and anxieties many feel and know how the joy of reading can stimulate young minds ease tensions and provide hope Elisabetta Dami will read on her personal Instagram account in English from 15 00 15 30 GMT 17 00 17 30 CET Dami whose books have sold more than 180 million copies around the world and are published in 50 different languages will also respond to comments and questions via the platform Several other noted children s authors have agreed to join the Read the World initiative details of which will be available soon at https www unicef org coronavirus read the world About IPA The IPA is the world s largest federation of publishers associations Established in 1896 it is an industry body with a human rights mandate whose mission is to promote and protect publishing and raise awareness of publishing as a force for economic cultural and social development Working in cooperation with the World Intellectual Property Organization WIPO and other supranational bodies the IPA champions the interests of book and journal publishing at national and supranational level Internationally the IPA actively opposes censorship and promotes copyright freedom to publish including through the IPA Prix Voltaire and literacy Follow the IPA on Twitter and Facebook About UNICEF UNICEF works in some of the world s toughest places to reach the world s most disadvantaged children Across more than 190 countries and territories we work for every child everywhere to build a better world for everyone Follow UNICEF on Twitter and Facebook About WHO The World Health Organization WHO is the United Nations specialized agency for health It is an inter governmental organization and works in collaboration with its Member States usually through the Ministries of Health The World Health Organization is responsible for providing leadership on global health matters shaping the health research agenda setting norms and standards articulating evidence based policy options providing technical support to countries and monitoring and assessing health trends Learn more at www who int Follow WHO on Twitter Instagram and Facebook', 'https://www.who.int/news-room/detail/02-04-2020-ipa-who-and-unicef-launch-read-the-world-on-international-children-s-book-day-to-support-children-and-young-people-in-isolation', 22, 'pending', '2020-04-02 15:10:06', NULL),
(271, 'OHCHR, IOM, UNHCR and WHO joint press release: the rights and health of refugees, migrants and stateless must be protected in COVID-19 response', 'In the face of the COVID 19 crisis we are all vulnerable The virus has shown that it does not discriminate but many refugees those forcibly displaced the stateless and migrants are at heightened risk Three quarters of the world s refugees and many migrants are hosted in developing regions where health systems are already overwhelmed and under capacitated Many live in overcrowded camps settlements makeshift shelters or reception centers where they lack adequate access to health services clean water and sanitation The situation for refugees and migrants held in formal and informal places of detention in cramped and unsanitary conditions is particularly worrying Considering the lethal consequences a COVID 19 outbreak would have they should be released without delay Migrant children and their families and those detained without a sufficient legal basis should be immediately released This disease can be controlled only if there is an inclusive approach which protects every individual s rights to life and health Migrants and refugees are disproportionately vulnerable to exclusion stigma and discrimination particulary when undocumented To avert a catastrophe governments must do all they can to protect the rights and the health of everyone Protecting the rights and the health of all people will in fact help control the spread of the virus It is vital that everyone including all migrants and refugees are ensured equal access to health services and are effectively included in national responses to COVID 19 including prevention testing and treatment Inclusion will help not only to protect the rights of refugees and migrants but will also serve to protect public health and stem the global spread of COVID 19 While many nations protect and host refugee and migrant populations they are often not equipped to respond to crises such as Covid 19 To ensure refugees and migrants have adequate access to national health services States may need additional financial support This is where the world s financial institutions can play a leading role in making funds available While countries are closing their borders and limiting cross border movements there are ways to manage border restrictions in a manner which respects international human rights and refugee protection standards including the principle of non refoulement through quarantine and health checks More than ever as COVID 19 poses a global threat to our collective humanity our primary focus should be on the preservation of life regardless of status This crisis demands a coherent effective international approach that leaves no one behind At this crucial moment we all need to rally around a common objective fighting this deadly virus Many refugees displaced stateless people and migrants have skills and resources that can also be part of the solution We cannot allow fear or intolerance to undermine rights or compromise the effectiveness of responses to the global pandemic We are all in this together We can only defeat this virus when each and every one of us is protected', 'https://www.who.int/news-room/detail/31-03-2020-ohchr-iom-unhcr-and-who-joint-press-release-the-rights-and-health-of-refugees-migrants-and-stateless-must-be-protected-in-covid-19-response', 22, 'pending', '2020-04-02 15:10:06', NULL),
(272, 'Medical Product Alert N°3/2020', 'This Medical Product Alert warns consumers healthcare professionals and health authorities against a growing number of falsified medical products that claim to prevent detect treat or cure COVID 19 The Coronavirus disease COVID 19 pandemic caused by the virus SARS CoV 2 has increased demand for medicines vaccines diagnostics and reagents all related to COVID 19 creating an opportunity for ill intended persons to distribute falsified medical products Due diligence is required from all actors in the procurement use and administration of medical products in particular those affected by the current crisis of or related to COVID 19 1 FALSIFIED IN VITRO DIAGNOSTICS AND LABORATORY REAGENTS WHO has received multiple reports regarding falsified in vitro diagnostics IVDs and laboratory reagents for the detection of SARS CoV 2 Please refer to WHO s Emergency Use Listing for a list of diagnostics approved for clinical use by WHO To date eight countries Australia Brazil Canada PR China Russian Federation Singapore Republic of Korea United States of America have listed IVDs for COVID 19 diagnosis based on expedited regulatory assessments Please note that in the European Union regulatory compliance for SARS CoV 2 diagnostics are self declared by the manufacturer To assist Member States and stakeholders WHO has published the links to these emergency lists together with contact details These links provide information on IVDs authorized for use in the jurisdictions of the International Medical Device Regulators Forum as well as policies and guidance WHO will provide updated versions as new information becomes available End users are encouraged to check the labelling against the information posted by regulatory authorities upon listing to ensure they are in possession of the genuine product This information might include product name product code expiry date instructions for use and manufacturer details Unregulated websites supplying medicines and or vaccines particularly those concealing their physical address or landline telephone number are frequently the source of unlicensed substandard and falsified medical products WHO has been made aware of various unregistered websites claiming that products on sale can treat or prevent COVID 19 Such products are likely to be falsified medicines In addition some websites may appear to provide easy access to legitimate medicines that are otherwise not readily available End buyers and consumers should be especially wary of such online scams and exert due diligence when purchasing any medical product whether online or not 2 FALSIFIED MEDICINES AND VACCINES At this stage WHO does not recommend any medicines to treat or cure COVID 19 However the SOLIDARITY trial led by WHO is reviewing potential treatments for COVID 19 WHO requests increased vigilance from national health authorities healthcare professionals members of the public and supply chain stakeholders worldwide to prevent the distribution of these falsified medical products Increased vigilance should focus on hospitals clinics health centres clinical laboratories wholesalers distributors pharmacies and any other suppliers of medical products All medical products must be obtained from authentic and reliable sources Their authenticity and condition of the product should be carefully checked Consumers are advised to seek advice from a healthcare professional in case of doubt National health authorities are requested to immediately notify WHO if these falsified products are discovered in their country If you have any information concerning the manufacture distribution or supply of these products please contact rapidalert who int WHO Global Surveillance and Monitoring System for Substandard and Falsified Medical ProductsFor further information please visit our website https www who int medicines regulation ssffc en', 'https://www.who.int/news-room/detail/31-03-2020-medical-product-alert-n-3-2020', 22, 'pending', '2020-04-02 15:10:06', NULL),
(273, 'Joint Statement by QU Dongyu, Tedros Adhanom Ghebreyesus and Roberto Azevedo, Directors-General of the Food and Agriculture Organization of the United Nations (FAO), the World Health Organization (WHO) and the World Trade Organization (WTO)', 'Millions of people around the world depend on international trade for their food security and livelihoods As countries move to enact measures aiming to halt the accelerating COVID 19 pandemic care must be taken to minimise potential impacts on the food supply or unintended consequences on global trade and food security When acting to protect the health and well being of their citizens countries should ensure that any trade related measures do not disrupt the food supply chain Such disruptions including hampering the movement of agricultural and food industry workers and extending border delays for food containers result in the spoilage of perishables and increasing food waste Food trade restrictions could also be linked to unjustified concerns on food safety If such a scenario were to materialize it would disrupt the food supply chain with particularly pronounced consequences for the most vulnerable and food insecure populations Uncertainty about food availability can spark a wave of export restrictions creating a shortage on the global market Such reactions can alter the balance between food supply and demand resulting in price spikes and increased price volatility We learned from previous crises that such measures are particularly damaging for low income food deficit countries and to the efforts of humanitarian organizations to procure food for those in desperate need We must prevent the repeat of such damaging measures It is at times like this that more not less international cooperation becomes vital In the midst of the COVID 19 lockdowns every effort must be made to ensure that trade flows as freely as possible specially to avoid food shortage Similarly it is also critical that food producers and food workers at processing and retail level are protected to minimise the spread of the disease within this sector and maintain food supply chains Consumers in particular the most vulnerable must continue to be able to access food within their communities under strict safety requirements We must also ensure that information on food related trade measures levels of food production consumption and stocks as well as on food prices is available to all in real time This reduces uncertainty and allows producers consumers and traders to make informed decisions Above all it helps contain panic buying and the hoarding of food and other essential items Now is the time to show solidarity act responsibly and adhere to our common goal of enhancing food security food safety and nutrition and improving the general welfare of people around the world We must ensure that our response to COVID 19 does not unintentionally create unwarranted shortages of essential items and exacerbate hunger and malnutrition', 'https://www.who.int/news-room/detail/30-03-2020-joint-statement-by-qu-dongyu-tedros-adhanom-ghebreyesus-and-roberto-azevedo-directors-general-of-the-food-and-agriculture-organization-of-the-united-nations-(fao)-the-world-health-organization-(who)-and-the-world-trade-organization-(wto)', 22, 'pending', '2020-04-02 15:10:06', NULL),
(274, 'WHO releases guidelines to help countries maintain essential health services during the COVID-19 pandemic', 'The COVID 19 pandemic is straining health systems worldwide The rapidly increasing demand on health facilities and health care workers threatens to leave some health systems overstretched and unable to operate effectively Previous outbreaks have demonstrated that when health systems are overwhelmed mortality from vaccine preventable and other treatable conditions can also increase dramatically During the 2014 2015 Ebola outbreak the increased number of deaths caused by measles malaria HIV AIDS and tuberculosis attributable to health system failures exceeded deaths from Ebola 1 2 The best defense against any outbreak is a strong health system stressed WHO Director General Tedros Adhanom Ghebreyesus COVID 19 is revealing how fragile many of the world s health systems and services are forcing countries to make difficult choices on how to best meet the needs of their people To help countries navigate through these challenges the World Health Organization WHO has updated operational planning guidelines in balancing the demands of responding directly to COVID 19 while maintaining essential health service delivery and mitigating the risk of system collapse This includes a set of targeted immediate actions that countries should consider at national regional and local level to reorganize and maintain access to high quality essential health services for all Countries should identify essential services that will be prioritized in their efforts to maintain continuity of service delivery and make strategic shifts to ensure that increasingly limited resources provide maximum benefit for the population They also need to comply with the highest standard in precautions especially in hygiene practices and the provision of adequate supplies including personal protective equipment This requires robust planning and coordinated actions between governments and health facilities and their managers Some examples of essential services include routine vaccination reproductive health services including care during pregnancy and childbirth care of young infants and older adults management of mental health conditions as well as noncommunicable diseases and infectious diseases like HIV malaria and TB critical inpatient therapies management of emergency health conditions auxiliary services like basic diagnostic imaging laboratory services and blood bank services among others Well organized and prepared health systems can continue to provide equitable access to essential service delivery throughout an emergency limiting direct mortality and avoiding increased indirect mortality The guidelines stress the importance of keeping up to date information This requires frequent transparent communications with the public and strong community engagements so the public can maintain trust in the system to safely meet their essential needs and to control infection risk in health facilities This will help ensure that people continue to seek care when appropriate and adhere to public health advice 1 Elston J W T Cartwright C Ndumbi P Wright J 2017 The health impact of the 2014 15 Ebola outbreak Public Health 143 60 70 2 Parpia A S Ndeffo Mbah M L Wenzel N S Galvani A P 2016 Effects of response to 2014 2015 Ebola outbreak on deaths from malaria HIV AIDS and tuberculosis West Africa Emerging infectious diseases 22 3 433 For interviews please contact Tarik Jasarevic To access the full guidance please visit https www who int emergencies diseases novel coronavirus 2019 technical guidance maintaining essential health services and systems For further information and guidance on COVID 19 please visit https www who int emergencies diseases novel coronavirus 2019', 'https://www.who.int/news-room/detail/30-03-2020-who-releases-guidelines-to-help-countries-maintain-essential-health-services-during-the-covid-19-pandemic', 22, 'pending', '2020-04-02 15:10:06', NULL),
(275, 'Medical Product Alert N°2/2020', 'This Medical Product Alert relates to a confirmed falsified human immunodeficiency virus HIV in vitro diagnostic medical device IVD that has been identified circulating in Guyana and Kenya Through its Global Surveillance and Monitoring System GSMS for substandard falsified medical products WHO was informed that at least 8 240 falsified rapid diagnostic tests to detect HIV 1 2 have been distributed in Guyana at end user level The product is Uni Gold HIV and claims to be manufactured by Trinity Biotech plc Subsequent reports revealed that the same falsified product is also circulating in Kenya Uni Gold HIV is a single use rapid diagnostic test an immunoassay for the qualitative detection of antibodies to HIV 1 and HIV 2 in serum plasma and whole blood Uni Gold HIV is intended for use in point of care settings as an aid in diagnosis of HIV 1 and HIV 2 infection The WHO testing strategy recommends three HIV reactive test results to confirm an HIV positive status in a patient The use of this falsified Uni Gold HIV subject of WHO medical product alert n 2 of 2020 is likely to lead to delayed diagnosis of HIV status Table 1 Specific details of the falsified product Uni Gold HIV subject of WHO Medical Product Alert n 2 of 2020 Product Name Uni Gold HIV Lot Number HIV7120026 Expiry Date 5 DEC 2020 Stated manufacturer Trinity Biotech The packaging of this falsified HIV test kit is in English The genuine manufacturer Trinity Biotech plc has confirmed that They did not manufacture the falsified product in Table 1 Genuine lot HIV7120026 was made by Trinity Biotech plc and expired in 2019 The expiry date is incorrect and does not correspond with their batch manufacturing records Photographs and advice to the public are available below Figure 1 Falsified Uni Gold HIV lot number HIV7120026 displaying falsified expiry date Figure 2 Falsified Uni Gold HIV displaying labelling inconsistencies Advice on action to be taken by end users Please check to see if any Uni Gold HIV test kits in your facility have lot number HIV7120026 If you are in possession of these falsified test kits with lot number HIV7120026 Please do not use Please immediately contact the organization that supplied you with the product either your HIV testing programme nongovernmental organization or local distributor Please contact Trinity Biotech plc Phone 353 1 276 9800 E mail hiv trinitybiotech com Please contact your national health authorities All medical products must be obtained from authentic and reliable sources Their authenticity and condition should be carefully checked Advice on action to be taken by national health authorities WHO requests increased scrutiny within the supply chains of all countries particularly at testing sites health facilities community based clinical laboratories medical stores warehouses and at the facilities of relevant economic operators agents authorized representatives distributors wholesalers etc If these falsified test kits with lot number HIV7120026 are discovered please do not use National health authorities are asked to immediately inform WHO if these falsified products are discovered in their country using the WHO IVD complaint form If you have any information concerning the manufacture distribution or supply of this product please contact rapidalert who int WHO Global Surveillance and Monitoring System for Substandard and Falsified Medical Products For further information please visit our website https www who int medicines regulation ssffc en', 'https://www.who.int/news-room/detail/27-03-2020-medical-product-alert-n-2-2020', 22, 'pending', '2020-04-02 15:10:06', NULL),
(276, 'New WHO Guide to help countries expand access to essential medicines', 'WHO s new user guide for countries Selection of medicines at country level is based on the WHO Model List of Essential Medicines It sets out the key actions countries should undertake to develop and update their own national essential medicines lists based on the treatment needs of their populations and their capacity to reimburse payments for medicines The document also aims to support countries in progressing towards universal health coverage Today approximately half of the world s population is unable to access essential medicines The large majority of these people live in poorer countries but rising prices of new medicines are also becoming a challenge for health systems in wealthy countries A careful selection of essential medicines is the first step in ensuring a population can obtain the quality assured medicines it needs at an affordable price Countries need to do more to ensure that all people and communities can access highly effective medicines WHO s new manual is a resource to do just that The document intended for policy makers in charge of national medicines and reimbursement lists aims to increase transparency on how essential medicines are selected Most national lists of essential medicines have several differences when compared with WHO s model list which lists only medicines of proven safety and efficacy Some national lists include medicines that bring little extra benefit to patients Decision makers should refer to the WHO global list to gauge the public health value of listing certain medicines for their populations The essential medicines concept Essential medicines are those that satisfy the priority health care needs of the population selected with due regard to disease prevalence and public health relevance evidence of efficacy and safety and comparative cost effectiveness intended to be available within the context of functioning health systems at all times in adequate amounts in the appropriate dosage forms with assured quality and adequate information and at a price the individual and community can afford The essential medicines concept is global and forward looking It incorporates the need to regularly update medicines selections to reflect new therapeutic options and changing therapeutic needs the need to ensure drug quality and the need for continued development of better medicines medicines for emerging diseases and medicines to meet changing resistance patterns Achieving universal health coverage and equity in public health depends on access to essential high quality and affordable health related technologies for all To achieve access for all by 2030 at least two billion more people will need to have access to essential health services by 2030 In an effort to make the Model List of Essential Medicines more readily accessible WHO recently developed an electronic version of the list bringing the traditional EML to computer screens tablets and smartphones in a freely accessible downloadable online database Link to manual Selection of essential medicines at country level Link to e EML Model List of Essential Medicines', 'https://www.who.int/news-room/detail/30-03-2020-new-who-guide-to-help-countries-expand-access-to-essential-medicines', 22, 'pending', '2020-04-02 15:10:06', NULL),
(277, 'World TB Day 2020 Newsletter', 'Latest news and updates from WHO Dear colleagues and friends World TB Day this year comes at a sobering time as the world grapples with the COVID 19 pandemic We stand in solidarity with those affected those at the frontlines of the fight to combat COVID 19 as well as those who continue efforts to support those ill with longstanding health problems like TB HIV and other diseases However we cannot forget the millions and their families who battle TB every day and lose their lives to this ancient disease which remains the world s top infectious killer As eloquently emphasized by WHO Director General Dr Tedros Adhanom Ghebreyesus in his press briefing on COVID 19 yesterday I d like to remind everyone that although COVID 19 is dominating the world s attention there is another respiratory disease that is both preventable and treatable but kills 1 5 million people every year that disease is tuberculosis It s Time the focus for World TB Day this year is therefore on urgently accelerating the TB response to save lives and end suffering even in times of crisis This will be essential if we are to reach the targets and commitments made by Heads of State at the 2018 UN High Level Meeting on TB We have made important strides against the TB epidemic to date We announced last year that more people received life saving treatment for tuberculosis in 2018 than ever before largely due to improved detection and diagnosis Globally 7 million people were diagnosed and treated for TB up from 6 4 million in 2017 enabling the world to meet one of the milestones towards the United Nations political declaration targets on TB and the WHO Director General Flagship Initiative Find Treat All End TB jointly with Stop TB Partnership and the Global Fund This has been a big win for the TB community WHO is working with countries to roll out important guidelines including a comprehensive package on TB preventive treatment released today and updated MDR TB guidelines to promote the use of all oral regimens for patients with drug resistant TB which would be helpful particularly at this point when visiting health centers is a challenge Furthermore WHO has developed a note to guide and urge countries to ensure continuity of TB services during the COVID 19 pandemic We are strengthening our collaboration with civil society more information is highlighted in the WHO Civil Society Taskforce Progress Review released today Youth mobilization is being ramped up through the WHO 1 1 Youth Initiative to end TB and the Global Youth Declaration to End TB Multisectoral accountability is being promoted in countries through our framework and we have finalized a new global strategy on TB research and innovation that will be reviewed by the World Health Assembly Yet the gains we have made are at risk if there is any slackening of commitment and action especially in times of crisis We are at a crossroads and we need to unite forces to take the path of success that will save lives and end suffering I was especially heartened today to see the TB community coming together like never before We all took our events to the virtual realm due to COVID 19 lockdowns The WHO Online Talk Show held this afternoon had a powerful line up of speakers that included TB survivors and advocates civil society high level government representatives heads of agencies researchers and partners As of this evening we have surpassed 10 000 views on YouTube I also participated in townhalls organized by Stop TB Partnership Our joint efforts have indeed ensured a continuing spotlight on those affected by TB and clearly shows that no matter what the barrier we can surpass it if we work together I am proud to stand shoulder to shoulder with you all virtually and recommit to champion End TB efforts till we reach the finish line It s time to deliver on our promises and ensure no one is left behind It s time to End TB Dr Tereza KasaevaDirectorGlobal TB ProgrammeWorld Health Organization World TB Day Talk Show In the backdrop of the global battle against COVID 19 WHO organized a special online talk show to mark World TB Day 2020 The talk show had a powerful line up of speakers from among TB survivors and advocates civil society high level government representatives heads of agencies researchers and partners The video was streamed live on WHO s Youtube channel crossing over 10 000 views in a few hours Watch the talk show video Spotlight on TB Preventive Treatment New WHO recommendations to prevent tuberculosis aim to save millions of lives 24 March 2020 News release Geneva New World Health Organization WHO guidance will help countries accelerate efforts to stop people with tuberculosis TB infection becoming sick with TB by giving them preventive treatment A quarter of the world s population is estimated to be infected with TB bacteria These people are neither sick nor contagious However they are at greater risk of developing TB disease especially those with weakened immunity Offering them TB preventive treatment will not only protect them from becoming sick but also cut down on the risk of transmission in the community Read more The full package is available below and at our World TB Day Campaign Page WHO Civil Society Taskforce on TB Progress Review The WHO Civil Society Taskforce provides a platform for meaningful engagement of civil society building on the commitment of the Director General with emphasis on harnessing the untapped potential in engagement with civil society and affected communities al all levels To mark World TB Day 2020 the Task Force has released a Progress Review highlighting key achievements since its formation in 2018 Access link here WHO eTB guidelines A digital platform to promote adolopment of TB recommendations WHO Global TB Programme McMaster University The WHO Global Tuberculosis TB Programme in collaboration with McMaster University Canada is developing a smart platform to improve access to and use of all WHO recommendations on TB prevention and care The WHO eTB guidelines platform will facilitate the adoption adaptation and implementation adolopment by countries of recommendations across the continuum of care This digital platform will provide a variety of users TB programme managers healthcare workers including nurses researchers patients and affected communities with easy access to all essential information about WHO s current policy guidance on TB The first set of recommendations on TB preventive treatment were released on this new platform on World TB Day WHO eTB guidelines platform Infographic TB and COVID 19 24 March 2020 News release Geneva As the world comes together to tackle the COVID 19 pandemic it is important to ensure that essential health services and operations are continued to protect the lives of people with TB and other diseases or health conditions Health services including national programmes to combat TB need to be actively engaged in ensuring an effective and rapid response to COVID 19 while ensuring that TB services are maintained Read more Let s never forget It s time to end TB Ksenia Schenina Ksenia Schenina 24 March 2020 Photo story On World TB Day 2020 the theme Its time stresses the urgency to end the TB epidemic TB survivor and advocate Ksenia Schenina talks about her struggle with the disease the persistence of stigma and the role that remembrance can play in fighting it Through her TB memorial project she aims to remember those who passed away from this terrible and ancient disease We do it to show what kind of people they were what kind of things they liked what kind of music they listened to and what their favorite movies were if they liked fishing or dreamt of a flight to space she says Read more Commentary To end TB we must invest in research and innovation 24 March 2020 Commentary If the world is to get anywhere near ending TB a disease that killed more than 1 5 million people in 2018 something significant needs to change TB remains the world s leading infectious killer and yet in the last 50 years only three new drugs and regimes have been developed to combat the disease What we need is more research and more tools in the pipeline better diagnostics more effective vaccines and safer shorter drug regimes explains Dr Tereza Kasaeva Director of the World Health Organization Global Tuberculosis Programme Read more Emily A Day in the Life of a TB Nurse Maria Emily C Ballesteros Watch this story of Emily a nurse managing the tuberculosis TB program of the City Health Office in Tuguegarao City Her dream for Tuguegarao is to one day see zero TB cases and that no one dies from this infectious disease Nurses and healthcare workers play a critical role in TB prevention and care It s time to invest in them to improve healthcare for all We thank all the nurses midwives and healthcare workers working to EndTB Watch the video Updates and messages New research tool supports scale up of digital technologies to End TB 24 March 2020 TDR news item National anti tuberculosis efforts are increasingly involving digital technologies such as mobile applications to support treatment adherence and electronic surveillance systems that enable real time monitoring of a country s TB situation Read more World TB Day 2020 It s Time for solidarity 24 March 2020 HIV TB news item At this unique time in history when the world is grappling with the COVID 19 pandemic the WHO Department of Global HIV Hepatitis and STI Programmes stands in solidarity with governments and communities as they seek to maintain health services and continue to address the needs of patients suffering from HIV and tuberculosis TB Read more New shorter treatment to prevent TB to be rolled out in five high TB burden countries 24 March 2020 news itemThree month regimen expected to prevent TB in those at highest risk of developing the disease including people living with HIV and children under the age of five Today the Aurum Institute and its partners as part of the IMPAACT4TB project announced that five high burden TB countries will roll out a new shorter drug regimen known as 3HP to prevent TB The announcement comes as countries around the world mark World TB Day which takes place every year on March 24th Countries that will initially provide the new regimen with funding from Unitaid U S PEPFAR and the Global Fund include Cambodia Ethiopia Kenya Malawi South Africa and Zimbabwe More than 120 000 patient courses of 3HP will be delivered by the project to 12 countries in 2020 An additional 1 million patient courses are expected to reach low and middle income countries by the end of the year through the combined support of Unitaid Global Fund the Stop TB Partnership s Global Drug Facility GDF and PEPFAR Read more', 'https://www.who.int/news-room/detail/30-03-2020-world-tb-day-2020-newsletter', 22, 'pending', '2020-04-02 15:10:06', NULL),
(278, 'Information sharing on COVID-19', 'WHO s focus at all times is to ensure that all areas of the globe have the information they need to manage the health of their people In a recent interview the WHO official who headed the joint international mission to China did not answer a question on Taiwan s response to the COVID 19 outbreak The question of Taiwanese membership in WHO is up to WHO Member States not WHO staff However WHO is working closely with all health authorities who are facing the current coronavirus pandemic including Taiwanese health experts The Taiwanese caseload is low relative to population We continue to follow developments closely WHO is taking lessons learned from all areas including Taiwanese health authorities to share best practices globally With respect to the COVID 19 outbreak the WHO Secretariat works with Taiwanese health experts and authorities following established procedures to facilitate a fast and effective response and ensure connection and information flow There is a Taiwanese International Health Regulations Point of Contact who receives IHR 2005 communications and has access to the Event Information Site EIS Platform a password protected database and information exchange mechanism supporting the IHR 2005 The Taiwanese Field Epidemiology Training Program is a member of the Training Programs in Epidemiology and Public Health Interventions Network also known as TEPHINET WHO shares Global Outbreak Alert and Response Network alerts and requests for assistance with TEPHINET and those messages are cascaded to the TEPHINET members Two Taiwanese public health experts participated in the Global Research and Innovation Forum organized by WHO on 11 12 February 2020 thus contributing alongside other world scientists including from mainland China to critical research questions and to finding ways to work together to advance the response WHO staff work around the world to respond to this pandemic with the best evidence based guidance and operational support available for all people based on public health needs Membership in WHO and status issues are decided by Member States and the rules they set at WHO s governing body the World Health Assembly Information about COVID 19 can be found here https www who int emergencies diseases novel coronavirus 2019', 'https://www.who.int/news-room/detail/29-03-2020-information-sharing-on-covid-19', 22, 'pending', '2020-04-02 15:10:06', NULL);
INSERT INTO `rss_articles` (`id`, `title`, `body`, `href`, `rss_id`, `status`, `created_at`, `updated_at`) VALUES
(279, 'Gynaecologist is suspended for 12 months after sexual advances were reported in wake of #MeToo', 'A leading obstetrician and gynaecologist has been suspended from the UK medical register for 12 months after a tribunal found that he had made inappropriate sexual advances to female', 'http://feeds.bmj.com/~r/bmj/recent/~3/A6Vtl1ECcZQ/bmj.m1380.short', 26, 'pending', '2020-04-02 15:10:06', NULL),
(280, 'Covid-19: Rules on sharing confidential patient information are relaxed in England', 'The Department of Health and Social Care for England has relaxed the rules on sharing patients confidential data and is requiring healthcare bodies to provide patient information to each other to', 'http://feeds.bmj.com/~r/bmj/recent/~3/xptWKII-JBw/bmj.m1378.short', 26, 'pending', '2020-04-02 15:10:06', NULL),
(281, 'Covid-19: four fifths of cases are asymptomatic, China figures indicate', 'New evidence has emerged from China indicating that the large majority of coronavirus infections do not result in symptoms Chinese authorities began publishing daily figures on 1 April on the number', 'http://feeds.bmj.com/~r/bmj/recent/~3/bp9us28SB8c/bmj.m1375.short', 26, 'pending', '2020-04-02 15:10:06', NULL),
(282, 'Cooperation as an alternative to nationalisation of the pharmaceutical industry', 'Head to Head 7 MarchSerial title in print Drug industry debateMazzucato and Li and Darzi provide compelling arguments for and against the nationalisation of the pharmaceutical industry 1 Mazzucato', 'http://feeds.bmj.com/~r/bmj/recent/~3/uGoCg_c-jOw/bmj.m1314.short', 26, 'published', '2020-04-02 15:10:06', '2020-04-02 20:00:01'),
(283, 'Machine learning and artificial intelligence research for patient benefit: 20 critical questions on transparency, replicability, ethics, and effectiveness', 'An error was included in the accepted version of this paper by Vollmer and colleagues BMJ 2020 368 l6927 doi 10 1136 bmj l6927 published 20 March 2020 and was not picked up before publication', 'http://feeds.bmj.com/~r/bmj/recent/~3/XC1tIgL8d9w/bmj.m1312.short', 26, 'published', '2020-04-02 15:10:06', '2020-04-02 19:59:47'),
(284, 'Covid-19: Hospitals can remove 15% cap on testing of NHS staff', 'NHS hospitals have been told to remove the 15 cap on the proportion of tests for covid 19 infection that they allocate to staff as the government strives to get more staff who are currently', 'http://feeds.bmj.com/~r/bmj/recent/~3/EgWlv9GtzG0/bmj.m1339.short', 26, 'pending', '2020-04-02 15:10:06', NULL),
(285, '\"2019-ncov\" OR nCov OR (coronavirus AND wuhan[TIAB]) OR \"novel coronavirus\" OR (pneumonia AND wuhan[TIAB]) OR COVID-19[TW] OR 2019ncov[TW] AND ( ( \"2019/12/01\"[PDat] : \"3000/12/31\"[PDat] ) ); +212 new citations', '212 new pubmed citations were retrieved for your search Click on the search hyperlink below to display the complete search results 2019 ncov OR nCov OR coronavirus AND wuhan TIAB OR novel coronavirus OR pneumonia AND wuhan TIAB OR COVID 19 TW OR 2019ncov TW AND 2019 12 01 PDat 3000 12 31 PDat These pubmed results were generated on 2020 04 04 PubMed comprises more than millions of citations for biomedical literature from MEDLINE life science journals and online books Citations may include links to full text content from PubMed Central and publisher web sites', 'https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Search&amp;db=pubmed&amp;term=%28%20%28%222019-ncov%22%20OR%20nCov%20OR%20%28coronavirus%20AND%20wuhan%5BTIAB%5D%29%20OR%20%22novel%20coronavirus%22%20OR%20%28pneumonia%20AND%20wuhan%5BTIAB%5D%29%20OR%20COVID-19%5BTW%5D%20OR%202019ncov%5BTW%5D%20AND%20%28%20%28%20%222019%2F12%2F01%22%5BPDat%5D%20%3A%20%223000%2F12%2F31%22%5BPDat%5D%20%29%20%29%29%20AND%20%222020%2F04%2F03%2007.08%22%5BMHDA%5D%3A%222020%2F04%2F04%2008.01%22%5BMHDA%5D%29', 21, 'pending', '2020-04-04 11:51:28', NULL),
(286, 'National Ethics Committees and COVID-19', 'On Monday April 6 WHO will host a virtual meeting to facilitate communication collaboration and exchange between National Ethics Committees from around the world', 'https://www.who.int/news-room/detail/04-04-2020-national-ethics-committees-and-covid-19', 22, 'pending', '2020-04-04 11:51:28', NULL),
(287, 'WHO and UNICEF to partner on pandemic response through COVID-19 Solidarity Response Fund', 'WHO and UNICEF today announced an agreement to work together on COVID 19 response through the historic COVID 19 Solidarity Response Fund powered by the United Nations Foundation and Swiss Philanthropy Foundation The COVID 19 Solidarity Response Fund has been set up to facilitate an unprecedented global response by supporting the WHO Strategic Preparedness and Response Plan As part of the agreement an initial portion of the money from the Fund which currently stands at more than 127 million will flow to UNICEF for its work with vulnerable children and communities all over the world COVID 19 is an unprecedented pandemic requiring extraordinary global solidarity to urgently respond said Dr Tedros Adhanom Ghebreyesus WHO Director General I m pleased that UNICEF joined the Solidarity Response Fund With their extensive experience both in fundraising and in implementing programmes this partnership will help us to work together closely to save lives The money collected through the fund will be used among others to train and equip communities and health care workers to prevent detect and treat COVID 19 It will help countries expand their health care capacity and mitigate its social impact especially on women children and vulnerable social groups And it will accelerate research and development of treatments and preventive vaccines As a key partner in this joined up effort UNICEF will lead emergency efforts to ensure families and communities in the most vulnerable countries are fully engaged in the response and have access to water sanitation and hygiene and other infection prevention and control measures UNICEF will also ensure children caretakers and frontline responders such as social workers teachers and healthcare workers are supported through evidence based guidance through its vast community outreach and country programs This is an extraordinary emergency that demands an extraordinary response and we need all hands on deck individuals corporations foundations governments and other organizations around the world said UNICEF Executive Director Henrietta Fore UNICEF is pleased to join the Solidarity Response Fund It will bolster our efforts to strengthen health and sanitation systems and help protect the most vulnerable families from knock on impacts of COVID 19 on already overstretched health systems Funds raised will be spent in alignment with the global response plan and where needs are greatest At the direction of WHO leadership it is expected that resources will go directly toward WHO for its work to track the spread of the virus assess gaps and needs equip frontline health workers with personal protective equipment ensure lab and testing tools are available in countries around the world and keep communities and frontline responders informed with the latest technical guidance UNICEF to ensure children and families around the world are equipped with all the evidence based information and latest WHO guidance as well as locally relevant information to protect themselves from the spread of COVID 19 to support vulnerable countries by providing access to water sanitation and hygiene and basic infection prevention and control measures and to provide access to care for vulnerable families and children CEPI the Coalition for Epidemic Preparedness Innovations a key partner leading the financing for research and development for novel vaccines to combat COVID 19 working closely with WHO The COVID 19 Solidarity Response Fund was set up at WHO s request by the UN Foundation and Swiss Philanthropy Foundation and launched three weeks ago It is the only way for individuals and organizations to contribute directly to WHO s global efforts to tackle the pandemic To date the fund has 127 million raised or committed from more than 219 000 individuals from all over the world plus more than 90 global companies and organizations The partnership is also a tremendous demonstration of solidarity across UN organizations in coordinating partnering and supporting each other in dealing with the immediate and longer term impact of the pandemic There has never been a more urgent need for global cooperation said Elizabeth Cousens President CEO of the UN Foundation The COVID 19 pandemic shows us that we all can play a part to stop the spread The incredible generosity shown to the COVID 19 Solidarity Response Fund from around the world will help WHO UNICEF CEPI and partners accelerate their lifesaving work especially to support the most vulnerable communities and speed the development of a vaccine Notes to editors About UNICEF UNICEF works in some of the world s toughest places to reach the world s most disadvantaged children Across more than 190 countries and territories we work for every child everywhere to build a better world for everyone About WHO WHO is the United Nations specialized agency for health It is an inter governmental organization and works in collaboration with its Member States usually through the Ministries of Health The World Health Organization is responsible for providing leadership on global health matters shaping the health research agenda setting norms and standards articulating evidence based policy options providing technical support to countries and monitoring and assessing health trends Learn more at www who int About the United Nations Foundation The UN Foundation brings together ideas people and resources to help the United Nations drive global progress and tackle urgent problems Our hallmark is to collaborate for lasting change and innovate to address humanity s greatest challenges Learn more at www unfoundation org', 'https://www.who.int/news-room/detail/03-04-2020-who-and-unicef-to-partner-on-pandemic-response-through-covid-19-solidarity-response-fund', 22, 'pending', '2020-04-04 11:51:28', NULL),
(288, 'Digital technology for COVID-19 response', 'WHO has received overwhelming pro bono support from technology companies to fight the COVID 19 pandemic The pandemic has triggered an unprecedented demand for digital health technology solutions and has revealed successful solutions such as for population screening tracking the infection prioritizing the use and allocation of resources and designing targeted responses', 'https://www.who.int/news-room/detail/03-04-2020-digital-technology-for-covid-19-response', 22, 'pending', '2020-04-04 11:51:28', NULL),
(289, 'Chagas disease: providing free paediatric medicine can enhance diagnosis and treatment', 'Documentation leading to the donation of an essential antiparasitic medicine for the treatment of Chagas disease to the World Health Organization WHO is in the final stage of preparation A three year agreement between the Mundo Sano Foundation Brazil and WHO is expected to make available 108 000 tablets of the paediatric formulation of benznidazole a first line medicine against Chagas disease Treatment with benznidazole in the early stages of infection can cure Chagas disease', 'https://www.who.int/news-room/detail/02-04-2020-chagas-disease-providing-free-paediatric-medicine-can-enhance-diagnosis-and-treatment', 22, 'pending', '2020-04-04 11:51:28', NULL),
(290, 'WHO to continue support for Chagas disease programme that promotes patient self-care', 'The World Health Organization WHO and the Catalan Ministry of Health say they will jointly support the dissemination of a programme that provides support to patients suffering from Chagas disease to manage their own health and promote self care', 'https://www.who.int/news-room/detail/29-03-2020-who-to-continue-support-for-chagas-disease-programme-that-promotes-patient-self-care', 22, 'pending', '2020-04-04 11:51:28', NULL),
(291, 'Medical Product Alert N°2/2020 version 2', 'Test de d pistage rapide du VIH falsifi circulant dans les r gions OMS des Am riques et de l Afrique This Medical Product Alert relates to a confirmed falsified human immunodeficiency virus HIV in vitro diagnostic medical device IVD that has been identified circulating in Guyana and Kenya Through its Global Surveillance and Monitoring System GSMS for substandard falsified medical products WHO was informed that at least 8 240 falsified rapid diagnostic tests to detect HIV 1 2 have been distributed in Guyana at end user level The product is Uni Gold HIV and claims to be manufactured by Trinity Biotech plc Subsequent reports revealed that the same falsified product is also circulating in Kenya Uni Gold HIV is a single use rapid diagnostic test an immunoassay for the qualitative detection of antibodies to HIV 1 and HIV 2 in serum plasma and whole blood Uni Gold HIV is intended for use in point of care settings as an aid in diagnosis of HIV 1 and HIV 2 infection The WHO testing strategy recommends three HIV reactive test results to confirm an HIV positive status in a patient The use of this falsified Uni Gold HIV subject of WHO medical product alert n 2 of 2020 is likely to lead to delayed diagnosis of HIV status Table 1 Specific details of the falsified product Uni Gold HIV subject of WHO Medical Product Alert n 2 of 2020 Product Name Uni Gold HIV Uni Gold HIV Product code 1206502 1206502 Lot Number HIV7120026 HIV6120030 Expiry Date 5 DEC 2020 29 JUL 20 Stated manufacturer Trinity Biotech Trinity Biotech The packaging of this falsified HIV test kit is in English The genuine manufacturer Trinity Biotech plc has confirmed that They did not manufacture the falsified product in Table 1 Genuine lot HIV7120026 and HIV6120030 was made by Trinity Biotech plc and expired in 2019 The expiry date is incorrect and does not correspond with their batch manufacturing records Photographs of the above referenced products are available on page 2 and advice to the public is available on page 3 Figure 1 Falsified Uni Gold HIV lot number HIV7120026 displaying falsified expiry date Figure 2 Falsified Uni Gold HIV displaying labelling inconsistencies Figure 3 Falsified Uni Gold HIV lot number HIV6120030 displaying falsified expiry date Advice on action to be taken by end users Please check to see if any Uni Gold HIV test kits in your facility have lot number HIV7120026 or HIV6120030 If you are in possession of these falsified test kits with lot number HIV7120026 or HIV6120030 Please do not use Please immediately contact the organization that supplied you with the product either your HIV testing programme nongovernmental organization or local distributor Please contact Trinity Biotech plcPhone 353 1 276 9800E mail hiv trinitybiotech com Please contact your national health authorities All medical products must be obtained from authentic and reliable sources Their authenticity and condition should be carefully checked Advice on action to be taken by national health authorities WHO requests increased scrutiny within the supply chains of all countries particularly at testing sites health facilities community based clinical laboratories medical stores warehouses and at the facilities of relevant economic operators agents authorized representatives distributors wholesalers etc If falsified test kits with lot numbers HIV7120026 or HIV6120030 are discovered please do not use National health authorities are asked to immediately inform WHO if these falsified products are discovered in their country using the WHO IVD complaint form If you have any information concerning the manufacture distribution or supply of this product please contact rapidalert who int WHO Global Surveillance and Monitoring System for Substandard and Falsified Medical Products For further information please visit our website https www who int medicines regulation ssffc en', 'https://www.who.int/news-room/detail/27-03-2020-medical-product-alert-n-2-2020', 22, 'pending', '2020-04-04 11:51:28', NULL),
(292, 'Are UK doctors getting sufficient protective equipment against covid-19?', 'We have amended this feature article BMJ 2020 369 m1297 doi 10 1136 bmj m1297 in light of Public Health England s updated guidance on personal protective equipment published the same day as the', 'http://feeds.bmj.com/~r/bmj/recent/~3/bUkmPE7c6bk/bmj.m1396.short', 26, 'pending', '2020-04-04 11:51:28', NULL),
(293, 'Covid-19: PHE upgrades PPE advice for all patient contacts with risk of infection', 'New guidelines on use of personal protective equipment PPE by healthcare workers significantly expands the potential use of eye protection and fluid resistant surgical masks including to doctors', 'http://feeds.bmj.com/~r/bmj/recent/~3/agEIl-25ZSI/bmj.m1391.short', 26, 'pending', '2020-04-04 11:51:28', NULL),
(294, 'Artificial intelligence versus clinicians', 'Could machines replace human physicians Substantial private investments are being devoted to achieving exactly that and some success has been reported in areas such as breast screening 1 fuelling', 'http://feeds.bmj.com/~r/bmj/recent/~3/4qsZTtxHi4w/bmj.m1326.short', 26, 'pending', '2020-04-04 11:51:28', NULL),
(295, 'Regional coordination and bottom-up response of general practitioners in Belgium and the Netherlands', 'General practitioners are at the core of the healthcare response to the emerging covid 19 epidemic in European health systems 1 The coordination of primary care differs across countries we describe', 'http://feeds.bmj.com/~r/bmj/recent/~3/UCSczCstm1c/bmj.m1377.short', 26, 'pending', '2020-04-04 11:51:28', NULL),
(296, 'Covid-19: Increased demand for steroid inhalers causes &amp;#x201C;distressing&amp;#x201D; shortages', 'Steroid inhaler manufacturers are experiencing significant demand as people in the UK try to stock up in light of the covid 19 pandemic causing distressing shortages the Department of Health', 'http://feeds.bmj.com/~r/bmj/recent/~3/JwP9HLuvv2w/bmj.m1393.short', 26, 'pending', '2020-04-04 11:51:28', NULL),
(297, 'Covid-19: government promises 100 000 tests per day in England by end of April', 'The government has pledged to carry out 100 000 tests for covid 19 per day in England by the end of April ramping up its current capacity The promise by the health secretary Matt Hancock follows', 'http://feeds.bmj.com/~r/bmj/recent/~3/PMsqGXoOYbU/bmj.m1392.short', 26, 'pending', '2020-04-04 11:51:28', NULL),
(298, 'Rapid Progression to Acute Respiratory Distress Syndrome: Review of Current Understanding of Critical Illness from COVID-19 Infection.', 'Related Articles Rapid Progression to Acute Respiratory Distress Syndrome Review of Current Understanding of Critical Illness from COVID 19 Infection Ann Acad Med Singapore 2020 Jan 49 1 1 9 Authors Goh KJ Choong MC Cheong EH Kalimuddin S Duu Wen S Phua GC Chan KS Haja Mohideen S Abstract The coronavirus disease 2019 COVID 19 outbreak that started in Wuhan Hubei province China in December 2019 has now extended across the globe with 100 000 cases and 3 000 deaths reported in 93 countries as of 7 March 2020 We report a case of COVID 19 infection in a 64 year old man who developed rapidly worsening respiratory failure and acute respiratory distress syndrome ARDS that required intubation As the clinical spectrum of COVID 19 ranges widely from mild illness to ARDS with a high risk of mortality there is a need for more research to identify early markers of disease severity Current evidence suggests that patients with advanced age pre existing comorbidities or dyspnoea should be closely monitored especially at 1 2 weeks after symptom onset It remains to be seen if laboratory findings such as lymphopenia or elevated lactate dehydrogenase may serve as early surrogates for critical illness or markers of disease recovery Management of ARDS in COVID 19 remains supportive while we await results of drug trials More studies are needed to understand the incidence and outcomes of ARDS and critical illness from COVID 19 which will be important for critical care management and resource planning PMID 32200400 PubMed in process', 'https://www.ncbi.nlm.nih.gov/pubmed/32200400?dopt=Abstract', 21, 'pending', '2020-03-24 07:00:05', '2020-03-29 05:04:46'),
(299, 'Mitigating Risk of COVID-19 in Dialysis Facilities.', 'Related Articles Mitigating Risk of COVID 19 in Dialysis Facilities Clin J Am Soc Nephrol 2020 Mar 20 Authors Kliger AS Silberzweig J PMID 32198130 PubMed as supplied by publisher', 'https://www.ncbi.nlm.nih.gov/pubmed/32198130?dopt=Abstract', 21, 'published', '2020-03-24 07:00:05', '2020-03-24 07:04:18'),
(300, '\"2019-ncov\" OR nCov OR (coronavirus AND wuhan[TIAB]) OR \"novel coronavirus\" OR (pneumonia AND wuhan[TIAB]) OR COVID-19[TW] OR 2019ncov[TW] AND ( ( \"2019/12/01\"[PDat] : \"3000/12/31\"[PDat] ) ); +110 new citations', '110 new pubmed citations were retrieved for your search Click on the search hyperlink below to display the complete search results 2019 ncov OR nCov OR coronavirus AND wuhan TIAB OR novel coronavirus OR pneumonia AND wuhan TIAB OR COVID 19 TW OR 2019ncov TW AND 2019 12 01 PDat 3000 12 31 PDat These pubmed results were generated on 2020 04 05 PubMed comprises more than millions of citations for biomedical literature from MEDLINE life science journals and online books Citations may include links to full text content from PubMed Central and publisher web sites', 'https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Search&amp;db=pubmed&amp;term=%28%20%28%222019-ncov%22%20OR%20nCov%20OR%20%28coronavirus%20AND%20wuhan%5BTIAB%5D%29%20OR%20%22novel%20coronavirus%22%20OR%20%28pneumonia%20AND%20wuhan%5BTIAB%5D%29%20OR%20COVID-19%5BTW%5D%20OR%202019ncov%5BTW%5D%20AND%20%28%20%28%20%222019%2F12%2F01%22%5BPDat%5D%20%3A%20%223000%2F12%2F31%22%5BPDat%5D%20%29%20%29%29%20AND%20%222020%2F04%2F04%2007.21%22%5BMHDA%5D%3A%222020%2F04%2F05%2006.05%22%5BMHDA%5D%29', 21, 'pending', '2020-04-05 09:05:20', NULL),
(301, 'Ebola virus disease – Democratic Republic of the Congo', 'Since 17 February 2020 no new cases have been reported in the ongoing Ebola virus disease EVD outbreak in the Democratic Republic of the Congo While this is a positive development there is still a high risk of re emergence of EVD given the current challenges related to limited resources amidst other local and global emergencies continued insecurity and population displacement in previous hotspots and limited access to some affected communities It is therefore critical to maintain surveillance and response operations in the period leading up to the declaration of the end of the outbreak as well as after the declaration as outlined in the WHO recommended criteria for declaring the end of the EVD outbreak Ongoing outbreak response efforts continue which include investigating and validating new alert cases supporting appropriate care and rapid diagnosis of suspected cases which continue to be detected supporting survivors through a multi disciplinary programme and strategically transitioning activities From 24 to 31 March an average of 4082 alerts were reported and investigated daily Of these alerts 274 were validated as suspected cases requiring specialized care and laboratory testing to rule out EVD From 23 to 29 March 2376 samples were tested including 1322 blood samples from alive suspected cases 365 swabs from community deaths and 689 samples from re tested patients Overall laboratory activity decreased by 14 compared to the prior week', 'http://www.who.int/entity/csr/don/02-April-2020-ebola-drc/en/index.html', 24, 'pending', '2020-04-05 09:05:20', NULL),
(302, 'Ebola virus disease – Democratic Republic of the Congo', 'There have been no new cases of Ebola virus disease EVD reported in the ongoing outbreak in the Democratic Republic of the Congo since 17 February 2020 However because there is still a risk of re emergence of EVD it is critical to maintain surveillance and response operations until and after the end of outbreak declaration as outlined in the WHO recommended criteria for declaring the end of the EVD outbreak Unfortunately the response faces increasing limitations that could result in delayed detection and control of flare ups These limitations include a funding shortfall ongoing insecurity and lack of access to some areas and limited staffing and resources amidst other local and global emergencies', 'http://www.who.int/entity/csr/don/19-March-2020-ebola-drc/en/index.html', 24, 'pending', '2020-04-05 09:05:20', NULL),
(303, 'Ebola virus disease – Democratic Republic of the Congo', 'It has been over 21 days since the last confirmed case of Ebola virus disease EVD has been reported Figure 1 On 9 March the last 46 contacts finished their follow up These are important milestones in the outbreak as over one maximum incubation period has passed without any confirmed cases of EVD However there is still a high risk of re emergence of EVD and a critical need to maintain response operations as outlined in the WHO recommended criteria for declaring the end of the EVD outbreak Extensive surveillance pathogen detection clinical management and other response activities are currently ongoing These include but are not limited to investigating and validating new alert cases supporting appropriate care and rapid diagnostics of suspected cases which continue to be detected each day and supporting survivors through a multi disciplinary programme to help mitigate potential risks of re emergence Over the course of the past week 4 10 March 2020 over 32 000 alerts were reported and investigated and 2584 alerts were validated as suspected cases requiring specialized care and laboratory testing to rule out EVD From 2 to 8 March 2818 samples were tested including 1574 blood samples from alive suspected cases 376 swabs from community deaths and 868 samples from re tested patients Overall this was a 16 decrease in testing compared to the previous week', 'http://www.who.int/entity/csr/don/12-March-2020-ebola-drc/en/index.html', 24, 'pending', '2020-04-05 09:05:20', NULL),
(304, 'Ebola virus disease – Democratic Republic of the Congo', 'No new cases of Ebola virus disease have been reported since 17 February and on 3 March the only person confirmed to have EVD in the last 21 days Figure 1 was discharged from an Ebola Treatment Centre after recovering and testing negative twice for the virus This is an important milestone in the outbreak However there is still a high risk of re emergence of EVD and a critical need to maintain response operations as outlined in the WHO recommended criteria for declaring the end of the EVD outbreak As of 3 March 2020 a total of 3444 EVD cases were reported from 29 health zones Table 1 Figure 2 including 3310 confirmed and 134 probable cases of which 2264 cases died overall case fatality ratio 66 Of the total confirmed and probable cases 56 n 1927 were female 28 n 973 were children aged less than 18 years and 5 n 171 were health care workers', 'http://www.who.int/entity/csr/don/05-March-2020-ebola-drc/en/index.html', 24, 'pending', '2020-04-05 09:05:20', NULL),
(305, 'Ebola virus disease – Democratic Republic of the Congo', 'From 19 to 25 February no new confirmed cases of Ebola virus disease EVD were reported This was the first time since the beginning of the response that no new confirmed cases were reported over a seven day period Figure 1 The most recent case was reported in Beni Health Zone North Kivu Province on 17 February While the lack of new confirmed cases reported in the last seven days is a major achievement the outbreak remains active and risk of additional cases emerging remains high In the past 21 days 5 to 25 February 2020 four confirmed cases were reported from two health areas in Beni Health Zone in North Kivu Province Figure 2 Table 1 Even with strengthened surveillance operations transmission of Ebola virus outside of groups currently under surveillance cannot be excluded Ebola virus also persists in some survivors body fluids with potential to infect others In at least one instance during this outbreak relapse in which a person who has recovered from EVD develops symptoms again was observed sparking a new chain of transmission which has taken several months to interrupt To mitigate a potential resurgence of the outbreak it is critical to maintain response capacities to rapidly detect and respond to any new cases and to prioritize survivor support and monitoring and the maintenance of cooperative relationships with the survivors associations Substantial surveillance pathogen detection and clinical management activities are currently ongoing including validating alerts following remaining contacts who were potentially exposed to the virus supporting rapid diagnostics of suspected cases and working with community members to strengthen surveillance on people who pass away in the communities As of 25 February 510 contacts are currently under surveillance of which 97 were followed daily in the last seven days In the last seven days more than 5100 alerts per day were reported and investigated of which over 400 alerts including 70 community deaths were validated as suspected EVD cases requiring laboratory testing and specialized care within the established Ebola treatment and transit centres On average suspect cases stay in these facilities for three days before EVD can be definitively ruled out i e after two negative polymerase chain reaction tests 48 hours apart while care is provided for their illness under isolation precautions Timely testing of suspected cases continues to be provided across 11 operational laboratories deployed in cities that have been affected by the outbreak From 17 to 23 February more than 3600 samples were tested', 'http://www.who.int/entity/csr/don/27-february-2020-ebola-drc/en/index.html', 24, 'pending', '2020-04-05 09:05:20', NULL),
(306, 'Ebola virus disease – Democratic Republic of the Congo', 'During the past week the incidence of new Ebola virus disease EVD cases has remained low Figure 1 From 12 to 18 February one new confirmed case was reported The case was reported in Beni Health Zone North Kivu Province and had an epidemiological link to a confirmed case reported on 5 February As the case was alerted and transferred to an Ebola Treated Centre four days after symptom onset there remains a risk that onward transmission to contacts may have occurred and further cases may be expected from the currently active chain of transmission Ebola virus may also persist in some survivors body fluids for several months and in a limited number of instances transmissions from exposure to body fluids of survivors have been documented during this outbreak The ongoing programme for survivor care helps mitigate the risks of re introduction events To maintain operations and prevent re emergence of the outbreak WHO is requesting funding Under the Strategic Response Plan SRP 4 1 WHO s financial need for the Ebola Response from January to June 2020 is US 83 million Thanks to the generosity of many donors during 2019 WHO has some carry over funding which has been applied to maintain operations through February 2020 USD 40 million is currently needed to ensure continuity of response and preparedness activities to bring the case incidence to zero and continue building strong resilient health systems', 'http://www.who.int/entity/csr/don/20-february-2020-ebola-drc/en/index.html', 24, 'pending', '2020-04-05 09:05:20', NULL),
(307, 'Ebola virus disease – Democratic Republic of the Congo', 'This week the case incidence continued to be low in the Ebola virus disease EVD outbreak in the Democratic Republic of the Congo Figure 1 From 5 to 11 February three new confirmed cases were reported in Beni Health Zone North Kivu Province All three cases have epidemiological links to a transmission chain originating in Aloya Health Area Mabalako Health Zone with possible nosocomial exposure in Beni The most recent case reported from Beni Health Zone on 11 February was isolated one day after symptom onset Early detection of cases reduces the probability of transmission of EVD in the community and significantly improves the clinical outcome for the patients In the past 21 days 22 January to 11 February 2020 12 confirmed cases including three community deaths were reported from four health areas within two active health zones in North Kivu Province Figure 2 Table 1 Beni n 11 and Mabalako n 1 It has been 42 days since Katwa Health Zone has reported new cases The continued reduction of geographic spread of EVD cases and the declining trend in case incidence observed in the past 21 days are encouraging however these improvements remain fragile and should not be interpreted as an indication that response efforts can be reduced Continued vigilance is essential to improve infection prevention and control in health care facilities as well as ensuring early identification and follow up of cases and contacts', 'http://www.who.int/entity/csr/don/13-february-2020-ebola-drc/en/index.html', 24, 'pending', '2020-04-05 09:05:20', NULL),
(308, 'Ebola virus disease – Democratic Republic of the Congo', 'From 29 January to 4 February four new confirmed cases were reported in the ongoing Ebola virus disease EVD outbreak in the Democratic Republic of the Congo', 'http://www.who.int/entity/csr/don/06-february-2020-ebola-drc/en/index.html', 24, 'pending', '2020-04-05 09:05:20', NULL),
(311, '\"2019-ncov\" OR nCov OR (coronavirus AND wuhan[TIAB]) OR \"novel coronavirus\" OR (pneumonia AND wuhan[TIAB]) OR COVID-19[TW] OR 2019ncov[TW] AND ( ( \"2019/12/01\"[PDat] : \"3000/12/31\"[PDat] ) ); +110 new citations', '110 new pubmed citations were retrieved for your search Click on the search hyperlink below to display the complete search results 2019 ncov OR nCov OR coronavirus AND wuhan TIAB OR novel coronavirus OR pneumonia AND wuhan TIAB OR COVID 19 TW OR 2019ncov TW AND 2019 12 01 PDat 3000 12 31 PDat These pubmed results were generated on 2020 04 05 PubMed comprises more than millions of citations for biomedical literature from MEDLINE life science journals and online books Citations may include links to full text content from PubMed Central and publisher web sites', 'https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Search&amp;db=pubmed&amp;term=%28%20%28%222019-ncov%22%20OR%20nCov%20OR%20%28coronavirus%20AND%20wuhan%5BTIAB%5D%29%20OR%20%22novel%20coronavirus%22%20OR%20%28pneumonia%20AND%20wuhan%5BTIAB%5D%29%20OR%20COVID-19%5BTW%5D%20OR%202019ncov%5BTW%5D%20AND%20%28%20%28%20%222019%2F12%2F01%22%5BPDat%5D%20%3A%20%223000%2F12%2F31%22%5BPDat%5D%20%29%20%29%29%20AND%20%222020%2F04%2F05%2004.00%22%5BMHDA%5D%3A%222020%2F04%2F05%2008.14%22%5BMHDA%5D%29', 21, 'pending', '2020-04-05 12:59:03', NULL),
(312, '\"2019-ncov\" OR nCov OR (coronavirus AND wuhan[TIAB]) OR \"novel coronavirus\" OR (pneumonia AND wuhan[TIAB]) OR COVID-19[TW] OR 2019ncov[TW] AND ( ( \"2019/12/01\"[PDat] : \"3000/12/31\"[PDat] ) ); +150 new citations', '150 new pubmed citations were retrieved for your search Click on the search hyperlink below to display the complete search results 2019 ncov OR nCov OR coronavirus AND wuhan TIAB OR novel coronavirus OR pneumonia AND wuhan TIAB OR COVID 19 TW OR 2019ncov TW AND 2019 12 01 PDat 3000 12 31 PDat These pubmed results were generated on 2020 04 08 PubMed comprises more than millions of citations for biomedical literature from MEDLINE life science journals and online books Citations may include links to full text content from PubMed Central and publisher web sites', 'https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Search&amp;db=pubmed&amp;term=%28%20%28%222019-ncov%22%20OR%20nCov%20OR%20%28coronavirus%20AND%20wuhan%5BTIAB%5D%29%20OR%20%22novel%20coronavirus%22%20OR%20%28pneumonia%20AND%20wuhan%5BTIAB%5D%29%20OR%20COVID-19%5BTW%5D%20OR%202019ncov%5BTW%5D%20AND%20%28%20%28%20%222019%2F12%2F01%22%5BPDat%5D%20%3A%20%223000%2F12%2F31%22%5BPDat%5D%20%29%20%29%29%20AND%20%222020%2F04%2F07%2009.43%22%5BMHDA%5D%3A%222020%2F04%2F08%2008.01%22%5BMHDA%5D%29', 21, 'pending', '2020-04-08 19:30:23', NULL),
(313, 'WHO Timeline - COVID-19', '31 Dec 2019China reported a cluster of cases of pneumonia in Wuhan Hubei Province A novel coronavirus was eventually identified 1 January 2020WHO had set up the IMST Incident Management Support Team across the three levels of the organization headquarters regional headquarters and country level putting the organization on an emergency footing for dealing with the outbreak 4 January 2020WHO reported on social media that there was a cluster of pneumonia cases with no deaths in Wuhan Hubei province 5 January 2020WHO published our first Disease Outbreak News on the new virus This is a flagship technical publication to the scientific and public health community as well as global media It contained a risk assessment and advice and reported on what China had told the organization about the status of patients and the public health response on the cluster of pneumonia cases in Wuhan 10 January 2020WHO issued a comprehensive package of technical guidance online with advice to all countries on how to detect test and manage potential cases based on what was known about the virus at the time Evidence at that time suggested there was no or limited human to human transmission Based on experience with SARS and MERS and known modes of transmission of respiratory viruses infection and prevention control guidance were published to protect health workers recommending droplet and contact precautions when caring for patients and airborne precautions for aerosol generating procedures conducted by health workers 12 January 2020China shared the genetic sequence of COVID 19 13 January 2020 Officials confirm case of COVID 19 in Thailand the first recorded case outside of China 14 January 2020 Dr Maria Van Kerkhove noted in a press briefing there had been limited human to human transmission of the coronavirus in the 41 confirmed cases mainly through family members and that there was a risk of a possible wider outbreak Dr Kerkhove noted that human to human transmission would not be surprising given our experience with SARS MERS and other respiratory pathogens 20 21 January 2020WHO experts from its China and Western Pacific regional offices conducted a brief field visit to Wuhan 22 January 2020WHO mission to China issued a statement saying that there was evidence of human to human transmission in Wuhan but more investigation was needed to understand the full extent of transmission 22 23 January 2020The WHO Director General convened an Emergency Committee EC under the International Health Regulations IHR 2005 to assess whether the outbreak constituted a public health emergency of international concern The independent members from around the world could not reach a consensus based on the evidence available at the time They asked to be reconvened within 10 days after receiving more information 28 January 2020A senior WHO delegation led by the Director General travelled to Beijing to meet China s leadership learn more about China s response and to offer any technical assistance While in Beijing Dr Tedros agreed with Chinese government leaders that an international team of leading scientists would travel to China on a mission to better understand the context the overall response and exchange information and experience 11 12 February 2020 WHO convened a Research and Innovation Forum on COVID 19 attended by more than 400 experts and funders from around the world which included presentations by George Gao Director General of China CDC and Zunyou Wu China CDC s chief epidemiologist 16 24 February 2020The WHO China Joint mission which included experts from Canada Germany Japan Nigeria Republic of Korea Russia Singapore and the US CDC NIH spent time in Beijing and also travelled to Wuhan and two other cities They spoke with health officials scientists and health workers in health facilities maintaining physical distancing The report of the joint mission can be found here https www who int docs default source coronaviruse who china joint mission on covid 19 final report pdf', 'https://www.who.int/news-room/detail/08-04-2020-who-timeline---covid-19', 22, 'pending', '2020-04-08 19:30:23', NULL);
INSERT INTO `rss_articles` (`id`, `title`, `body`, `href`, `rss_id`, `status`, `created_at`, `updated_at`) VALUES
(314, 'Statement of the Twenty-Fourth IHR Emergency Committee', 'The Twenty fourth meeting of the Emergency Committee under the International Health Regulations 2005 IHR on the international spread of poliovirus was convened by the Director General on 26 March 2020 with committee members only attending via teleconference supported by the WHO Secretariat In order to ease the burden on affected State Parties in the exceptional situation following the determination of the COVID 19 outbreak as a Public Health Emergency of International Concern PHEIC on 30 January 2020 characterized as a pandemic on 11 March 2020 the invited State Parties were asked to present their reports electronically only instead of attending via teleconference Reports were received from Afghanistan Burkina Faso Central African Republic Cote d Ivoire Democratic Republic of Congo DR Congo Ethiopia Ghana Pakistan and Philippines The Emergency Committee reviewed the data on wild poliovirus WPV1 and circulating vaccine derived polioviruses cVDPV The WHO Secretariat presented a report of progress for affected IHR States Parties subject to Temporary Recommendations Wild poliovirus The Committee remains gravely concerned by the significant increase in WPV1 cases globally in 2019 and 2020 with 175 cases in 2019 compared to 33 in 2018 and already 32 cases as at 17 March 2020 compared to six for the same period in 2019 with no significant success yet in reversing this trend In Pakistan transmission continues to be widespread as indicated by both acute flaccid paralysis AFP surveillance and environmental sampling While the issues of vaccine hesitancy and refusals by individuals and communities and problems with management of the national polio program are being addressed these are yet to have impact on the current worrying epidemiology The added pressure on the program due to detection of cVDPV2 and ongoing spread in several provinces see below has continued into 2020 In Afghanistan the security situation remains very challenging Inaccessibility and missed children particularly in the Southern Region have led to a large cohort of susceptible children in this part of Afghanistan The risk of a major upsurge of cases is growing with other parts of the country that have been free of WPV1 for some time now at risk of outbreaks This would again increase the risk of international spread The Committee noted that based on sequencing of viruses there were recent instances of international spread of viruses from Pakistan to Afghanistan and also from Afghanistan to Pakistan The recent increased frequency of WPV1 international spread between the two countries suggests that rising transmission in Pakistan and Afghanistan correlates with increasing risk of WPV1 exportation beyond the single epidemiological block formed by the two countries The Committee noted the continued cooperation and coordination between Afghanistan and Pakistan particularly in reaching high risk mobile populations that frequently cross the international border and welcomed the all age vaccination now being taken at key border points between the two countries Vaccine derived poliovirus VDPV The multiple cirulating VDPV cVDPV outbreaks in four WHO regions African Eastern Mediterranean South east Asian and Western Pacific Regions are very concerning with two new countries reporting outbreaks since the last meeting Malaysia and Burkina Faso Unlike historical experience cross border spread of cVDPV2 has become quite common with recent spread from Angola to DR Congo and Zambia and from Chad and CAR to Cameroon and from Ghana to Burkina Faso In addition local emergences attributable to mOPV2 use have recently occurred in Togo Chad and Ethiopia The Committee noted that the GPEI has published a strategy to address cVDPV2 outbreaks but was extremely concerned that the monovalent OPV2 stockpile was still depleted The Committee strongly supports the development and proposed Emergency Use Listing of the novel OPV2 vaccine which should become available mid 2020 and which it is hoped will result in no or very little seeding of further outbreaks Impact of COVID 19 The Committee noted the very recent policy guidance of the GPEI GPEI recommendations for countries during the COVID 19 pandemic This document summarizes the recommendations from the Polio Oversight Board meeting on 24 March 2020 which calls for postponement of both preventive and outbreak response campaigns while ensuring surveillance and nOPV2 development and roll out plans continue in full The COVID 19 Polio programme continuity plan The operational guide was developed in collaboration with the regional polio eradication teams and the GPEI Partners to ensure essential GPEI functions continue polio programme personnel and staff are kept safe and to plan for a fast and effective resumption of polio eradication activities including supplementary immunization activities as soon as the public health situation with COVID 19 allows The Committee is extremely concerned about the impact of the COVID 19 pandemic on the risk of heightened transmission of polio and consequently the potential for international spread and significant reversal of polio eradication Conclusion The Committee unanimously agreed that the risk of international spread of poliovirus remains a Public Health Emergency of International Concern PHEIC and recommended the extension of Temporary Recommendations for a further three months However noting that some if not many international borders are closed to prevent international spread of COVID 19 State Parties may not currently be able to enforce the Temporary Recommendations in all places The Committee strongly urges countries subject to these recommendations to maintain a high state of readiness to implement them as soon as possible ensuring the continued safety of travelers as well as health professionals The Committee recognizes the concerns regarding the lengthy duration of the polio PHEIC but concludes that the current situation is extraordinary with clear ongoing risk of international spread and ongoing need for coordinated international response The Committee considered the following factors in reaching this conclusion Rising risk of WPV1 international spread The progress made in recent years appears to have reversed with the Committee s assessment that the risk of international spread is at the highest point since 2014 when the PHEIC was declared This risk assessment is based on the following the WPV1 exportation in 2019 from Pakistan to Iran and to Afghanistan and more recently spread from Afghanistan to Pakistan ongoing rise in the number of WPV1 cases and positive environmental samples in Pakistan and to a lesser extent Afghanistan the quickly increasing cohort of unvaccinated children in Afghanistan with the risk of a major outbreak imminent if nothing is done to access these children the urgent need to overhaul the leadership and strategy of the program in Pakistan which although already commenced is likely take some time to lead to more effective control of transmission and ultimately eradication increasing community and individual resistance to the polio program Rising risk of cVDPV international spread The clearly documented increased spread in recent months of cVDPV2 demonstrate the unusual nature of the current situation as international spread of cVDPV in the past has been very infrequent The number of new emergences of cVDPV2 in Africa raises further concern The risk of new outbreaks in new countries is considered extremely high even probable COVID 19 This new and unprecedented pandemic is likely to substantially negatively impact the polio eradication program and outbreak control efforts There is a risk of exportation of both WPV1 and cVDPV to known high risk countries to which it may take a lot of time and effort to adequately respond Falling PV2 immunity Global population mucosal immunity to type 2 polioviruses PV2 continues to fall as the cohort of children born after OPV2 withdrawal grows exacerbated by poor coverage with IPV particularly in some of the cVDPV infected countries Multiple outbreaks The evolving and unusual epidemiology resulting in rapid emergence and evolution of cVDPV2 strains is extraordinary and not yet fully understood and represents an additional risk that is yet to be quantified Weak routine immunization Many countries have weak immunization systems that can be further impacted by various humanitarian emergencies including COVID19 and the number of countries in which immunization systems have been weakened or disrupted by conflict and complex emergencies poses a growing risk leaving populations in these fragile states vulnerable to outbreaks of polio Surveillance gaps The appearance of highly diverged VDPVs in the Philippines Somalia and Indonesia are examples of inadequate polio surveillance heightening concerns that transmission could be missed in various countries Furthermore the missed transmission in China for a year illustrates that even countries with generally good surveillance can miss VDPV transmission COVID 19 is likely to have a negative impact on polio surveillance also Lack of access Inaccessibility continues to be a major risk particularly in several countries currently infected with WPV or cVDPV i e Afghanistan Nigeria Niger Somalia and Myanmar which all have sizable populations that have been unreached with polio vaccine for prolonged periods Population movement The risk is amplified by population movement whether for family social economic or cultural reasons or in the context of populations displaced by insecurity and returning refugees There is a need for international coordination to address these risks A regional approach and strong cross border cooperation is required to respond to these risks as much international spread of polio occurs over land borders Risk categories The Committee provided the Director General with the following advice aimed at reducing the risk of international spread of WPV1 and cVDPVs based on the risk stratification as follows States infected with WPV1 cVDPV1 or cVDPV3 with potential risk of international spread States infected with cVDPV2 with potential risk of international spread States no longer infected by WPV1 or cVDPV but which remain vulnerable to re infection by WPV or cVDPV Criteria to assess States as no longer infected by WPV1 or cVDPV Poliovirus Case 12 months after the onset date of the most recent case PLUS one month to account for case detection investigation laboratory testing and reporting period OR when all reported AFP cases with onset within 12 months of last case have been tested for polio and excluded for WPV1 or cVDPV and environmental or other samples collected within 12 months of the last case have also tested negative whichever is the longer Environmental or other isolation of WPV1 or cVDPV no poliovirus case 12 months after collection of the most recent positive environmental or other sample such as from a healthy child PLUS one month to account for the laboratory testing and reporting period These criteria may be varied for the endemic countries where more rigorous assessment is needed in reference to surveillance gaps e g Borno State Nigeria Once a country meets these criteria as no longer infected the country will be considered vulnerable for a further 12 months After this period the country will no longer be subject to Temporary Recommendations unless the Committee has concerns based on the final report TEMPORARY RECOMMENDATIONS States infected with WPV1 cVDPV1 or cVDPV3 with potential risk of international spread WPV1 Afghanistan most recent detection 25 February 2020 Pakistan most recent detection 2 March 2020 Nigeria most recent detection 27 Sept 2016 cVDPV1 Malaysia most recent detection 26 October 2019 Myanmar most recent detection 9 August 2019 Philippines most recent detection 28 October 2019 These countries should Officially declare if not already done at the level of head of state or government that the interruption of poliovirus transmission is a national public health emergency and implement all required measures to support polio eradication where such declaration has already been made this emergency status should be maintained as long as the response is required Ensure that all residents and long term visitors i e four weeks of all ages receive a dose of bivalent oral poliovirus vaccine bOPV or inactivated poliovirus vaccine IPV between four weeks and 12 months prior to international travel Ensure that those undertaking urgent travel i e within four weeks who have not received a dose of bOPV or IPV in the previous four weeks to 12 months receive a dose of polio vaccine at least by the time of departure as this will still provide benefit particularly for frequent travelers Ensure that such travelers are provided with an International Certificate of Vaccination or Prophylaxis in the form specified in Annex 6 of the IHR to record their polio vaccination and serve as proof of vaccination Restrict at the point of departure the international travel of any resident lacking documentation of appropriate polio vaccination These recommendations apply to international travelers from all points of departure irrespective of the means of conveyance e g road air sea Further intensify cross border efforts by significantly improving coordination at the national regional and local levels to substantially increase vaccination coverage of travelers crossing the border and of high risk cross border populations Improved coordination of cross border efforts should include closer supervision and monitoring of the quality of vaccination at border transit points as well as tracking of the proportion of travelers that are identified as unvaccinated after they have crossed the border Further intensify efforts to increase routine immunization coverage including sharing coverage data as high routine immunization coverage is an essential element of the polio eradication strategy particularly as the world moves closer to eradication Maintain these measures until the following criteria have been met i at least six months have passed without new infections and ii there is documentation of full application of high quality eradication activities in all infected and high risk areas in the absence of such documentation these measures should be maintained until the state meets the above assessment criteria for being no longer infected Provide to the Director General a regular report on the implementation of the Temporary Recommendations on international travel States infected with cVDPV2s with potential or demonstrated risk of international spread Afghanistan most recent detection 8 January 2020 Angola most recent detection 9 February 2020 Benin most recent detection 9 December 2020 Burkina Faso most recent detection 11 January 2020 Cameroon most recent detection 30 January 2020 CAR most recent detection 5 February 2020 Chad most recent detection 5 February 2020 Cote d Ivoire most recent detection 11 February 2020 China most recent detection 25 April 2019 DR Congo most recent detection 22 January 2020 Ethiopia most recent detection 21 February 2020 Ghana most recent detection 28 January 2020 Malaysia most recent detection 18 January 2020 Niger most recent detection 3 April 2019 Nigeria most recent detection1 January 2020 Pakistan most recent detection 12 February 2020 Philippines most recent detection 16 January 2020 Somalia most recent detection 4 February 2020 Togo most recent detection 10 January 2020 Zambia most recent detection 25 November 2019 These countries should Officially declare if not already done at the level of head of state or government that the interruption of poliovirus transmission is a national public health emergency and implement all required measures to support polio eradication where such declaration has already been made this emergency status should be maintained Noting the existence of a separate mechanism for responding to type 2 poliovirus infections consider requesting vaccines from the global mOPV2 stockpile based on the recommendations of the Advisory Group on mOPV2 Encourage residents and long term visitors to receive a dose of IPV four weeks to 12 months prior to international travel those undertaking urgent travel i e within four weeks should be encouraged to receive a dose at least by the time of departure Ensure that travelers who receive such vaccination have access to an appropriate document to record their polio vaccination status Intensify regional cooperation and cross border coordination to enhance surveillance for prompt detection of poliovirus and vaccinate refugees travelers and cross border populations according to the advice of the Advisory Group Further intensify efforts to increase routine immunization coverage including sharing coverage data as high routine immunization coverage is an essential element of the polio eradication strategy particularly as the world moves closer to eradication Maintain these measures until the following criteria have been met i at least six months have passed without the detection of circulation of VDPV2 in the country from any source and ii there is documentation of full application of high quality eradication activities in all infected and high risk areas in the absence of such documentation these measures should be maintained until the state meets the criteria of a state no longer infected At the end of 12 months without evidence of transmission provide a report to the Director General on measures taken to implement the Temporary Recommendations States no longer infected by WPV1 or cVDPV but which remain vulnerable to re infection by WPV or cVDPV WPV1 none cVDPV Kenya cVDPV2 last env positive specimen 21 March 2018 Mozambique cVDPV2 last virus detected 17 December 2018 PNG cVDPV1 last environmental positive specimen 6 November 2018 Indonesia cVDPV1 last virus detected 13 February 2019 These countries should Urgently strengthen routine immunization to boost population immunity Enhance surveillance quality including considering introducing supplementary methods such as environmental surveillance to reduce the risk of undetected WPV1 and cVDPV transmission particularly among high risk mobile and vulnerable populations Intensify efforts to ensure vaccination of mobile and cross border populations Internally Displaced Persons refugees and other vulnerable groups Enhance regional cooperation and cross border coordination to ensure prompt detection of WPV1 and cVDPV and vaccination of high risk population groups Maintain these measures with documentation of full application of high quality surveillance and vaccination activities At the end of 12 months without evidence of reintroduction of WPV1 or new emergence and circulation of cVDPV provide a report to the Director General on measures taken to implement the Temporary Recommendations Additional considerations Impact of COVID 19 on the polio program The committee urges all countries but particularly those at high risk of polio to maintain a high level of polio surveillance throughout the pandemic period noting that the postponement of polio immunization campaigns whether preventive or in response to outbreaks may lead to an increase in polio transmission including international spread Maintainenance of access to laboratory diagnosis in the face of widespread transport and shipping disruption is critical Secondly countries affected by campaign postponement should strive to maintain a high degree of operational readiness in order that immunization activities including border vaccination can resume quickly adhering to principles of good hygiene and safety for the vaccinee as well as for the health professionals to prevent COVID 19 spread This includes ensuring teams have access to appropriate personal protective equipment Given the risk of international spread countries need to ensure that they are ready to use appropriate vaccines as recommended by the Strategic Advisory Group of Experts on Immunization in response to new outbreaks The committee urged countries to maximize the use of polio assets to synergistically address the COVID19 pandemic noting that polio affected countries may be vulnerable to poorer outcomes in the pandemic due to health care system fragility and poorer health status of the population generally Lastly the pandemic should serve as a reminder to high risk countries with poor immunization coverage that infectious disease outbreaks can lead to social and economic disruption as well as straining the health care system and countries can increase their population resilience and recovery through prioiritising robust immunization programmes This is relevant not only to polio but to all other vaccine preventable diseases particularly measles Based on the current situation regarding WPV1 and cVDPV and the reports provided by affected countries the Director General accepted the Committee s assessment and on 7 April 2020 determined that the situation relating to poliovirus continues to constitute a PHEIC with respect to WPV1 and cVDPV The Director General endorsed the Committee s recommendations for countries meeting the definition for States infected with WPV1 cVDPV1 or cVDPV3 with potential risk for international spread States infected with cVDPV2 with potential risk for international spread and for States no longer infected by WPV1 or cVDPV but which remain vulnerable to re infection by WPV or cVDPV and extended the Temporary Recommendations under the IHR to reduce the risk of the international spread of poliovirus effective 7 April 2020', 'https://www.who.int/news-room/detail/08-04-2020-statement-of-the-twenty-fourth-ihr-emergency-committee', 22, 'pending', '2020-04-08 19:30:23', NULL),
(315, 'Joint Leader\'s statement - Violence against children: A hidden crisis of the COVID-19 pandemic', 'The COVID 19 pandemic is having a devastating impact across the world Efforts to contain the coronavirus are vital to the health of the world s population but they are also exposing children to increased risk of violence including maltreatment gender based violence and sexual exploitation As leaders of organisations committed to ending violence against children we come together in solidarity to share our deep concern call for action and pledge our support to protect children from violence and reduce the impact of COVID 19 on children in every country and community A third of the global population is on COVID 19 lockdown and school closures have impacted more than 1 5 billion children Movement restrictions loss of income isolation overcrowding and high levels of stress and anxiety are increasing the likelihood that children experience and observe physical psychological and sexual abuse at home particularly those children already living in violent or dysfunctional family situations And while online communities have become central to maintain many children s learning support and play it is also increasing their exposure to cyberbullying risky online behavior and sexual exploitation The situation is aggravated by children s lack of access to schoolfriends teachers social workers and the safe space and services that schools provide The most vulnerable children including refugees migrants and children who are internally displaced deprived of liberty living without parental care living on the street and in urban slums with disabilities and living in conflict affected areas are a particular concern For many growing economic vulnerability will increase the threat of child labour child marriage and child trafficking We must act now Together we call on governments the international community and leaders in every sector to urgently respond with a united effort to protect children from the heightened risk of violence exploitation and abuse as part of the broader response to COVID 19 Governments have a central role to play They must ensure that COVID 19 prevention and response plans integrate age appropriate and gender sensitive measures to protect all children from violence neglect and abuse Child protection services and workers must be designated as essential and resourced accordingly Working with and supporting governments our collective response must include maintaining essential health and social welfare services including mental health and psychosocial support providing child protection case management and emergency alternative care arrangements ensuring social protection for the most vulnerable children and households continuing care and protection for children in institutions and communicating with and engaging parents caregivers and children themselves with evidence based information and advice National helplines school counsellors and other child friendly reporting mechanisms enable children in distress to reach out for help and must be adapted to the challenges of COVID 19 Given the heightened risks of online harms technology companies and telecoms providers must do everything they can to keep children safe online This includes providing access to cost free child helplines age appropriate services and safe e education platforms and using their platforms to share child online safety advice They must also do more to detect and stop harmful activity against children online including grooming and the creation and distribution of child sexual abuse images and videos As global organisations working to end violence against children we will continue to advocate for and invest in effective child protection solutions We will collectively develop and share technical resources and guidance for policymakers practitioners parents caregivers and children themselves And we will support the courageous health child protection and humanitarian professionals working around the clock to keep children safe during these unprecedented times In recent years the global community has made significant gains in protecting children from violence We must not allow those gains to be lost during the current turmoil We must do all we can to keep children safe now And we must plan ahead together so that once the immediate health crisis is over we can get back on track towards the goal of ending all forms of violence abuse and neglect of children', 'https://www.who.int/news-room/detail/08-04-2020-joint-leader-s-statement---violence-against-children-a-hidden-crisis-of-the-covid-19-pandemic', 22, 'pending', '2020-04-08 19:30:23', NULL),
(316, '#ThanksHealthHeros - World Health Day Message', 'Today is World Health Day This day is especially poignant as the focus is on nurses and health workers who are on the frontline of the COVID 19 response across the world They are the real heroes risking their lives to save the millions affected by COVID 19 as well as other deadly diseases like tuberculosis TB They play a major role in providing high quality respectful treatment and care and leading community dialogue to address fears and questions It is imperative that we come together to invest more empower and protect the nursing and health workforce Without nurses and health workers we cannot achieve Health for All or end diseases like TB which claim millions of lives each year The World Health Organization is calling for your support on World Health Day to ensure that the nursing and midwifery workforces are strong enough to ensure that everyone everywhere gets the healthcare they need Today we would like to salute and thank nurses midwives and other health workers around the world who are battling difficult situations to save lives and we pay tribute to those who lost their lives protecting others Emily A Day in the Life of a TB Nurse lt div gt lt small gt lt a href https youtubeembedcode com pl gt youtubeembedcode pl lt a gt lt small gt lt div gt lt div gt lt small gt lt a href http add link exchange com gt w add link exchange com lt a gt lt small gt lt div gt Watch this story of Emily a nurse managing the TB programme of the City Health Office in Tuguegarao City Philippines Her dream for Tuguegarao is to one day see zero TB cases and that no one dies from this infectious disease Nurses and healthcare workers play a critical role in TB prevention and care It s time to invest in them to improve healthcare for all We thank all the nurses and healthcare workers working to EndTB', 'https://www.who.int/news-room/detail/07-04-2020-thankshealthheros---world-health-day-message', 22, 'pending', '2020-04-08 19:30:23', NULL),
(317, 'WHO lists two COVID-19 tests for emergency use', 'WHO has listed the first two diagnostic tests for emergency use during the Covid 19 pandemic The move should help increase access to quality assured accurate tests for the disease It also means that the tests can now be supplied by the United Nations and other procurement agencies supporting the COVID 19 response Both in vitro diagnostics the tests are genesig Real Time PCR Coronavirus COVID 19 and cobas SARS CoV 2 Qualitative assay for use on the cobas 6800 8800 Systems The emergency use listing of these products will enable countries to increase testing with quality assured diagnostics says Dr Mari ngela Sim o WHO Assistant Director General for Medicines and Health Products Facilitating access to accurate tests is essential for countries to address the pandemic with the best tools possible The Emergency Use Listing procedure EUL was established to expedite the availability of diagnostics needed in public health emergency situations It is intended to help procurement agencies and countries navigate the large presence of different devices on the market and by assessing them provides assurance of the products quality and performance The genesig Real Time PCR Coronavirus COVID 19 Primerdesign United Kingdom is an open system more suitable for laboratories with moderate sample testing capacity while the cobas SARS CoV 2 for use on the cobas 6800 8800 Systems Roche United States of America is a closed system assay for larger laboratories EUL listed products https www who int diagnostics laboratory 200407 eul sars cov2 product list pdf ua 1 Roche test https www who int diagnostics laboratory eul 0504 046 00 cobas sars cov2 qualitative assay ifu pdf ua 1 Primerdesign test https www who int diagnostics laboratory eul 0489 185 00 path covid19 ce ivd ifu issue 2 0 pdf ua 1', 'https://www.who.int/news-room/detail/07-04-2020-who-lists-two-covid-19-tests-for-emergency-use', 22, 'pending', '2020-04-08 19:30:23', NULL),
(318, '#BeActive for the UN International Day of Sport for Development and Peace', 'FIFA has joined forces with the United Nations UN and the World Health Organization WHO in supporting the BeActive campaign launched on the UN International Day of Sport for Development and Peace to encourage people to be HealthyAtHome as the world comes together in the fight against COVID 19 today and every day WHO recommends all healthy adults do at least 30 minutes a day of physical activity and children at least 60 minutes per day As part of this BeActive and remain HealthyAtHome include the following suggestions along with any other form of recreation to stay healthy at home Taking some online exercise classes Dancing Playing active video games Jumping rope and Practising muscle strength and balance training We are delighted that football is strongly supporting the International Day of Sport for Development and Peace by asking everyone to BeActive and to remain healthy at home during this difficult time said Ant nio Guterres Secretary General of the United Nations FIFA has asked the football community from member associations and clubs to players and fans to show their support to put their rivalries aside and to show a new solidarity so we can overcome the coronavirus This is an important lesson not only for today but for every day More than ever especially now one thing must be clear to everyone health comes first said FIFA President Gianni Infantino FIFA is delighted to support both the United Nations and the World Health Organization in amplifying the BeActive campaign today and we are encouraged that the football community is also playing an active role in ensuring the message understood globally For the first time ever we are all on the same team and together with team spirit and positive energy we will win WHO is proud to collaborate as part of the UN family with FIFA and football lovers worldwide to promote the importance of being active for both physical and mental health said Dr Tedros Adhanom Ghebreyesus Director General of the World Health Organization The BeActive campaign supports WHO s drive to help people be healthy at home The campaign kicks off with Real Madrid CF FC Barcelona Liverpool FC and Manchester United FC asking football fans to set aside their rivalries and to come together to BeActive in order to defeat the coronavirus Other clubs including Club Am rica CD Guadalajara Beijing Guoan FC Shanghai Shenhua FC Mohun Bagan AC East Bengal FC Melbourne City FC Sydney FC Auckland City FC Team Wellington FC CA River Plate Olympique de Marseille TP Mazembe CR Flamengo and SE Palmeiras will also join the initiative in the coming days As part of the campaign world famous players share the following message At this time even rivals need to stick together We have to keep our distance but we do not lose our focus We can show solidarity by being active and active means following the guidelines from the WHO The video campaign will be published on various FIFA digital channels with regular subsequent updates from clubs and players across the world during subsequent days BeActive is also being supported with graphics toolkits for the 211 FIFA member associations and various media agencies to facilitate additional localisation and to further amplify the message WHO the UN s specialized health agency and FIFA football s world governing body collaborate closely to promote healthy lifestyles through football globally and launched the Pass the message to kick out coronavirus campaign last month to share advice effective measures to protect people from COVID 19 The video campaign can also be downloaded here for editorial purposes', 'https://www.who.int/news-room/detail/06-04-2020-beactive-for-the-un-international-day-of-sport-for-development-and-peace', 22, 'pending', '2020-04-08 19:30:23', NULL),
(319, 'Updated WHO Information Note: Ensuring continuity of TB services during the COVID-19 pandemic', 'Geneva The World Health Organization WHO Global TB Programme along with WHO regional and country offices has developed an updated information note in collaboration with stakeholders This note is intended to assist national TB programmes and health personnel to urgently maintain continuity of essential services for people affected with TB during the COVID 19 pandemic driven by innovative people centred approaches as well as maximizing joint support to tackle both diseases It is important that the progress made in TB prevention and care is not reversed by the COVID19 pandemic Finding and treating people with TB remain the fundamental pillars of TB prevention and care and those would require maintained attention This updated note has additional details on clinical management considerations to manage TB and COVID 19 as well as new information on testing', 'https://www.who.int/news-room/detail/04-04-2020-updated-who-information-note-ensuring-continuity-of-tb-services-during-the-covid-19-pandemic', 22, 'pending', '2020-04-08 19:30:23', NULL),
(320, 'WHO and partners call for urgent investment in nurses', 'A new report The State of the World s Nursing 2020 provides an in depth look at the largest component of the health workforce Findings identify important gaps in the nursing workforce and priority areas for investment in nursing education jobs and leadership to strengthen nursing around the world and improve health for all', 'https://www.who.int/news-room/detail/07-04-2020-who-and-partners-call-for-urgent-investment-in-nurses', 22, 'pending', '2020-04-08 19:30:23', NULL),
(321, 'First ever State of the World’s Nursing report launched amid COVID19 pandemic', '7 April 2020 Nurses account for more than half of all the world s health workers providing vital services throughout the health system Around the world they are demonstrating their compassion bravery and courage as they respond to the COVID 19 pandemic and never before has their value been more clearly demonstrated A new report by WHO in partnership with the International Council of Nurses and Nursing Now released today reveals that there are just under 28 million nurses worldwide Between 2013 and 2018 nursing numbers increased by 4 7 million But this still leaves a global shortfall of 5 9 million with the greatest gaps found in countries in Africa South East Asia and the WHO Eastern Mediterranean region as well as some parts of Latin America The State of the World s Nursing 2020 provides an in depth look at the largest component of the health workforce Findings identify important gaps in the nursing workforce and priority areas for investment in nursing education jobs and leadership to strengthen nursing around the world and improve health for all Quotes Nurses are the backbone of any health system Today many nurses find themselves on the frontline in the battle against Covid 19 This report is a stark reminder of the unique role they play and a wakeup call to ensure they get the support they need to keep the world healthy Dr Tedros Adhanom Ghebreyesus WHO Director General Politicians understand the cost of educating and maintaining a professional nursing workforce but only now are many of them recognising their true value Every penny invested in nursing raises the wellbeing of people and families in tangible ways that are clear for everyone to see This report highlights the nursing contribution and confirms that investment in the nursing profession is a benefit to society not a cost Annette Kennedy ICN President This report places much needed data and evidence behind calls to strengthen nursing leadership advance nursing practice and educate the nursing workforce for the future said The policy options reflect actions we believe all countries can take over the next ten years to ensure there are enough nurses in all countries and that nurses use of the full extent of their education training and professional scope to enhance primary health care delivery and respond to health emergencies such as COVID 19 This must start with broad and intersectoral dialogue which positions the nursing evidence in the context of a country s health system health workforce and health priorities Lord Nigel Crisp Co Chair of Nursing Now', 'https://www.who.int/news-room/detail/06-04-2020-world-health-worker-week-2020', 22, 'pending', '2020-04-08 19:30:23', NULL),
(322, 'WHO and Global Citizen announce: \'One World: Together at home\' Global Special to support healthcare workers in the fight against the COVID-19 pandemic', 'One World Together At Home Global Special to Air on Saturday April 18 in Celebration and Support of Healthcare Workes Broadcast to Feature Real Experiences from Doctors Nurses and Families Around the World Historic Broadcast to be Hosted by Jimmy Fallon of The Tonight Show Jimmy Kimmel of Jimmy Kimmel Live and Stephen Colbert of The Late Show with Stephen Colbert Friends from Sesame Street Also on Hand to Help Unify and Inspire People Around the World to Take Meaningful Actions that Increase Support for the Global COVID 19 Response Curated in Collaboration with Lady Gaga Broadcast to Include Alanis Morissette Andrea Bocelli Billie Eilish Billie Joe Armstrong of Green Day Burna Boy Chris Martin David Beckham Eddie Vedder Elton John FINNEAS Idris and Sabrina Elba J Balvin John Legend Kacey Musgraves Keith Urban Kelly Clarkson Kerry Washington Lang Lang Lizzo Maluma Paul McCartney Priyanka Chopra Jonas Shah Rukh Khan and Stevie Wonder', 'https://www.who.int/news-room/detail/06-04-2020-who-and-global-citizen-announce-one-world-together-at-home-global-special-to-support-healthcare-workers-in-the-fight-against-the-covid-19-pandemic', 22, 'pending', '2020-04-08 19:30:23', NULL),
(323, 'Making available free paediatric medicine can accelerate elimination of congenital Chagas disease', 'The donation of an essential antiparasitic medicine can potentially accelerate the elimination of Chagas disease infection in children A pediatric presentation of benznidazole with accurate dosage and will soon be made available freely to address a long standing gap in the treatment of congenital infections of Chagas disease', 'https://www.who.int/news-room/detail/02-04-2020-making-available-free-paediatric-medicine-can-accelerate-elimination-of-congenital-chagas-disease', 22, 'pending', '2020-04-08 19:30:23', NULL),
(324, 'Middle East respiratory syndrome coronavirus (MERS-CoV) – The Kingdom of Saudi Arabia', 'From 1 through 29 February 2020 the National IHR Focal Point of Saudi Arabia reported 18 additional cases of MERS CoV infection including five associated deaths The cases were reported from Riyadh seven cases Hafer Albatin two cases Najran two cases Eastern two cases Aljouf one case Makkah one case Hail one case Taif one case and Jeddah one case regions Among reported cases of MERS CoV infection majority 16 cases were male and only two cases were female The age of reported cases ranged from 34 to 81 years No cases were reported among healthcare workers The link below provides details of the 18 reported cases', 'http://www.who.int/entity/csr/don/08-april-2020-mers-saudi-arabia/en/index.html', 24, 'pending', '2020-04-08 19:30:23', NULL),
(325, 'Ebola virus disease – Democratic Republic of the Congo', 'From 22 to 28 January five new confirmed cases were reported in the ongoing Ebola virus disease EVD outbreak in the Democratic Republic of the Congo', 'http://www.who.int/entity/csr/don/30-january-2020-ebola-drc/en/index.html', 24, 'pending', '2020-04-08 19:30:23', NULL),
(326, 'Ebola virus disease – Democratic Republic of the Congo', 'Nine new confirmed cases were reported from 15 to 21 January in the ongoing Ebola virus disease EVD outbreak in the Democratic Republic of the Congo', 'http://www.who.int/entity/csr/don/23-january-2020-ebola-drc/en/index.html', 24, 'pending', '2020-04-08 19:30:23', NULL),
(327, 'Covid-19: Africa records over 10 000 cases as lockdowns take hold', 'Africa so far the continent least affected by covid 19 registered 10 268 confirmed cases and 491 deaths on 7 April passing a worrying landmark for public health experts who are still hopeful that', 'http://feeds.bmj.com/~r/bmj/recent/~3/UBx-RvCMoMw/bmj.m1439.short', 26, 'pending', '2020-04-08 19:30:23', NULL),
(328, 'Use of electronic medical records in development and validation of risk prediction models of hospital readmission: systematic review', 'AbstractObjectiveTo provide focused evaluation of predictive modeling of electronic medical record EMR data to predict 30 day hospital readmission DesignSystematic review Data sourceOvid Medline', 'http://feeds.bmj.com/~r/bmj/recent/~3/LcBafxP3xPE/bmj.m958.short', 26, 'pending', '2020-04-08 19:30:23', NULL),
(329, 'Andrew Wu', 'bmj 369 apr07 11 m1429 FAF1faAndrew Wu was a consultant surgeon musician artist and sailing enthusiast He devoted his whole working life and career to the NHS and to his patients His legacy', 'http://feeds.bmj.com/~r/bmj/recent/~3/HVEbrBDvZDA/bmj.m1429.short', 26, 'pending', '2020-04-08 19:30:23', NULL),
(330, 'Jane Elizabeth Irwin', 'bmj 369 apr07 9 m1427 FAF1faJane Elizabeth Irwin was born in Birkenhead Both her parents were doctors and she was raised in Preston where her father was a consultant radiologist She was educated', 'http://feeds.bmj.com/~r/bmj/recent/~3/bc8JI5vjgnw/bmj.m1427.short', 26, 'pending', '2020-04-08 19:30:23', NULL),
(331, 'Mark Erik Victor Petersen', 'bmj 369 apr07 8 m1426 FAF1faMark Erik Victor Petersen a brilliant scientist and compassionate physician was appointed as consultant cardiologist for Gloucestershire NHS Healthcare Trust in 1996 He', 'http://feeds.bmj.com/~r/bmj/recent/~3/URUBEfXNoGg/bmj.m1426.short', 26, 'pending', '2020-04-08 19:30:23', NULL),
(332, 'Rosemary Jane Chambers', 'Rosemary Jane Chambers Jane was born in England but at the age of 4 she was evacuated with her mother and one sister to New Zealand to avoid the second world war After returning to England to', 'http://feeds.bmj.com/~r/bmj/recent/~3/87QQFZveNeI/bmj.m1425.short', 26, 'pending', '2020-04-08 19:30:23', NULL),
(333, '\"2019-ncov\" OR nCov OR (coronavirus AND wuhan[TIAB]) OR \"novel coronavirus\" OR (pneumonia AND wuhan[TIAB]) OR COVID-19[TW] OR 2019ncov[TW] AND ( ( \"2019/12/01\"[PDat] : \"3000/12/31\"[PDat] ) ); +467 new citations', '467 new pubmed citations were retrieved for your search Click on the search hyperlink below to display the complete search results 2019 ncov OR nCov OR coronavirus AND wuhan TIAB OR novel coronavirus OR pneumonia AND wuhan TIAB OR COVID 19 TW OR 2019ncov TW AND 2019 12 01 PDat 3000 12 31 PDat These pubmed results were generated on 2020 05 06 PubMed comprises more than millions of citations for biomedical literature from MEDLINE life science journals and online books Citations may include links to full text content from PubMed Central and publisher web sites', 'https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Search&amp;db=pubmed&amp;term=%28%20%28%222019-ncov%22%20OR%20nCov%20OR%20%28coronavirus%20AND%20wuhan%5BTIAB%5D%29%20OR%20%22novel%20coronavirus%22%20OR%20%28pneumonia%20AND%20wuhan%5BTIAB%5D%29%20OR%20COVID-19%5BTW%5D%20OR%202019ncov%5BTW%5D%20AND%20%28%20%28%20%222019%2F12%2F01%22%5BPDat%5D%20%3A%20%223000%2F12%2F31%22%5BPDat%5D%20%29%20%29%29%20AND%20%222020%2F05%2F05%2007.04%22%5BMHDA%5D%3A%222020%2F05%2F06%2008.02%22%5BMHDA%5D%29', 21, 'pending', '2020-05-06 17:21:02', NULL),
(334, 'Billions worldwide living with herpes', 'About half a billion people worldwide are living with genital herpes and several billion have an oral herpes infection new estimates show highlighting the need to improve awareness and scale up services to prevent and treat herpes About 13 of the world s population aged 15 to 49 years were living with herpes simplex virus type 2 HSV 2 infection in 2016 the latest year for which data is available HSV 2 is almost exclusively sexually transmitted causing genital herpes Infection can lead to recurring often painful genital sores in up to a third of people infected Herpes simplex virus type 1 HSV 1 is mainly transmitted by oral to oral contact to cause oral herpes infection sometimes leading to painful sores in or around the mouth cold sores However HSV 1 can also be transmitted to the genital area through oral sex causing genital herpes Around 67 of the world s population aged 0 to 49 had HSV 1 infection in 2016 an estimated 3 7 billion people Most of these infections were oral however between 122 million to 192 million people were estimated to have genital HSV 1 infection Genital herpes is a substantial health concern worldwide beyond the potential pain and discomfort suffered by people living with the infection the associated social consequences can have a profound effect on sexual and reproductive health says Dr Ian Askew Director of the Department of Sexual and Reproductive Health and Research at the World Health Organization WHO Herpes and HIV People with HSV 2 infection are at least three times more likely to become infected with HIV if exposed Thus HSV 2 likely plays a substantial role in the spread of HIV globally Women are more susceptible to both HSV 2 and HIV Women living in the WHO Africa Region have the highest HSV 2 prevalence and exposure to HIV putting them at greatest risk of HIV infection No cure vaccine needed There is no cure for herpes Antiviral medications such as acyclovir famciclovir and valacyclovir can help to reduce the severity and frequency of symptoms but cannot cure the infection Better awareness improved access to antiviral medications and heightened HIV prevention efforts for those with genital HSV symptoms are needed globally In addition development of better treatment and prevention interventions is needed particularly HSV vaccines A vaccine against HSV infection would not only help to promote and protect the health and well being of millions of people particularly women worldwide it could also potentially have an impact on slowing the spread of HIV if developed and provided alongside other HIV prevention strategies says Dr Meg Doherty Director of the WHO Department of Global HIV Hepatitis and STI Programmes Authored by staff at the University of Bristol the WHO and Weill Cornell Medical College Qatar and published in the Bulletin of the World Health Organization this new study estimates the global infection prevalence and incidence of HSV 1 and HSV 2 in 2016', 'https://www.who.int/news-room/detail/01-05-2020-billions-worldwide-living-with-herpes', 22, 'pending', '2020-05-06 17:21:02', NULL);
